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Abstract 
This thesis investigated quantitative SPECT/CT imaging of lutetium-177 (177Lu): assessing and 
quantifying variation in reported activity between clinical sites to help inform researchers 
attempting to compare quantitative imaging and molecular radiotherapy dosimetry performed 
at different clinical sites and to provide guidance on which methods and parameters to use in 
order to minimise activity uncertainty. 
The initial work involved assisting in the development of a practical, consensus-based 
calibration protocol for quantitative SPECT/CT imaging, followed by a pan-European hospital 
inter-comparison exercise in which participants were required to quantify the activity in a 177Lu 
source using local clinical protocols. The calibration protocol was also tested at each site. 
Finally, all calibration, imaging, reconstruction and segmentation methods and parameters used 
in the local clinical protocols were replicated on a single gamma camera to assess the impact of 
each method and parameter on activity quantification and make recommendations as to which 
methods and parameters to use for quantitative SPECT/CT imaging of 177Lu.  
The activities measured by the participants (seven clinical sites) differed from the true activity 
by up to 70% for an active volume surrounded by a less active shell and by up to 316% for the 
less active shell. Use of the calibration protocol (five clinical sites) reduced the difference 
between true and measured activity from a maximum of 19% to 12% for the active volume but 
increased the difference for the less active shell, from a maximum of 117% to 235%. 
The methods comparison work compared and identified methods and parameters that 
increased the accuracy of the measured activity volumes and values. In particular, the 
preferable calibration method was demonstrated to be one that uses objects of a similar size 
and geometry to the regions of interest for which quantification is required. In situations where 
this is not feasible, the use of planar Petri dishes performed best as a generic calibration 
method. Large volume dispersed sources performing best for quantifying areas of low activity 
located adjacent to areas of high activity. The use of the 208 keV photopeak only is 
recommended, as inclusion of the 113 keV photopeak decreases accuracy of quantitation. 
Careful use of post-reconstruction filters has been shown to have a beneficial effect on 
quantitative accuracy. Segmentation of image data should be performed using the CT data 
rather than SPECT data for volume delineation where possible, with thresholding based on the 
SPECT data followed by adjustments using the CT data giving improved results for activity 
quantification. 
This work revealed a general tendency to overestimate the accuracy with which volumes and 
activities can be reported. Uncertainties were underestimated by several of the participants in 
the inter-comparison exercise and the calibration protocol that was tested also gave 
underestimated uncertainties. 
Finally, the conclusions, recommendations and clinical impact of this work is presented, along 
with details of further work that could be performed to contribute to the body of research in 
this area. 
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1. Introduction 
This chapter starts by providing a chronological history of Nuclear Medicine and introduces the 
concepts of Molecular Radiotherapy, Quantitative Imaging, Dosimetry for Molecular 
Radiotherapy and Metrology. The project that part funded this PhD work, Metrology for 
Molecular Radiotherapy, is discussed and finally the aims of the PhD are outlined. 
1.1 The History of Nuclear Medicine 
Nuclear Medicine is the field of medicine that administers radionuclides to patients for the 
purposes of medical diagnosis. Molecular Radiotherapy is a sub-section of Nuclear Medicine in 
which radionuclides are administered in order to treat benign or malignant disease.  
The history of Nuclear Medicine can be traced back to 1913 when Frederick Proescher 
published the first recorded study of human intravenous administration of a radionuclide for 
medical purposes. He administered radium-226 to patients to treat a number of diseases, and 
claimed that the therapy (“molecular radiotherapy”) was particularly successful for the 
treatment of high blood pressure, pernicious anaemia and leukaemia (1).  
In 1927, Herrmann L Blumgart published his work using an intravenous injection of an aqueous 
solution of lead-214 and bismuth-214 and a cloud chamber to measure the velocity of blood 
flow in patients by detecting the radioactivity in the opposite arm to that in which the solution 
had been administered (2–4).  
The invention of the cyclotron in 1932 (5) and the construction of the world’s first nuclear 
reactor at the Oak Ridge National Laboratory in 1942 (6) enabled, for the very first time, the 
artificial production of new radionuclides. Animal studies were soon underway to investigate 
the potential medical uses of these newly discovered radionuclides.  
In 1940, John H Lawrence published a paper on the first clinical use of an artificially produced 
radionuclide, describing his successful preliminary results of using phosphorous-32 to treat 
mylogenous leukemia and polycythemia (7). Two years later, in 1942, Charles Pecher published 
his preliminary results using strontium-89 to treat secondary bone cancer (due to metastatic 
prostate cancer) (8). Further work performed in the late 1930s and throughout the 1940s by a 
number of groups involved the use of newly discovered iodine-131 (131I) to investigate and treat 
both malignant and benign thyroid disease (9–11). In 1951, the US Food and Drug 
Administration (FDA) approved the use of sodium iodide-131 for the treatment of thyroid 
disorders. This was the first radiopharmaceutical to obtain approval for medical use by the FDA. 
This therapy is hugely successful and even today, makes up the majority of molecular 
radiotherapy treatments performed globally. 
The following decade saw the development of the technology to enable the visualisation of the 
distribution of radionuclides within the body. In 1951, Benedict Cassen published his invention 
(12) – the rectilinear scanner capable of imaging γ (gamma) rays. This was a simple scintillation 
counter which moved back and forth across the patient and was designed for use in the imaging 
of the thyroid with 131I. In 1958, Hal Anger developed the Anger camera (13) which was a two 
dimensional imaging system and offered the possibility of performing dynamic imaging studies 
with γ-emitting radionuclides. Since it was designed to image γ-rays, it became known as the 
gamma camera. The major limitation for Nuclear Medicine at this time was the fact that there 
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were only a handful of radionuclides that could be imaged, and these radionuclides were 
specific for only a handful of organs.  
The turning point for Nuclear Medicine imaging came in 1964 when Paul Harper and his 
colleagues demonstrated the use of technetium-99m (99mTc) tracers for imaging the brain, 
kidneys, thyroid and liver (14). 99mTc has since proved to be a very flexible radionuclide which 
can be labelled to a wide variety of compounds enabling the imaging of virtually any part of the 
body. Today, 99mTc is by far the most widely used γ-emitting radionuclide in Nuclear Medicine.  
In 1976, the development of single photon emission computed tomography (SPECT) enabled 
three dimensional imaging of γ-emitting radionuclides to be performed using gamma cameras 
(15). The first commercial rotating SPECT gamma camera system was brought to the market in 
1977 by Searle Radiographics (16). It is often very useful to register a patient radionuclide 
dataset with an anatomical CT dataset as this enables accurate localisation of the areas of 
uptake (or lack of uptake) and subsequent retention or excretion of the administered 
radionuclide. In 2000, General Electric Healthcare (GE) introduced to the market the first 
commercially available dual modality SPECT/CT gamma camera system which reduced the 
co-registration errors between SPECT and CT datasets acquired on different systems and 
allowed the imaging to be performed in a single patient appointment (17). SPECT imaging, CT 
imaging and the gamma camera are discussed in more detail in section 3.1.2 (Single Photon 
Emission Computed Tomography (SPECT)) on page 37, section 3.1.3 (Computed Tomography 
(CT)) on page 38 and section 3.2 (The Gamma Camera) on page 39. 
Some radionuclides emit positrons, which almost immediately annihilate with a nearby electron 
to produce a pair of annihilation photons that are emitted at 180° to each other, see section 
3.2.1.3 (Pair production) on page 41. Whilst positron emitting radionuclides can be imaged on 
SPECT systems, positron emission tomography (PET) systems have been developed specifically 
for imaging these radionuclides. The first PET system was developed in 1973 (18) and the first 
commercial version was introduced to the market by EG&G ORTEC in 1978 (19). The first 
commercial PET/CT was introduced to the market by GE in 2001 (20).  
1.2 Molecular Radiotherapy 
In the past couple of decades, there has been a huge increase in the number of molecular 
radiotherapy radiopharmaceuticals available on the market, including evermore exotic 
radionuclides (21,22) such as lutetium-177 (177Lu), yttrium-90 (90Y) and radium-223 (223Ra). 
This is reflected in the increasing number of patients treated with molecular radiotherapy. 
Clinical centres in the UK that responded to a widely publicised survey treated over 3 000 
patients with molecular radiotherapy in the UK in 2017: an increase of 82% from 2007 (23). 
Since the very purpose of these molecular radiotherapy treatments are to treat and destroy 
disease by causing lethal radiation damage in the diseased (target) areas, there is potential to 
also cause radiation damage in disease-free (non-target) areas of the body due to uptake of the 
therapeutic radiopharmaceutical in non-target areas or uptake in target areas that are located 
close to non-target areas. Therefore the administered quantities of radioactivity, generally 
referred to as “activity”, of molecular radiotherapy radiopharmaceuticals are limited to reduce 
the likelihood of such damage.  
For further details, see section 2.1 (Molecular Radiotherapy) on page 22. 
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1.3 Quantitative Imaging 
Many of the radionuclides used for molecular radiotherapy can be imaged using either a gamma 
camera or a PET system. For therapeutic radiopharmaceuticals containing radionuclides that 
are difficult to image, a diagnostic radiopharmaceutical (containing an alternative radionuclide) 
that behaves in the same biological manner as the therapeutic radiopharmaceutical can be used 
as a surrogate. Imaging may be performed on patients prior to molecular radiotherapy, to 
ensure that the therapy will target the desired treatment area(s), and/or following therapy, to 
assess the biodistribution of the therapeutic radiopharmaceutical, and/or a few weeks to 
months following therapy, to assess the outcome of the therapy (i.e. whether the treated areas 
of disease have been destroyed or have reduced in size/functionality).  
This imaging is often used to compare uptake of the therapeutic radiopharmaceutical in 
different regions of the body in a single image, to ensure that the uptake within the desired 
target area(s) is greater than the uptake in the non-target area(s) in order to minimise the risk 
of radiation damage to non-target areas. When multiple images are acquired with an interval of 
several weeks or months between them, the images can be used to assess changes in uptake in 
the same region between the images. If the images have been acquired before therapy and a few 
weeks to month after therapy, they can demonstrate whether or not the patient has responded 
to the therapy.  
Whilst the complete destruction of an area of disease, or the growth of a new area of disease, 
can be assessed visually on a standard clinical image, when assessing reduction or increase in 
the size or functionality of areas of disease it is more common to report the changes 
quantitatively, in terms of size (such as mm or cm3) or uptake (either in comparison to uptake in 
non-target areas, or directly in terms of activity or activity concentration in the volume). In 
order to assess the quantity of radionuclide in clinical images, the images must be quantitative. 
This requires the gamma camera or PET system to be accurately calibrated to ensure that a 
reported activity, or activity concentration, for an area of interest is correct.  
For further detail, see chapter 3 (Physics of Quantitative Imaging) on page 36. 
1.4 Molecular Radiotherapy Dosimetry 
Dosimetry is the term used to describe the calculation of the energy delivered to the patient by 
radiation treatment. In external beam radiotherapy, dosimetry is well-established and 
treatments are prescribed and planned in terms of the absorbed dose. In comparison, molecular 
radiotherapy treatments are usually prescribed in terms of activity.  
Absorbed dose calculations in external beam radiotherapy are performed by complex treatment 
planning software that models the radiation distribution based on a CT scan of the patient. In 
contrast, absorbed dose calculations for molecular radiotherapy are performed based on the 
activity, or activity concentration, in the Nuclear Medicine SPECT or two-dimensional planar 
images (or PET images). 
Treatment planning absorbed dose calculations can be utilised in one of two ways (or a 
combination of the two): treatment can be planned to ensure that a target absorbed dose to the 
treatment volume is delivered, or to ensure that the absorbed dose delivered to radiosensitive 
non-target tissue is limited. In external beam radiotherapy, both of these approaches are used. 
In molecular radiotherapy, prospective dosimetry is rarely performed, and in situations where 
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it is performed it is usually performed to check, or limit, doses to radiosensitive non-target 
tissues rather than to deliver a specific absorbed dose to the treatment volume(s). The dose 
limits used in molecular radiotherapy are often borrowed from external beam radiotherapy as 
there is limited molecular radiotherapy dosimetry data available.  
Further detail is given in section 2.2 (Molecular Radiotherapy Dosimetry) on page 25. 
1.5 Metrology 
Metrology is the science of measurement (obtaining a true value for a quantity, traceable to a 
standard) and its application. Metrology institutes provide “ground truth” standard 
measurements against which other researchers and users can calibrate their devices. Ensuring 
that any measurements are traceable to a standard is vital in order to guarantee the precision 
and accuracy of the final measurement. If there is no “ground truth” standard value against 
which to compare the final measurement, it is impossible to be confident that the results 
obtained are valid and not subject to systematic error.  
Within the fields of Nuclear Medicine and Molecular Radiotherapy this has traditionally been 
limited to the measurement of activity using radionuclide calibrators (see section 2.3.2.1 
(Radionuclide Calibrators) on page 32), although there has also been an attempt to standardise 
quantitative measurements in PET imaging – for further details see section 2.3.2.5 (Quantitative 
PET Imaging) on page 35. 
To increase the involvement of Metrology Institutes in Nuclear Medicine and Molecular 
Radiotherapy, the Metrology for Molecular Radiotherapy (MetroMRT) project collaboration was 
established and awarded funding. This PhD was closely involved in the MetroMRT project and 
the project funded some of the costs of the research. The elements of the project relevant to this 
PhD work are discussed next. 
1.5.1 Metrology for Molecular Radiotherapy (MetroMRT) Project 
The Metrology for Molecular Radiotherapy (MetroMRT) project was an international 
collaborative project funded by the European Metrology Research Programme. This three year 
project consisted of six European Metrology Institutes and more than 20 clinical sites in 8 
countries, bringing together experts in metrology and nuclear medicine dosimetry. The 
purpose of this project was to investigate the metrology of molecular radiotherapy and 
quantify the uncertainties associated with the various measurements performed in the 
process, and make recommendations as to how the process can be improved and simplified 
such that all hospitals performing molecular radiotherapy can have ready access to 
guidance on how dosimetry should be performed, and a knowledge as to the likely 
uncertainties in their dosimetry method. One of the desired outputs from this project was 
the publication of a calibration protocol for performing quantitative imaging for the 
purposes of molecular radiotherapy and a good practice guide on the same topic, see 
section 4.2.2 (Calibration Protocol) for the PhD researcher’s involvement in the development 
of the protocol. 
The hospital inter-comparison work, see chapter 5 (Hospital Inter-Comparison) for details, 
was performed as part of this project and this work was included in the final project report. 
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1.5.1.1 Choice of Radionuclides 
As discussed later in this thesis, in section 2.1.1 (Overview of Molecular Radiotherapy), the most 
commonly used molecular radiotherapy beta-emitting radionuclides are 131I, 177Lu and 90Y. The 
project chose to focus on two of these three radionuclides and decided not to include 90Y since it 
is a pure beta (β) emitter whereas 131I and 177Lu also emit γ-rays. Whilst beta-emitting 
radionuclides can be indirectly imaged on a SPECT/CT gamma camera by imaging the 
bremsstrahlung photons emitted when negatively charged β-particles are deflected and 
decelerated by nearby positively charged atomic nuclei, it was felt that choosing the two 
radionuclides with the most similar imaging characteristics (i.e. both γ-emitters) would simplify 
the process of developing a calibration protocol. The relevant imaging properties of 131I and 
177Lu are summarised in Table 1. 
 131I 177Lu 
Half-life, days 8.0233 6.647 
Decay modes β 
γ (100%) 
β 
γ (17%) 
Primary γ energies, keV 284 (6%) 
364 (81%) 
637 (7%) 
113 (6%) 
208 (10%) 
Table 1. Imaging properties of 131I and 177Lu. The therapeutic properties of 131I and 177Lu can be found in Table 2. 
Data from reference (24). 
Only one radionuclide could be included in the hospital inter-comparison exercise and the 
project participants decided to perform the inter-comparison exercise using 177Lu rather than 
131I due to it being relatively new to the market, and rapidly increasing in use. 
1.5.1.2 Choice of Phantoms 
There was a strong preference within the project to ensure that any calibration methods or 
imaging work performed as part of this project, or recommended in outcomes from the project, 
be techniques that could be readily implemented in a clinical setting, using commercially 
available equipment and phantoms. As a result, all imaging work performed as part of this 
thesis deliberately utilised only commercially available products, which are detailed in each 
relevant section. 
1.5.1.3 Molecular Radiotherapy Dosimetry (MRTDosimetry) Project 
The MetroMRT project was funded for three years, from June 2012 to May 2015, and a further 
three years of funding was successfully obtained for a follow-on project entitled Molecular 
Radiotherapy Dosimetry (MRTDosimetry), from June 2016 to May 2019. As with MetroMRT, 
MRTDosimetry was an international collaboration between six European Metrology Institutes 
and 12 clinical sites in nine countries. MRTDosimetry was funded by the European Metrology 
Programme for Innovation and Research (EMPIR) which is the successor programme to EMRP, 
co-ordinating research projects with start dates between 2014 and 2020. 
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1.6 Aims of PhD 
Metrology in molecular radiotherapy dosimetry is too a vast subject to attempt to cover in a 
single PhD thesis. This PhD thesis has therefore focussed on the quantitative imaging link in the 
dosimetry chain (see section 2.2.2 (The Dosimetry Chain in Molecular Radiotherapy) on page 27 
for further details), specifically SPECT/CT imaging of 177Lu. The intent was to assess and 
quantify inter-hospital variation in reported activity to help inform researchers attempting to 
compare quantitative imaging performed at multiple hospitals and to provide guidance on 
which methods and parameters to use in order to minimise activity uncertainty. 
Specifically, the aims of the PhD were to: 
1. Assist in developing a practical, consensus-based calibration protocol for quantitative 
SPECT/CT imaging for γ-emitting radiopharmaceuticals as part of the MetroMRT 
project. 
2. Perform a hospital inter-comparison exercise for quantitative SPECT/CT imaging of 
177Lu, using both the local clinical protocols decided by the hospital and the calibration 
protocol developed in aim 1. 
3. Replicate all calibration, imaging, reconstruction and segmentation methods and 
parameters used in the local clinical protocols in aim 2 on a single gamma camera. 
Assess the impact of each method and parameter on activity quantification and make 
recommendations as to which methods and parameters to use for quantitative 
SPECT/CT imaging of 177Lu. 
The hypotheses were that the use of a common calibration and imaging protocol would reduce 
inter-hospital variability in reported activity values and that activity uncertainty can be reduced 
if careful selection of quantitative imaging parameters is performed. 
Whilst a similar inter-comparison exercise, traceable to primary standards, has been performed 
for barium-133 (133Ba), see section 2.3.2.2 (Quantitative SPECT Imaging: IAEA Inter-Comparison 
Exercise) for details, no such work has been performed previously for 177Lu. Similarly, there has 
been no previous work investigating the impact of so many individual quantitative imaging 
methods and parameters for 177Lu SPECT/CT imaging on the uncertainty in reported activity, let 
alone work in which all measurements were traceable to primary standards. 
The thesis is divided into the following chapters: 
o Introduction 
o Background 
o Molecular Radiotherapy: details the current state of Molecular Radiotherapy in 
the UK 
o Molecular Radiotherapy Dosimetry: details the use and importance of dosimetry 
in the field of Molecular Radiotherapy 
o Metrology: discusses the chain of traceability and the contributions that Metrology 
Institutes have made to Nuclear Medicine and Molecular Radiotherapy  
o Physics of Quantitative Imaging 
o Instrumentation for Nuclear Medicine and Molecular Radiotherapy: details the 
radionuclide calibrator and provides an overview of SPECT and CT imaging 
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o The Gamma Camera: details the gamma interactions relevant to SPECT imaging 
and the main components of the gamma camera 
o Quantitative Imaging: provides details of the main factors affecting quantitative 
SPECT imaging, including discussion of relevant results from published literature 
o Early Work: Development of Calibration Protocol: details the PhD researcher’s 
involvement in the development of the calibration protocol 
o Hospital Inter-Comparison: presents the results from a pan-European inter-comparison 
exercise for quantitative SPECT/CT imaging of 177Lu 
o Hospital Inter-Comparison Using a Common Calibration Protocol: provides 
assessment of the use of the MetroMRT calibration protocol as part of the pan-European 
inter-comparison exercise 
o Methods Comparison: contains the results for all methods used by the hospitals in the 
inter-comparison exercise replicated on a single gamma camera to assess the impact of 
each individual parameter on image quantification. 
o Conclusions, Clinical Impact, Recommendations and Future Work 
A list of presentations and publications arising from this work is provided in Appendix 1 with 
template worksheets provided in Appendix 2. 
  
22 
 
2. Background 
This chapter provides further detail about Molecular Radiotherapy, Molecular Radiotherapy 
Dosimetry and Metrology. It also summarises the involvement, to date, of National Metrology 
Institutes in Nuclear Medicine and Molecular Radiotherapy, with the exception of the MetroMRT 
and MRTDosimetry projects which are summarised in section 1.5 (Metrology) on page 18. The 
Gamma Camera and Quantitative Imaging are discussed in further detail in chapter 3. 
2.1 Molecular Radiotherapy 
2.1.1 Overview of Molecular Radiotherapy 
 
Generally, molecular radiotherapy utilises β-emitting radionuclides. Unlike γ-rays, which are a 
form of electromagnetic radiation and therefore have zero mass, β radiation is particulate. A 
β particle is an electron and, since it is both particulate and charged, it interacts with nearby 
atoms and is quickly stopped within the patient’s body, depositing its energy at the site of the 
interaction. Table 2 outlines some of the properties of the three most commonly used β-emitting 
molecular radiotherapy radionuclides, 131I, 177Lu and 90Y. The mean range of the particles in 
water is dependent on the energy of the β particles. Mean range in water can be assumed to be 
approximately equal to the mean range in soft tissue since the density of soft tissue is almost 
identical to that of water. 90Y has the longest mean β range of 4.3mm in water and 177Y is the 
shortest at 0.25mm. This short range means that the energy of the β particles are deposited very 
close to the location of the radiopharmaceutical and cell damage occurs only to those cells 
located within a few mm of the radiopharmaceutical, making it ideal for targeted treatment.  
 
 131I 177Lu 90Y 
Half-life, days 8.0233 6.647 2.6684 
Decay modes β 
γ (100%) 
β 
γ (17%) 
β 
Mean β energy, keV 181 134 926 
Mean β range in water, mm 0.4 0.25 4.3 
Maximum β energy, keV 807 498 2279 
Maximum β range in water, mm 3.6 1.9 11.8 
 
Table 2. Therapeutic properties of three of the most commonly used molecular radiotherapy beta-emitting 
radionuclides. Data from references (24,25) 
In recent years, α-emitting radionuclides have also been developed for molecular radiotherapy 
and one in particular, 223Ra, is now widely used for treatment of prostate cancer bone 
metastases. Similarly to β radiation, α radiation is particulate and α particles consist of two 
protons and two neutrons – over 7000 times the mass of a β particle. This much higher mass 
results in greater energy deposition, and hence greater radiation damage per radioactive decay. 
Being a heavier particle, it is also far more likely to interact with nearby atoms and has a much 
shorter range – around 10µm (less than 10 cell diameters). 
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As discussed in section 1.1 (The History of Nuclear Medicine), 131I was the first 
radiopharmaceutical to obtain FDA approval (to treat benign and malignant thyroid disease) 
and, as demonstrated in Figure 1, it still accounts for the majority of molecular radiotherapies 
procedures in the UK. Figure 1 shows the results from a UK survey performed in 2017 into the 
use of molecular radiotherapy – responses from 31 centres were obtained. The survey showed 
that 52% of patients treated with molecular radiotherapy in the UK received 131I-sodium iodide 
for thyroid diseases, which accounted for 27% of the total administered molecular radiotherapy 
administrations. 31% of patients received 223Ra-dichloride (Xofigo) for bone metastases, 
accounting for 60% of the total administered molecular radiotherapy administrations. 7% of 
patients received 177Lu or 90Y-PRRT for neuroendocrine cancers, accounting for 6% (177Lu) and 
2% (90Y) of the total administered molecular radiotherapy administrations. The apparent 
discrepancy between patient numbers and total administrations is due to the fact that whilst 131I 
for thyroid diseases is given as a single administration (which can be repeated if medically 
necessary), 177Lu/90Y-PRRT and 223Ra therapies are given as several administrations over a 
number of months. The results from the survey are presented in Figure 1: 
 
 
Figure 1. Molecular radiotherapy administrations given in the UK in 2017. Top = total number of patients. 
Bottom = total number of administrations. mIBG, metaiodobenzylguanidine; PRRT, peptide receptor radionuclide 
therapy; RAI, radioiodine (131I-sodium iodide); SIRT, selective internal radionuclide therapy. Some therapies, such as 
PRRT for neuroendocrine tumours and 223RaCl2 (Xofigo) for bone metastases are given as multiple administrations 
over a period of several months. 31 responses were obtained. Copied from reference (23). 
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2.1.2 Administered Activities 
Molecular radiotherapy treatments are usually prescribed in terms of administered activity, and 
either a fixed total activity, or a fixed activity per unit body weight is used. The activities used 
are based on clinical trials (for the newer therapies) and historical experience (such as for 131I 
for thyroid disorders). In clinical trials, activity-escalation is used in which patient cohorts are 
given progressively larger activities (either total activity, or scaled by body weight) until serious 
adverse reactions to the radiation is achieved in 5% of patients. If clinical trials are successful, 
then administered activities are set to ensure that < 5% of patients will suffer serious adverse 
reactions to the radiation (transient or reversible adverse reactions to more than 5% of patients 
may be deemed acceptable).  
2.1.3 Theragnostics 
Theragnostics (a combination of the words “therapy” and “diagnostics”) is a term used to 
describe the area of medicine in which diagnostic studies are used to guide therapeutic 
treatments. Within the field of molecular radiotherapy, this refers to performing a diagnostic 
study using a γ-emitting radiopharmaceutical that is distributed in the patient body in the same 
manner as the β or α-emitting therapeutic radiopharmaceutical. The diagnostic study is 
performed prior to the planned therapy to ensure that the therapy will target the areas 
requiring treatment and to adjust the therapy if required.  
Although some β-emitting radionuclides also emit γ-rays (such as 131I and 177Lu) it is usually 
preferable to perform the diagnostic study with a diagnostic (γ-ray) radionuclide since this is a 
lower absorbed dose to patients due to the absence of β particles. However, for γ-emitting 
radionuclides that are administered multiple times over a treatment period, such as 
177Lu-somatostatin analogues are used to treat neuroendocrine tumours, post-therapy imaging 
can be performed after each administration and used to inform the next administration. In the 
case of 177Lu-somatostatin analogue therapies, pre-therapy imaging with a diagnostic 
radiopharmaceutical will still be performed prior to the first cycle of therapy to ensure that the 
first treatment cycle will be appropriately targeted. 
Some typical pairs of theragnostic radiopharmaceuticals used in molecular radiotherapy are 
summarised in Table 3: 
Radiopharmaceutical 
Therapeutic Diagnostic 
177Lu/90Y-somatostatin analogue 111In/99mTc/68Ga-somatostatin analogue 
131I-sodium iodide 123I-sodium iodide 
223Ra-dichloride 99mTc-methylene diphosphonate 
Table 3. Theragnostic pairs of radiopharmaceuticals used in molecular radiotherapy. 
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2.1.4 Uses of 177Lu in Molecular Radiotherapy 
177Lu is predominantly used in molecular radiotherapy for the treatment of neuroendocrine 
cancers. Neuroendocrine tumours are defined as those that originate in the cells that make up 
the neuroendocrine system which produces and regulates hormones within the body.  Over 
5 000 people are diagnosed with neuroendocrine tumours in the UK each year, and in 2015 the 
annual incidence rate was 8.7 per 100 000 for females and 9.2 in males (26) but the authors 
believe these numbers to be underestimated to incompleteness in patient records. Patients are 
typically aged 65 – 69 at the point of diagnosis, and most of the cancers originate in the 
digestive system (26).  A unique feature of neuroendocrine tumours is that they express high 
levels of somatostatin receptors (27), meaning that somatostatin analogues can be used to “fill” 
the receptors and thereby reduce patient symptoms and slow disease progression. Molecular 
radiotherapy can be used to treat neuroendocrine tumours by administering patients with 
somatostatin analogue labelled with a radionuclide. In August 2018, the UK National Institute 
for Health and Care Excellence approved the use of 177Lu-oxodotreotide, a somatostatin 
analogue, for UK patients with unresectable or metastatic neuroendocrine tumours (28). 
The use of 177Lu in molecular radiotherapy is currently the subject of much research, and there 
are many additional molecular radiotherapy 177Lu-radiopharmaceuticals being developed 
around the world, with the following having been reported as having been used on patients: 
 Prostate-specific membrane antigen, for metastatic prostate cancer (29) – currently 
being reviewed by the UK National Institute for Health and Care Excellence for UK 
patients  
 Lilotomab satetraxetan, for non-Hodgkin lymphoma (30) 
 Pentixather, for multiple myeloma (31) 
 Various biphosphonates, for bone metastases (32–34) 
 Hydroxyapatite (35) and tin colloid (36), for rheumatoid arthritis 
2.2 Molecular Radiotherapy Dosimetry  
Quantification of absorbed dose due to molecular radiotherapy is generally performed in one of 
two ways: simple dosimetry calculations or complex voxel-based dose modelling. The two 
methods are discussed in the next section. 
2.2.1 Development of Internal Dosimetry Methodologies 
2.2.1.1 Dosimetry Calculations 
The first method for comprehensively calculating absorbed dose was published in 1948 (37). In 
1968, this was followed by the first publication written by the newly created Medical Internal 
Radiation Dose (MIRD) committee detailing a recommended method by which to perform 
absorbed dose calculations (38). The International Commission on Radiological Protection 
(ICRP) published a very similar method, with differing nomenclature, in 1982 (39) although this 
publication was intended to be used for safety of radiation workers rather than patients. Several 
updates have been published by MIRD and ICRP, with the most up-to-date versions published in 
2009 (40) and 2007 (41) respectively. An additional update was published in 2010 specifically 
for performing dosimetry calculations for α-emitting radionuclides (42). The nomenclature 
used in the 2009 MIRD publication was adjusted to bring it into agreement with that used by the 
ICRP, and is the nomenclature used in this text. 
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Absorbed dose, D(rT), delivered to a target region (rT), from a radiopharmaceutical 
homogeneously distributed within a source tissue, rS, is defined as the energy deposited in the 
target tissue (originating from the source tissue) per unit mass. However, in molecular 
radiotherapy the absorbed dose is time-dependent since the biodistribution of the 
radiopharmaceuticals changes over time and there are often multiple source tissues: 
                                                                     (  )  ∑  ̃(  )   (     )                                                Equation 1 
where  ̃(  ) is the cumulated activity in an individual source tissue, or the total number of 
radioactive decays that occur in the source tissue over the time period that the 
radiopharmaceutical is in the body.  (     ) is the absorbed dose per decay for the specific 
radionuclide and the specific source and target tissue combination. The unit of cumulated 
activity is therefore Bq.s and the unit of absorbed dose per decay is Gy.(Bq.s)-1, yielding the unit 
for absorbed dose of Gy.  
 ̃ is time-dependent, and is the integral of the function that describes the activity, A, in the tissue 
of interest as a function of time, t, with t extended to infinity: 
 ̃(  )  ∫  
 
 
(    )                   Equation 2 
 ̃ can either be measured using direct measurements of bodily tissues/excreta such as tissue 
biopsy, blood sampling, urine/faeces collection, or indirect measurements such as probe 
measurements to estimate total activity in the body, or quantitative imaging. Since  ̃ is an 
integral of a function, the more data points available for plotting the function, the more accurate 
the function will be. However, in the clinical setting there is always time, resource and staff 
constraints and so sometimes staff are required to perform dosimetry using just a single 
imaging time point plus biokinetic data (from blood/urine/probe measurements). In this 
situation, it is common to normalise the biokinetic data to the single imaging time point.  
S is the product of mean energy emitted per Bq of the radionuclide, Δ, and absorbed fraction of 
the emitted energy that is absorbed in the target region, φ, per unit mass of target region, M(rT) 
summed for all emitted radiation from the radiopharmaceutical: 
 (     )  ∑
    (       )
 (  )
                  Equation 3 
S is dependent on the type of radiation emitted from the radiopharmaceutical (which is often a 
combination of more than one type, such as the β-γ emitters often used for molecular 
radiotherapy), the energy of each radioactive emission and also on patient anatomy factors such 
as size, shape, mass and location of the source and target tissues in addition to the type of tissue 
(e.g. bone, lung, soft tissue) between the source and target tissues. One important thing to note 
is that target tissues often also take up the radiopharmaceutical, and in these cases one of the 
source tissues is actually the target tissue itself. A number of mathematical and tomographic 
phantoms  have been developed to represent typical patient anatomy, and have been used to 
calculate values for S, known as S-factors, (43–50). Although it is possible to adjust some of the 
patient characteristics of these phantoms (such as height, weight, gender, size of organs etc.) to 
make the phantoms more representative of the specific patient, these phantoms will never, by 
virtue of their design, be patient-specific. 
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2.2.1.2 Voxel-based Dosimetry Modelling 
An alternative method of estimating absorbed doses to patients is to use voxel-based modelling 
instead to perform patient-specific dosimetry. The benefits of using dosimetry calculation 
methods has been the ease and speed with which they can be performed, but with increasing 
computer capabilities, it is becoming more feasible to run Monte-Carlo based simulations for 
individual patients. This method requires a series of quantitative 2D (planar) or 3D (SPECT) 
nuclear medicine images and at least one image providing 3D anatomical data (such as CT). A 
Monte-Carlo simulation is then run for each nuclear medicine image to model the path through 
the patient’s bodily tissues, and energy deposition, for each and every radiation type and energy 
emitted by the radiopharmaceutical within the patient. This produces a 3D dose map for each 
time point, and from these maps a total cumulated dose can be calculated for the patient and the 
tissue(s) of interest. A number of Monte-Carlo codes are available that have been validated for 
modelling the range of radiation types, energies and human tissue types required for this task 
(51–55). 
2.2.2 The Dosimetry Chain in Molecular Radiotherapy 
Prospective dosimetry in molecular radiotherapy is performed as illustrated by the flowchart in 
Figure 2. In order to prescribe molecular radiotherapy based on absorbed doses, molecular 
radiotherapy dosimetry must be performed prior to therapy. The one exception to this is 
therapies that are given as multiple administrations – in this case, a fixed activity can be 
administered for the first therapy and the activity administered for the remaining therapies can 
be tailored accordingly. Alternatively, molecular radiotherapy dosimetry can be performed 
retrospectively, in which case a fixed activity is administered and the resultant absorbed dose is 
calculated and reported. 
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Figure 2. How to perform molecular radiotherapy dosimetry. The red box (quantification of radioactivity) is the 
area on which this PhD thesis was focussed. 
For prospective dosimetry only 
Administer the calculated 
therapeutic activity to the 
patient  
Calculate required therapy 
activity, in Bq, to achieve the 
required absorbed dose (or to 
avoid exceeding any dose limit 
on the tissue at risk) 
Perform dosimetry 
calculations or more complex 
modelling to ascertain the 
absorbed dose to the volumes 
of interest, per Bq of 
administered activity. 
Knowledge of 
radiosensitivity 
of the 
tissue/organ 
and properties 
of the 
radionuclide 
Quantification of cumulated 
activity in target volume 
and/or tissue at risk acquired 
at multiple time-points 
(ideally imaging-based 
though for some therapies a 
gamma probe or biological 
samples can be used instead) 
Patient administered a fixed 
activity: either a diagnostic 
activity, or a full therapeutic 
administration (where 
multiple cycles are to be 
administered) 
Patient referred for molecular 
radiotherapy 
Activity is measured in radionuclide calibrator. 
In situations where retrospective dosimetry is 
performed, the fixed activity therapeutic 
administration will be given. The fixed activities 
are usually stipulated by the 
radiopharmaceutical manufacturers based on 
clinical trials for newer molecular 
radiotherapies, or from guidance documents 
based on historical experience (such as for 131I 
for thyroid disorders). 
Either SPECT (three dimensional) or planar (two 
dimensional) imaging can be used. SPECT is 
often used in combination with CT to provide 
anatomical localisation of organs at risk. In some 
situations, cumulated activity can be estimated 
using patient samples (such as urine collection 
to assess kidney/bladder cumulated activity or 
blood collection to assess bone marrow 
cumulated activity). Probe measurements can be 
used to calculate whole body cumulated activity. 
Perform post-therapy imaging and 
retrospective dosimetry to confirm 
absorbed dose delivered 
Dosimetry calculations with published factors 
can be used for organ dosimetry (though they 
won’t be patient-specific), but for lesion-based 
dosimetry or patients with non-standard 
anatomy (for example, patients who have 
undergone surgery to remove cancer) modelling 
will be necessary. Published tissue 
radiosensitivity factors and radionuclide 
properties are used. 
Absorbed dose targets and limits are derived 
from published data, often based on external 
beam radiotherapy data.  
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2.2.3 The Need for Dosimetry in Molecular Radiotherapy 
In the past couple of decades, there has been a huge increase in the number of nuclear medicine 
therapies available on the market, including evermore exotic radionuclides (56). Unlike the now 
well-established therapies discovered in the 1940s, these therapies often deliver large absorbed 
doses to areas of the body that do not require treatment. Therefore, careful consideration needs 
to be given as to how best to treat the patient. As mentioned in section 2.1.2 (Administered 
Activities), this potential to cause radiation damage to non-target volumes is usually managed 
by setting the administered activity to a level such that < 5% of patients will experience 
significant adverse radiation effects. However, due to the variable nature of physiology between 
patients, this technique can give rise to huge variations in the radiation dose delivered to the 
treatment volume and organs at risk (57–61).  
A, now relatively old, study that nevertheless nicely demonstrated the effect of this variation in 
dose to the treatment volume on the treatment outcome was conducted by the Royal Marsden 
Hospital, London in 2010 (62). The study looked at 23 thyroid cancer patients who had been 
administered 3000MBq of 131I following near total thyroidectomy (i.e. all patients should have 
similar volumes of residual thyroid tissue – the target volume to be treated). If the physiology of 
all patients was similar, then a similar radiation dose should be delivered to the target volume 
in each patient. 18 of the 23 patients (78%) were deemed to have been successfully treated. The 
authors discovered that the maximum absorbed dose to the thyroid remnants ranged from 7 to 
570Gy. Furthermore, they found a strong correlation (p = 0.03) between absorbed dose and the 
success of the treatment, with successful treatment achieved in all patients receiving > 49Gy to 
the thyroid remnants. However, 5 of the patients who were successfully treated received 
absorbed doses to the thyroid remnants in excess of 100Gy. This work suggests that these five 
patients were grossly overtreated, and that the 5 patients who did not have a successful 
outcome would have been likely to have had a successful treatment if an absorbed dose of 
> 49Gy had been delivered to the thyroid remnants. The global consequence is that the majority 
of patients undergoing radionuclide therapies are either undertreated (and therefore receiving 
an inadequate, and hence unnecessary, radiation dose since the treatment would need to be 
repeated) or overtreated (and therefore also receiving an unnecessary radiation dose).  
Furthermore, there is a legal obligation to perform patient dosimetry. Originally enshrined in 
law in the European Council Directive EURATOM 97/43/Article 4 (Optimization), section 1b 
(63), and repealed by the European Council Directive EURATOM 2013/59/Article 56 
(Optimization), section 1 (64), both directives state that: 
“For all medical exposure of individuals for radiotherapeutic purposes […], exposures 
of target volumes shall be individually planned; taking into account that doses of 
non-target volumes and tissues shall be as low as reasonably achievable and consistent 
with the intended radiotherapeutic purpose of the exposure.” 
And the directives define radiotherapeutic as: 
“pertaining to radiotherapy including nuclear medicine for therapeutic purposes”. 
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2.2.4 Why is Dosimetry not Performed in Molecular Radiotherapy? 
Whilst the theory of performing molecular radiotherapy dosimetry is straightforward, the 
real-life application is more complicated. Unlike in external beam radiotherapy where the 
methods by which patient dosimetry is performed is highly regulated and prescribed (65), in 
molecular radiotherapy there is no consistent recommended method as to how the activity 
measurements or dosimetry calculations / modelling should be performed. The result of this is 
that no two centres perform molecular radiotherapy dosimetry in an identical manner, and so 
reported absorbed doses from one centre are not comparable with another centre. This means 
that what limited dosimetry data there is for molecular radiotherapy is unlikely to be directly 
applicable to other centres. Furthermore, most molecular radiotherapy treatments are 
administered under the authorisation of Nuclear Medicine Consultants who are not accustomed 
to working in terms of absorbed doses in the same manner that Oncology (cancer) Consultants 
are.  This lack of guidance, expertise, comparability and clinical demand has led to a reluctance 
to develop services in which molecular radiotherapy dosimetry is routinely performed, despite 
the legal obligation (66).  
2.3 Metrology 
2.3.1 Metrology and Traceability of Measurements 
Metrology is the science of measurement (obtaining a value for a quantity) and its application.  
The majority of countries worldwide have designated National Metrology Institutes (NMIs) that 
exist to provide national solutions to measurement problems and offer validated measurement 
services that are traceable to primary national standards. The term “traceable” refers to the 
ability to relate the obtained measurement to a primary standard, via a documented unbroken 
chain of calibrations and standards (67). NMIs ensure that the national primary standards are 
traceable to international primary standards via international inter-comparisons of 
measurement capabilities between NMIs. These inter-comparisons are organised by the Bureau 
International des Poids et Mesures (Paris, France) which is the world measurement standards 
organisation. Those NMIs that do not participate in the international inter-comparisons can 
calibrate their measurement equipment against the measurement equipment certified as a 
primary standard, and would be considered to be a Secondary Standards Laboratory. 
Measurement equipment that is calibrated against the national primary standard is referred to 
as a secondary standard and equipment calibrated against that equipment is referred to as 
reference instruments. Equipment against which nothing further is calibrated are referred to as 
field instruments, see Figure 3 for details. 
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Figure 3. Traceability Chain. Figure copied from reference (68).  
 
These traceability chains are vital to ensure that two persons measuring the same object or 
value in different locations would obtain the same result (within a given uncertainty). 
Uncertainties in measurements will increase with an increasing number of steps in the 
calibration chain as the uncertainties propagate down the calibration chain. Traceability is vital 
in order to allow meaningful comparisons between individual measurements. In the clinical 
setting, traceability is essential for patient safety and/or optimised treatments by ensuring that 
a patient prescribed a specific quantity of diagnostic or therapeutic would receive that same 
quantity regardless of the hospital they attended. That is to say, for example, that the equipment 
used to measure radioactivity at hospital A is as accurate (to a given precision) as the 
equipment at hospital B and therefore a patient prescribed 100MBq at hospital A would receive 
the same quantity of radioactivity as a patient prescribed 100MBq at hospital B. In addition to 
patient safety and treatment optimisation, traceability is critical in order to perform clinical 
studies where data from multiple centres are collected and compared: without traceability, 
there would be no assurance that the data from hospital A could be meaningfully compared to 
the data from hospital B. 
The NMI for the United Kingdom is the National Physical Laboratory, (NPL: Teddington, UK). 
Some countries, such as the USA, have a single NMI that maintains responsibility for all national 
standards. Others, including the UK, have one or more Designated Institutes that are responsible 
for some of the standards. Whilst NPL is responsible for most of the national standards for the 
UK, including those for radioactivity, the following 5 Designated Institutes are responsible for 
specific standards: 
 LGC – some chemical and biochemical standards 
 National Gear Metrology Laboratory – gear standards 
 National Institute for Biological Standards and Control – bio-activity standards 
 TUV-NEL – flow standards 
 Regulatory Delivery – responsible for legal metrology 
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2.3.2 Metrology in Nuclear Medicine and Molecular Radiotherapy 
2.3.2.1 Radionuclide Calibrators 
As discussed later in this thesis, in section 3.1.1 (Radionuclide Calibrator), the radionuclide 
calibrator is used to measure activity administered to patients, in units of Bq. 
NPL provide a radionuclide calibration service to UK hospitals, and have also designed a 
secondary standard radionuclide calibrator, the Fidelis radionuclide calibrator (69). This offers 
UK hospitals two methods to ensure traceability: they can purchase a secondary standard 
radionuclide calibrator and calibrate their field instruments against that or they can utilise the 
NPL calibration service to calibrate their reference instruments against the UK primary 
standard. Most NMIs around the world offer similar calibration services, and the Fidelis 
radionuclide calibrator, manufactured by Southern Scientific (Henfield, UK), is certified and 
calibrated directly against the national standard held at NPL and available for purchase 
worldwide.   
NPL have published guidance on how to establish and maintain traceability of medical 
radionuclide calibrators and recommended quality control tests (68). Table 4 outlines some of 
the recommended tolerances for reference and field instrument radionuclide calibrators: 
 
Table 4. Acceptable calibration tolerances for reference and field instruments. Copied from reference (68). 
The recommendations include advising that the accuracy of all medical radionuclide calibrators 
are checked annually using at least two different radionuclides. Since the majority of UK 
hospitals use the NPL radionuclide calibration services to perform this testing, NPL organise 
regular inter-comparison exercises between UK hospitals in which radionuclide sources are 
calibrated at NPL and sent to hospitals, where the hospital staff measure the sources in the 
radionuclide calibrators and report an activity value to NPL. These inter-comparison exercises 
allow assessment of measurement capabilities within hospitals and can also identify possible 
measurement problems, bringing them to the attention of the Nuclear Medicine community. For 
example, two 123I inter-comparison exercises, in 1996 and 1999, demonstrated very little 
improvement in measurement ability between the two comparisons (62% of participants 
reported activity values within ± 10% of the true activity in 1996 whilst in 1999 66% of 
participants reported activity values within ± 10% (70)). Following on from this 
inter-comparison exercise, most hospitals now utilise a thin copper filter to place inside the 
radionuclide calibrator when measuring 123I – this prevents the low energy X-rays from entering 
the radionuclide calibrator ionisation chamber and so reduces the impact of the different 
measurement geometries (for example, reducing the difference in activity measurement 
between a syringe and vial from 80% to 3%) (71). In a follow-up inter-comparison exercise 
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performed in 2015, after widespread uptake in the use of the copper filter, 94% of the 
participants reported activity values that were within ± 10% of the true activity (70). 
As stated in section 3.1.1 (Radionuclide Calibrator), UK guidance relating to the administration 
of radionuclides for molecular radiotherapy states that is customary to dispense therapeutic 
administrations to within ± 5% of the prescribed activity and traceability of radionuclide 
calibrators is essential in order to adhere to these desires.  
In addition to providing a metrology service for radionuclide calibrators, NPL also work in the 
area of nuclear data – standardising and improving the accuracy of data for radionuclides. The 
three main areas of interest for this group are medical, environmental and nuclear power 
radionuclides. The nuclear medicine group select the priority radionuclides to standardise 
based on which radionuclides are likely to be used in new radiopharmaceuticals, or there is a 
clinical demand for assistance with. For example, when 223Ra-dichloride was starting to be used 
in clinical trials, NPL performed standardisation measurements on 223Ra and discovered that the 
calibrator factor used to measure 223Ra activity in the clinical trials was incorrect by 9% (72). 
2.3.2.2 Quantitative SPECT Imaging: IAEA Inter-Comparison Exercise 
A multi-centre inter-comparison study has previously been performed using solid epoxy resin 
barium-133 (133Ba) sources as a surrogate for 131I, in order to compare the quantitative imaging 
results using various planar and SPECT imaging protocols (73).   
This work was a major component of the IAEA Coordinated Research Project E2.10.07 
(Development of Quantitative Nuclear Medicine Imaging for Patient Specific Dosimetry), which 
ran from June 2009 to July 2015.  
Due to the large distances between the nine participating countries (spread across 5 
continents), sending 131I sources to the participants was unfeasible because of the relatively 
short half-life of 131I (8.02 days). 133Ba was used instead due to the longer half-life (10.54 years) 
and similar decay scheme to 131I: the primary γ-ray energy of 131I is 364 keV whilst the primary 
γ-ray energy of 133Ba is 356 keV. The set of sources consisted of four 133Ba epoxy-filled 
poly(methyl methacrylate) cylinders, with nominal volumes of 2 ml, 4 ml, 6 ml and 23 ml. The 
sources were calibrated by the NMI for the United States of America: the National Institute of 
Standards and Technology (NIST) but participants were only informed of the nominal activity. 
The participants therefore calibrated their imaging systems using the smallest source, which 
was small enough to be measured in a radionuclide calibrator in order to obtain an activity 
value.  
The four sources were imaged in a water-filled phantom, and the participants used their local 
calibration measurements to report activities for the sources. The images were also sent to one 
of the authors who performed centralised data analysis. The study demonstrated significant 
variability in quantitative accuracy between participants, but concluded that standardised 
protocols were needed to ensure consistent results. 
 
 
34 
 
2.3.2.3 Quantitative SPECT Imaging: SEL-I-METRY Clinical Trial 
A current phase II clinical trial, called SEL-I-METRY, is underway in the UK and is examining the 
effectiveness of using Selumetinib in patients with thyroid cancer who are iodine-refractory, 
meaning that their thyroid cancer cells no longer take up iodine (74). As discussed in chapter 1, 
the first molecular radiotherapy treatment to obtain FDA approval was the use of 131I to treat 
thyroid disorders. It is generally a very successful therapy, but around 10% of patients (74) who 
receive 131I molecular radiotherapy for thyroid cancer will become iodine-refractory and cannot 
have further 131I therapy. The primary outcome of the trial is to investigate whether Selumetinib 
is successful in re-sensitising thyroid cancer cells to iodine. Patients enrolled on the trial will 
have a 123I SPECT/CT performed to ensure that there is no, or minimal, iodine uptake prior to 
starting Selumetinib. Following 28 days of treatment with Selumtinib, a second 123I SPECT/CT is 
performed. For patients in whom an increased iodine uptake is demonstrated, a further 2 – 3 
SPECT/CT scans are acquired of the patient up to 72 hours after administration of the 123I. These 
patients then receive 131I molecular radiotherapy, with 3 – 4 SPECT/CT scans acquired up to 
144 hours after administration of the 131I. The SPECT/CT scans are used to perform both 
prospective and retrospective dosimetry, and a secondary outcome of the trial is to assess the 
accuracy with which prospective dosimetry predicts the therapeutic absorbed dose. Eight 
hospitals in the UK are enrolled on this trial, with the dosimetry assessments performed 
centrally. This trial therefore required harmonisation between the imaging systems at each 
hospital to ensure that quantitative SPECT/CT data acquired at each hospital is both robust and 
comparable (75). NPL were closely involved with the research team in the development and 
testing of the calibration protocol for this trial to ensure traceability of the final measurements, 
paving the way for similar collaborative partnerships when designing future trials. 
2.3.2.4 Quantitative SPECT Imaging: ENEA 
The Italian NMI, the National Institute of Ionising Radiation Metrology (ENEA), has collaborated 
with a number of Italian hospitals to investigate the quantitative accuracy of 177Lu (76–78) and, 
more recently, 99mTc (79) SPECT/CT imaging.  
The 177Lu work assessed gamma camera calibration methods for quantitative imaging of 177Lu, 
including the choice of energy window (76) and calibration method (76,78). The researchers 
also investigated the accuracy of quantitative imaging of 177Lu when using an advanced vendor-
neutral image reconstruction algorithm, designed specifically for quantitative imaging (77). 
Performing quantitation using only the 208 keV γ-rays yielded superior quantitative accuracy to 
using only the 113 keV γ-rays. Contradictory results were obtained in terms of the optimal 
calibration method: one publication by the research group concluded that the optimal 
calibration method was a 16 ml radioactive sphere in water rather than a point source or a large 
volume source (76). A later paper by the same research group determined that the large volume 
source was a superior calibration method than the 16 ml sphere (78).  
The work performed for 99mTc investigated the accuracy of quantitative imaging when using an 
advanced vendor-specific image reconstruction algorithm designed specifically for quantitative 
imaging in comparison to an advanced vendor-neutral image reconstruction algorithm, also 
designed specifically for quantitative imaging (79). The use of the vendor-specific specific 
algorithm was demonstrated to produce more accurate results than the vendor-neutral 
algorithm. In addition, inhomogeneities were erroneously introduced into the reconstructed 
image when using the vendor-neutral algorithm. 
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2.3.2.5 Quantitative PET Imaging 
Unlike SPECT imaging, there are standardised protocols for quantitative PET imaging.  
To ensure consistency between PET centres, in 2008 the UK PET Research Network set up the 
National Cancer Research Institute PET Core Lab. This lab provides site accreditation for PET 
centres participating in clinical trials by requiring the centres to acquire specified phantom data 
on their PET systems using tightly defined image acquisition protocols. The acquired image data 
must adhere to standards set out by the Core Lab – if not, the centre cannot participate in PET 
clinical trials until their system meets the standards. There is an equivalent accreditation 
scheme for European PET clinical trials, run by the European Association of Nuclear Medicine 
and endorsed by the European Organisation for Research and Treatment of Cancer Imaging 
Group. However, these measurements are not truly metrological, since they are relative 
measurements and are not traceable to an NMI in the way that radionuclide calibrator or 
external beam radiotherapy measurements are.  
In the United States, NIST has worked with several groups involved in PET imaging in order to 
produce published guidelines and standards for use in clinical and pre-clinical PET imaging 
(80,81). 
2.3.3 Metrology in External Beam Radiotherapy 
The concept of metrology and inter-comparison exercises are firmly embedded within the 
external beam radiotherapy community and tolerances on external beam radiotherapy 
equipment are comparable to those for radionuclide calibrators. The tolerance for a field 
instrument radionuclide calibrator of ± 5% for accuracy and ± 1% for repeatability (68) whilst 
the tolerances in the accuracy and precision for a linear accelerator treatment machine used in 
external beam radiotherapy are up to ± 2% (82). It is customary to dispense therapeutic 
radionuclide administrations to within ± 5% (where possible) of the prescribed activity whilst 
in external beam radiotherapy, an absorbed dose of between -5% and +7% of the prescribed 
dose to the treatment volume is acceptable (65). 
NPL provides a range of calibration services for external beam radiotherapy departments. These 
services range from a postal service in which absorbed dose to dosimeters irradiated by the 
linear accelerators is reported, to calibrating the ionisation chambers used by hospitals to verify 
the output of their linear accelerators, to physically sending staff to hospitals to perform 
calibrations directly. 
Inter-comparison exercises are regularly organised within the UK and abroad and participation 
in such exercises are now a routine requirement in order to take part in many radiotherapy 
clinical trials (83). 
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3 Physics of Quantitative Imaging 
This chapter firstly summarises the instrumentation used for Nuclear Medicine and Molecular 
Radiotherapy (section 3.1). Section 3.2 (The Gamma Camera) expands on the information given 
in section 3.1.2 (Single Photon Emission Computed Tomography (SPECT)), regarding the 
physics of gamma interactions relevant for Nuclear Medicine and the design and individual 
components of gamma cameras. The considerations necessary in order to perform quantitative 
imaging of radionuclides on a gamma camera are then discussed in section 3.3 (Quantitative 
Imaging). 
3.1 Instrumentation for Nuclear Medicine and Molecular Radiotherapy 
3.1.1 Radionuclide Calibrator 
The radionuclide calibrator is the first step in the chain for any Nuclear Medicine or Molecular 
Radiotherapy procedure and is used to measure the quantity of radioactivity (usually referred 
to as “activity”) administered to a patient. The unit for activity is Becquerel (Bq) and is the total 
number of radioactive decays per second (s-1) for the measured sample. Typical activities given 
to patients are in the order of MBq for diagnostic procedures and GBq for therapeutic 
procedures (with the exception of α-emitting therapies, in which MBq activities are given). 
The radionuclide calibrator is a very simple piece of equipment consisting of gas-filled 
ionisation chamber connected to a stable high voltage supply and an electrometer (see Figure 4 
for details). They are very reliable and accurate pieces of equipment, and published national 
good practice guidance on the use of this equipment suggests a tolerance in the accuracy of 
± 2% for a secondary standard instrument and ± 5% for a field instrument, and a tolerance in 
the repeatability of ± 0.5% for a secondary standard instrument and ± 1% for a field instrument 
(68).  This compares well to the tolerances in the accuracy and precision for a linear accelerator 
treatment machine used for external beam radiotherapy, of up to ± 2% (82). UK guidance 
relating to the administration of radionuclides for molecular radiotherapy states that is 
customary to dispense therapeutic administrations to within ± 5% of the prescribed activity, 
but that it may only be possible (such as in the case of pre-prepared capsules) or desirable (in 
order to minimise radiation dose to the operator) to dispense to within ± 10% of the prescribed 
activity (84). Again, this compares well to the tolerances in the field of external beam 
radiotherapy where an absorbed dose of between -5% and +7% of the prescribed dose to the 
treatment volume is acceptable (65).  
 
Figure 4. Components of a radionuclide calibrator. Figure copied from reference (68). 
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3.1.2 Single Photon Emission Computed Tomography (SPECT) 
A SPECT system, or gamma camera, is the instrument used to image the distribution of a γ-ray 
emitting radiopharmaceutical within a patient (see Figure 5 for details). It consists of one or 
more large detectors in front of which the patient is positioned. The radiopharmaceutical within 
the patient emits γ-rays isotropically. A percentage of these γ-rays will be emitted towards the 
gamma camera and those travelling parallel to the collimator holes will pass through into the 
scintillation crystal, usually made from thallium-doped sodium iodide: NaI(Tl). The scintillation 
crystal absorbs the γ-ray and emits a light photon in response. The emitted light incident on the 
face of the photomultiplier tubes (PMTs) is converted into an electric pulse and amplified by a 
series of dynodes within the PMT. The total height of this electric pulse, from all PMTs, is 
proportional to the energy of the γ-ray, and if it is within a pre-defined range known as the 
photopeak window (typically set to be the energy peak of the radionuclide ± 7.5% or ± 10%), 
the system accepts it as a primary γ-ray. The amount of light recorded by each PMT is 
proportional to the solid angle between the PMT and the position of the emitted light photon, 
allowing the calculation of the position the light photon was emitted. A combined image of all 
the primary γ-rays detected by the detector is then displayed as two dimensional 
radiopharmaceutical distribution image(s). If a number of two dimensional images are acquired 
at different angles around the patient, then three dimensional images can be reconstructed from 
them. Further details, including information on how the three dimensional images are 
reconstructed, are given in section 3.2 (The Gamma Camera) on page 39. 
  
Figure 5. Components of a gamma camera. The red lines represent the γ-rays emitted from the patient. Copied 
from reference (25). 
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3.1.3 Computed Tomography (CT) 
CT is an imaging modality in which an external radiation source is used to acquire an anatomical 
image of the patient. It is often used in combination with three dimensional Nuclear Medicine 
imaging (SPECT or PET) to enable anatomical localisation of the radiopharmaceutical 
distribution. An x-ray tube is mounted on a rotating gantry opposite a detector and the patient 
is positioned between the two. The x-ray tube generates a narrow beam of x-rays that are 
directed through the body, some of which get attenuated by the soft tissue and bone in the body 
with the remainder reaching the detector array on the far side of the patient. Denser materials 
(such as bone) attenuate a greater proportion of the x-rays than less dense tissues such as air-
filled lung and soft tissue. The gantry rotates around the patient as the patient bed moves 
through the gantry. Images are obtained from all angles and a three dimensional anatomical 
image is reconstructed using the methods described in section 3.2.6.1 (Image Reconstruction) 
on page 48.  
 
Figure 6. Components of a CT system. Copied from reference (25). 
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3.2 The Gamma Camera 
3.2.1 Physics of gamma interactions 
There are three methods by which photons and γ-rays of the energies typically used in Nuclear 
Medicine interact with matter: the photoelectric effect, Compton scattering and pair production. 
The dominant interaction method depends on the energy of the γ-rays. For most gamma camera 
imaging radionuclides (typical γ-ray energies of 100 – 400 keV), the predominant interaction 
method within the patient is Compton scattering. For low energy γ-rays, interactions will be 
predominantly via the photoelectric effect whilst for higher energy γ-rays pair production will 
dominate: 
 
Figure 7. Mass attenuation coefficients for interactions in water. The mass attenuation coefficient of a tissue is 
the rate of energy loss of a photon or γ-ray as it passes through the tissue. The blue dotted line (τ) is the photoelectric 
effect, the pink dashed line (σ) is Compton scattering and the orange dot-dashed line (κ) is pair production. The 
orange line (µm) shows the total mass attenuation coefficient. Copied from reference (25). 
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3.2.1.1 Photoelectric effect 
In photoelectric effect interactions, the energy of a photon or γ-ray is completely absorbed by an 
atom and the absorbed energy is imparted to an orbital electron. The orbital electron is ejected 
from the atom, with an energy (Ep.e.) equal to the difference between the energy of the incident 
photon/γ-ray (Eɣ) and the binding energy of the orbital electron (Eb) (25): 
                       Equation 4 
 
Figure 8. Photoelectric effect. The energy of an incident photon or γ-ray is completely absorbed by an atom, and the 
absorbed energy is imparted to one of the orbiting electrons, which is ejected from the atom. Copied from reference 
(25). 
3.2.1.2 Compton scattering 
In Compton scattering interactions, the incident photon or γ-ray is not absorbed by the atom. 
Instead, it is a collision between the incident photon or γ-ray and an orbital electron, with the 
incident photon/γ-ray having energy (Eɣ) greatly in excess of the binding energy of the electron 
(Eb). Part of the photon/γ-ray energy is transferred to the electron (Eelectron), which is ejected 
from the atom. Due to conservation of energy and momentum, the photon/γ-ray is both 
deflected (conservation of momentum) and has a reduced energy(conservation of energy), with 
the energy, Escatter, dependent on the angle of deflection/scattering (25): 
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                 Equation 5 
The minimum value of Escatter is obtained when the angle of scatter is approximately 0° (i.e. when 
cosθ = 1) and the maximum value occurs when the angle of scatter approaches 180° (i.e. when 
cosθ = -1). 
Due to the conservation of momentum and energy mentioned above, the total energy 
transferred from the incident photon/γ-ray to the ejected electron (Eelectron) is (25): 
                                Equation 6 
The maximum total energy transferred to the ejected electron is therefore (25):  
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Figure 9. Compton scattering. An incident photon or γ-ray transfers some energy to an orbital electron, which is 
ejected from the atom. Due to conservation of energy and momentum, the photon or γ-ray is deflected away from its 
original path, and has a lower energy. Copied from reference (25). 
3.2.1.3 Pair production 
In pair production, the incident photon or γ-ray is absorbed by the atom and its energy is 
converted into a positron-electron pair. Since the energy required to produce a stationary 
positron (Eβ+) or electron (Eβ-) is 511keV, for pair production to occur, the incident photon or 
γ-ray must have a minimum energy (Eɣ) of 1.022 MeV (511 keV x 2). Any energy in excess of 
1.022 MeV is converted into kinetic energy for the positron-electron pair (25): 
                          Equation 8 
The newly created positron then annihilates with a nearby electron and the energy is released 
as a pair of annihilation photons/γ-rays, each of 511 keV, travelling at 180° to each other 
(conservation of momentum). The kinetic energy of the positron (i.e. any energy in excess of 
511 keV) is deposited at the interaction site: 
 
Figure 10. Pair production. An incident photon or γ-ray of 1.022MeV or more is absorbed by an atom and the 
energy is converted into a positron-electron pair. The positron subsequently annihilates with a nearby electron, 
producing a pair of 511keV annihilation photons, travelling at 180° to each other. Copied from reference (25). 
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3.2.1.4 Energy spectra 
An energy spectrum is defined as the intensity of γ-rays, or number of particles, as a function of 
γ-ray or particle energy. As mentioned in section 3.1.2 (Single Photon Emission Computed 
Tomography (SPECT)), in a gamma camera, the energy of the incident γ-ray is determined by 
the pulse height of the electric pulse output by the photomultiplier tubes – see sections 3.2.4 
(Photomultiplier Tubes (PMTs)) and 3.2.5 (Electronics and Signal Processing) for further 
details.  
Gamma energy spectra 
A typical gamma energy spectra for a radionuclide imaged on a gamma camera system consists 
of peak(s) centred around the energy of the γ-rays emitted by the radionuclide (known as 
photopeaks).  
In addition, there is a continuum of lower energy emissions detected by the gamma camera 
which are a result of some of the emitted γ-rays interacting within the body of the patient, or 
within the gamma camera itself. Since these interactions are predominantly due to Compton 
scattering, the continuum is often referred to as the “Compton region”. The edge of this 
continuum is often referred to as the “Compton edge”, and is the maximum energy of the 
electrons ejected during Compton scattering (Equation 7).  
Furthermore, when a γ-ray interacts with the dense lead collimator or lead shielding around the 
detector, causing an inner orbital electron to be ejected from the lead atom, an outer orbital 
electron will fill the vacancy in the inner orbital level and in the process will emit characteristic 
x-rays with energy equal to the difference between the two orbital energy levels. These 
characteristic x-rays will also be detected by the gamma camera – the lead emission lines 
relevant to Nuclear Medicine imaging are at 72 – 75 keV and 84 – 88 keV (85).  
In situations where the γ-emitting radionuclide also emits charged particles, such as β particles, 
bremsstrahlung γ-rays are generated which will contribute to the gamma spectrum. 
Bremsstrahlung γ-rays are created when charged particles are deflected and decelerated by the 
electric field of another charged particle, such as the nucleus of an atom, and the excess energy 
is converted into a γ-ray. The term bremsstrahlung was first used to describe these interactions 
in 1909 by Arnold Sommerfeld (86) and comes from the German words “bremsen” meaning "to 
brake" and “Strahlung” meaning "radiation". However, the bremsstrahlung γ-ray yield is 
generally small in comparison to the primary γ-ray (the γ-rays emitted directly by the 
radionuclide) yield – for 177Lu, Monte Carlo simulations have demonstrated that bremsstrahlung 
γ-rays make up 0.3% of the total number of γ-rays detected by a gamma camera (87). 
A typical gamma camera energy spectra for 177Lu can be seen in Figure 11: 
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Figure 11. Typical gamma camera energy spectra for 177Lu. The black spectra is the total spectra as detected by 
the gamma camera, whilst the red spectra shows only the detected photons that have undergone interactions within 
the patient or gamma camera, predominantly via Compton scattering. The black peaks at 113 and 208 keV (for 177Lu) 
are the true γ-rays as emitted by the radionuclide. The red and black “bump” around 85 keV is due to the 
characteristic lead x-rays emitted due to interactions in the lead collimator – characteristic x-rays are also emitted 
around 75keV, but in this spectra they are not visible above the Compton scattering. The vertical black-solid and 
black-dashed lines illustrate typical photopeak and scatter windows used in gamma camera imaging – the photopeak 
and use of scatter windows are discussed later in this chapter, in section 3.2.5 (Electronics and Signal Processing) and 
section 3.3.4 (Scatter). The bremsstrahlung γ-rays have a negligible contribution to this spectra and so are not visible 
above the Compton scattering. Copied from reference (88). 
Beta energy spectra 
The energy spectra for β-emitting radionuclides is markedly different to that of γ-emitting 
radionuclides: γ-emitting radionuclides have one or more discreet energy peak, whilst for 
β-emitting radionuclides, the energy spectrum is continuous. This is because β particles are 
created by the decay of a neutron in an unstable atomic nucleus into a proton, electron 
(β particle) and anti-neutrino. The excess kinetic energy (Ekinetic) from this decay is split between 
the β particle energy (Eβ) and the anti-neutrino energy (Eν) with each of them having anywhere 
between 0 and Ekinetic keV, such that (25): 
                  Equation 9 
Typical beta energy spectra for five beta-emitting radionuclides, including 177Lu, can be seen in 
Figure 12: 
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Figure 12. Typical beta spectra for five beta-emitting radionuclides. C(E) denotes the relative intensity of the 
beta particles of energy E. Copied from reference (89). 
3.2.2 Collimators 
Lead collimators consist of a lead plate containing a series of holes and the sensitivity and 
spatial resolution of the collimators will depend on the diameter (d) and length (l) of these holes 
plus the thickness (t) of the lead septa separating the holes in addition to the distance between 
the radioactivity and the collimator (x): 
 
 
 
 
 
 
 
 
 
Figure 13. Gamma camera collimator design. Photons travelling perpendicularly to the face of the detector will 
pass through the collimator holes to the crystal (thick black line). In addition, photons travelling approximately 
perpendicularly to the face of the collimator will also pass through the collimator holes (thin black lines). This means 
that photons detected as having passed through the central collimator hole, may actually have originated from 
anywhere along the red dashed line. Most photons that interact with the collimator septa (the black dashed lines) will 
be stopped by the lead septa, but if a photon has sufficient energy then it may pass through to the crystal (“septal 
penetration”).  
source 
t 
d 
l 
x 
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The sensitivity of a collimator is a measure of the number of γ-rays incident on the face of the 
collimator that will pass through to the scintillation crystal. Increasing the diameter (d) and/or 
shortening the length (l) of the collimator holes will allow more γ-rays to pass through, thus 
increasing the sensitivity. However, the trade-off to this is a reduction in the spatial resolution 
since γ-rays from a larger area of the object being imaged will be detected for a given position in 
the crystal. As a result, a standard clinical gamma will tend to use a combination of low-energy 
high-resolution (LEHR) and low-energy general-purpose (LEGP) or low-energy all-purpose 
(LEAP) collimators for routine use. These collimators are optimised for use with 99mTc-based 
radiopharmaceuticals (which emit γ-rays with an energy of 140 keV (90)) and other 
radionuclides that emit γ-rays of energies up to around 160 keV (91). Studies for which a lower 
spatial resolution will yield an acceptable clinical image are performed using LEGP collimators 
and, due to the increased sensitivity, using these collimators allows a reduction in administered 
radioactivity to the patient and/or reduced imaging time. Studies for which higher spatial 
resolution is required are performed using LEHR collimators, and higher activities and/or 
longer imaging times are necessary (25). 
The photons emitted by the radionuclides used for molecular radiotherapy tend to be of higher 
energy than the 140 keV γ-rays emitted by 99mTc radiopharmaceuticals, and so collimators with 
thicker septas are required in order to prevent the γ-rays from penetrating them (“septal 
penetration”).  Longer collimator holes (l) with wider diameters (d) are required in these higher 
energy collimators in order to eliminate γ-rays not travelling perpendicular to the face of the 
detector, whilst at the same time ensuring that the sensitivity of the collimator remains 
sufficient. Medium energy (ME) collimators tend to be optimised for imaging energies up to 
approximately 250 keV (91), such 67Ga, with primary γ-rays emissions of 93, 185 and 300 keV 
(90), 111In, with primary γ-ray emissions of 171 and 245 keV (90) and 177Lu with primary γ-ray 
emissions of 113 and 208 keV (90) whilst high energy (HE) collimators are optimised for higher 
energy γ-ray imaging (91) such as 131I, with γ-ray emissions of 364 keV (90). Typical spatial 
resolution at 10cm from the face of a gamma camera for collimators provided by the main 
manufacturers are outlined in Table 5. 
Manufacturer & 
camera 
GE Optima 640 Siemens Symbia Philips BrightView  
Collimator type LEHR LEGP ME HE LEHR LEAP ME HE LEHR LEGP ME HE 
Spatial 
resolution at 
10cm, mm 
7.4 9.4 9.4 12.0 7.5 9.4 12.5 13.4 7.4 8.9 10.9 12.1 
Table 5. Typical spatial resolution for 3/8” crystal gamma cameras as specified by the manufacturers. Data 
from reference (92–94). 
3.2.3 Crystal 
The γ-rays passing through the collimator enter the thallium-doped sodium iodide, NaI(Tl) 
scintillation crystal. The γ-rays are interact with the crystal, via photoelectric effect, Compton 
scattering or pair production – see section 3.2.1 (P) for further details. When the excited 
electrons produced by these interactions are recombined or de-excited, some of the energy is 
dissipated as visible light. The amount of light produced is proportional to the energy of the 
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γ-ray that caused it. Typically a few hundred to a few thousand light photons are produced for a 
single radiopharmaceutical γ-ray (25).   
3.2.4 Photomultiplier Tubes (PMTs) 
PMTs are used to amplify the very weak light pulse produced in the crystal and convert it into 
an electrical current. The light photon strikes the bialkali compound coated glass entrance 
window of the PMT. Bialkali compounds are photoemissive and eject electrons when struck by 
light photons. Typically 1 – 3 electrons are produced for every 10 light photons striking the 
photoemissive compound (25). A stable high voltage supply is held across the length of the PMT, 
with the entrance window held at a negative voltage and an anode at the far end of the PMT held 
at a positive voltage. Between the entrance window and the anode, there are a number, typically 
9 – 12 (25), of dynodes each held at 50 – 150 V higher than the previous dynode (25), with the 
exception of the first dynode which is held at 200 – 400 V higher than the entrance window. The 
negatively charged electrons are accelerated towards the positively charged dynodes, and each 
dynode is curved to focus the electrons towards the next dynode. The dynodes are coated with a 
secondary emissive compound that ejects electrons when struck by an incoming electron. 
Typically 3 – 6 electrons are ejected from a dynode for every incoming electron (25) and the 
number ejected is proportional to the energy of the incoming electron and the voltage difference 
between the two dynodes (which causes acceleration of the incoming electrons). The 
amplification of the number of electrons generates a relatively large electrical current at the 
anode, which is proportional to the energy of the incident light photon (and hence, also 
proportional to the energy of the original γ-ray).  
 
Figure 14. Components of a photomultiplier tube (PMT). Copied from reference (25). 
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3.2.5 Electronics and Signal Processing 
The electrical signals from the PMTs are then processed in order to produce a two dimensional 
image of the distribution of the γ-rays incident on the crystal. The light photons emitted in the 
crystal due to interaction of a γ-ray will be detected, and amplified, by a number of PMTs 
positioned around the location of the interaction. The amount of light detected by a single PMT 
is inversely proportional to the distance between the interaction site and the centre of the PMT. 
Therefore, the calculations shown in Figure 15 are performed to identify the location of the 
γ-ray interaction in the crystal:  
 
Figure 15. Gamma camera signal processing. Copied from reference (25). 
The signal from each of the PMTs that detected the light photons are summed to give a total 
electrical current which is proportional to energy of the original γ-ray. If the energy of the 
original γ-ray is within a pre-defined range, known as the photopeak window (typically set to be 
the energy peak of the radionuclide ±7.5% or ±10%), the system accepts it as a primary γ-ray – 
see Figure 11 for an example spectrum, including a typical choice of photopeak window (which 
is this instance is set to 208 keV ±7.5%). A combined image of all the primary γ-rays detected by 
the gamma camera is then displayed as the acquired radiopharmaceutical distribution image.  
3.2.6 Single Photon Emission Computed Tomography (SPECT) 
A planar image is a two dimensional image of the three dimensional activity distribution within 
a patient. In reducing a three dimensional distribution to a two dimensional image, depth 
information is inevitably lost. Furthermore, the distribution will be affected both by 
under/overlying tissue activity and by inhomogeneous attenuation of the activity due to 
variations in the thickness of non-active overlying tissue. This loss of depth information can be 
rectified by using tomographic imaging techniques (15). Tomographic imaging involves 
acquiring a number of planar image frames (projections) at different angles around the patient. 
Assuming no patient motion or activity re-distribution occurs during the acquisition period, 
mathematical algorithms can be used to generate a three dimensional image of the activity 
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distribution. SPECT cameras are now available with a combined CT scanner, known as a 
SPECT/CT gamma camera (17), which allows the three dimensional radiopharmaceutical 
distribution image to be co-registered with an anatomical CT image data, allowing clinicians to 
localise areas of radiopharmaceutical uptake with patient anatomy. 
3.2.6.1 Image Reconstruction 
There are two main methods of reconstructing tomographic images – iteratively or using 
filtered backprojection (FBP). Historically, FBP (95) was the method used for image 
reconstruction as it was quick and simple to perform but as computer technology has developed 
to enable faster processing times, iterative reconstruction is becoming the method of choice, 
due to the enhanced resolution (96), and is therefore the reconstruction technique used by the 
author.  
In FBP (95), each two dimensional projection image is divided into a set of parallel intensity 
profiles – see image A in Figure 16. The value of each element on an intensity profile represents 
the total number of photons detected at that point in the detector. The intensity profiles are 
stored in a sinogram, which consists of all the intensity profiles for every projection. A blank 
two dimensional image grid is created and the intensity profiles are “backprojected” across the 
blank image grid. The number of counts recorded in each element of an intensity profile is 
distributed uniformly between all the pixels on the corresponding backprojection path on the 
two dimensional image grid – see image B (top row) in Figure 16. Summing the backprojections 
of every element in each intensity profile gives an approximation of the activity distribution 
within the scanned slice and the more projections and intensity profiles used for the 
reconstruction, the more correct the final reconstructed image is – see image B (bottom row) in 
Figure 16. As can be seen in image B (bottom row) in Figure 16, performing image 
reconstruction in this way generates images with a high level of blurring as the counts are 
distributed uniformly across all pixels on a backprojection path. To reduce this blurring, a ramp 
filter is applied to the data to remove the low frequency data that causes the blurring. Filters are 
applied using Fourier transforms: a one dimensional Fourier transform is performed for the 
data from each element in an intensity profile. A ramp filter is applied to the Fourier transforms 
and then an inverse Fourier transform performed to produce filtered profiles. The filtered 
profiles are then backprojected to the blank image grid. However, the downside of the ramp 
filter is that it also enhances any high frequency noise in the image (see section 3.3.3  (Noise) for 
details on image noise). Ramp filters are therefore generally used in conjunction with a low pass 
filter to reduce high frequency noise. Figure 16 demonstrates the blurring that would be present 
when backprojection image reconstruction is performed without filtering. Figure 17 illustrates 
how FBP image reconstruction is performed, and the reduction in blurring compared to 
backprojection image reconstruction without filtering. 
49 
 
 
Figure 16. Backprojection image reconstruction. A: The two dimensional image data for each projection is divided 
into a number of parallel intensity projections. B (top row): The data from each element in an intensity profile is 
backprojected across a blank image matrix. B (bottom row): When this is performed at multiple angles, and the 
backprojections are combined, a blurred image of the original activity distribution is obtained. Copied from reference 
(25). 
 
Figure 17. Filtered backprojection (FBP) image reconstruction. The application of a ramp filter in Fourier space 
reduces the blurring in the reconstructed image (bottom right). In practice, a low pass filter is often used in 
conjunction with a ramp filter to also reduce the high frequency noise in the reconstructed image. Copied from 
reference (25). 
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When using iterative reconstruction, an initial estimation of the image is made (e.g. an image of 
uniform intensity). The planar image projections and sinogram that would have resulted from 
this initial estimate are created using forward projection and compared to the real sinogram. 
The difference between the estimated and real sinogram is used to adjust the estimated image 
to achieve closer agreement. This process, termed Maximum Likelihood Expectation 
Maximisation, is repeated until the estimated and real sinograms are in close agreement and 
further iterations produce negligible improvement, i.e. convergence is obtained (97). A modified 
version of this technique was proposed in 1994 to speed up the processing time – the Ordered 
Subsets Expectation Maximisation (OSEM) technique (98). In this method, the set of projections 
is divided into subsets, with an equal number of projections in each subset (e.g. a dataset with 
32 projections could be divided into 4 subsets, each containing 8 projections) and each iteration 
is performed with one subset, allowing more rapid convergence. The OSEM method is now the 
most commonly used iterative reconstruction technique in Nuclear Medicine (96). An 
illustration of how iterative reconstruction is performed is shown in Figure 18.  
 
Figure 18. Iterative reconstruction. Copied from reference (25). 
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3.3 Quantitative Imaging 
Quantitative imaging requires that the number and distribution of the counts in the 
reconstructed image is a true representation of the activity distribution within the patient. In a 
perfect system, the relationship between the detected counts per second (cps) in the image and 
the true activity (in MBq) in any region of the patient would be linear. However, in reality there 
are a number of factors in Nuclear Medicine imaging that can cause the count distribution in the 
reconstructed image to differ from the true activity distribution, and they are discussed in this 
section: 
3.3.1 Deadtime  
At high count rates, large counting losses can occur due to the deadtime, τ, of the gamma 
camera. τ is the length of time it takes the system to process each event (each individual photon 
emitted in the crystal). When two (or more) events occur within time τ, the gamma camera is 
unable to process both and so count losses occur. The components within counting systems can 
be either paralysable or non-paralysable. Gamma cameras consist of multiple components, each 
of which will have have its own deadtime – in most cases one component will dominate and the 
behaviour of that component can be used to describe the behaviour of the entire system. In a 
non-paralysable system, if an event occurs during the deadtime of the previous event, it is 
ignored by the system. Once the deadtime of the first event has elapsed, the system is able to 
detect and process the next event. However, most gamma camera systems contain components 
that behave as paralysable systems (25), meaning that each event introduces a deadtime 
regardless of whether the event is detected, effectively increasing the length of the deadtime. In 
addition, if a gamma camera has paralysable and non-paralysable components with similar 
deadtime, then both components will contribute to the total deadtime losses and the gamma 
camera will behave in a manner that is a hybrid of paralysable and non-paralysable (25). Figure 
19 illustrates the difference between paralysable and non-paralysable deadtime. 
 
Figure 19. Paralysable and non-paralysable deadtime. In paralysable systems, events are lost if they occur within 
time τ of any previous event, whereas in non-paralysable sytems, events are only lost if they occur within time τ of a 
previously detected event. Copied from reference (25). 
This means that as count rates increase such that deadtime effects occur, there is no longer a 
linear relationship between observed/detected cps, Ro, and true cps (or MBq), Rt, see Figure 20: 
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Figure 20. Effect of paralysable and non-paralysable deadtime on relationship between detected (observed) 
and true cps. The purple dashed line demonstrates the linear relationship between observed and true counts in the 
absence of deadtime whilst the grean line demonstrates the relationship for a paralysable system, such as a typical 
gamma camera. Copied from reference (25) 
 The relationship between Ro and Rt can be calculated using the following equations (25): 
                  
                Equation 10 
                  
  
     
            Equation 11 
If a gamma camera behaves in a hybrid manner, and τnon-paralysable > τparalysable, then the above 
equations can be combined to approximate the behaviour of the system (99): 
         
  
 
               (
                
            
  )              
         Equation 12 
Figure 21 illustrates this behaviour in graphical form: 
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Figure 21. Deadtime for paralysable, non-paralysable and hybrid paralysable/non-paralysable counting 
system. The dashed line is for a system or component with paralysable deadtime equal to 10 µs, the dash-dotted line 
is a system or component with non-paralyable deadtime equal to 20 µs and the solid line is a counting system 
consisting of the two previous components. Copied from reference (99). 
Whilst a relationship can be plotted between detected and true cps, for gamma cameras that 
behave as paralysable or hybrid systems the “fold-over” in the deadtime curve means that there 
is not a single unique solution to the true counts for a given detected cps. This means that, even 
with deadtime corrections, there is a maximum activity, beyond which quantitative imaging 
cannot be performed.  
A number of authors have investigated deadtime effects on gamma cameras, predominantly for 
99mTc, but also for 131I and 177Lu, and the results have been summarised in Table 6. All authors 
concluded that choice of energy window width and scattering material affect the deadtime 
behaviour, and so if deadtime corrections are to be performed on clinical images, the deadtime 
measurements must be performed in a manner that matches the clinical setting as closely as 
possible.  
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Author Year Gamma camera 
make 
Gamma camera 
model 
Radionuclide Deadtime behaviour 
Sorenson (99) 1975 
Searle 
Radiographics 
Pho/Gamma 
III(HP) 
99mTc 
Hybrid 
131I 
Delpon et al. 
(100) 
2002 GE DST-Xli 131I Paralysable 
Beauregard et 
al. (101) 
2011 Siemens Symbia T6 177Lu Paralysable 
Elschot et al. 
(102) 
2011 Philips Forte 99mTc Paralysable 
Guirado et al. 
(103) 
2012 
Siemens 
Symbia 
99mTc 
Either model can be 
used up to 200 kcps * 
Orbit Non-paralysable 
Picker Axis Paralysable 
Silosky et al. 
(104) 
2013 
Siemens Symbia 
99mTc 
Paralysable up to 300 
– 400kcps * 
Philips Brightview 
GE Millenium MG 
Uribe et al. 
(105) 
2018 Siemens Symbia T 177Lu Paralysable 
Gregory et al. 
(75) 
2019 
GE 
Optima 640 & 
Discovery 670 
131I 
Paralysable 
Siemens Intevo, T2 & T16 
Either model can be 
used 
Ryu et al. (106) 2019 Siemens Intevo 
99mTc 
177Lu 
Hybrid 
*Beyond the stated count rates, the behaviour of the gamma cameras deviated from the specified deadtime model(s) 
Table 6. Deadtime behaviour for gamma cameras. Recent published data regarding deadtime behaviour of clinical 
gamma cameras, plus the original publication by Sorenson introducing the idea of gamma cameras behaving in a 
hybrid manner of paralysable-non-paralysable systems.  
The most commonly used method to correct SPECT images for deadtime effects is to perform 
cps measurements on the gamma camera with known quantities of activity of the radionuclide 
of interest to obtain a deadtime curve. Fitting a curve to the data will provide a relationship 
between true cps and detected cps. These measurements are performed in conditions that have 
similar scattering properties to that seen within a patient – usually either performed with a 
large volume homogenous active solution (107) or a small volume active solution encased 
within a large volume phantom filled with solid acrylic or water (108). Water and acrylic are 
used since they both have similar scatter properties to the soft tissue within a patient. Once the 
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relationship between detected and true counts is obtained, then for each detected cps the true 
cps can be calculated (and hence a correction factor by which the detected cps must be 
multiplied in order to yield the true cps).  
The acquired patient data can then be corrected for deadtime effects by multiplying the total 
number of counts in each image pixel by the appropriate correction factor. There is not a clear 
consensus on how to apply this correction to acquired SPECT data – some authors suggest 
applying a single correction factor to the reconstructed SPECT data (75,101,105,107), whilst 
others recommend applying a correction factor to each planar image projection prior to 
reconstruction (88). 
Alternatively, other authors perform deadtime measurements as part of the image acquisition 
process (109,110). In this situation a small point source of the same radionuclide as that being 
imaged is attached to the gamma camera detector at the edge of the imaging field of view (such 
that it is outside the patient outline in each tomographic imaging projection). A second set of 
images are acquired without the patient present, to establish the true cps for the point source in 
the absence of deadtime effects due to the active patient. A region of interest is drawn around 
the point source and the deadtime correction factor for each imaging projection is calculated 
where the deadtime correction factor is the ratio of the point source cps without the patient 
present to the point source cps in the patient images. 
3.3.2 Partial Volume Effect  
The limited spatial resolution of a gamma camera gives rise to the Partial Volume Effect (PVE), 
where small “hot” (areas of high activity) or “cold” (areas of low activity) regions in SPECT 
images that are of the order of the resolution limit of the gamma camera become “blurred out” 
(25). This results in hot regions in a cooler background (such as tumours) appearing to contain 
a lower concentration of radioactivity than is true, and cold regions in a warm background (such 
as a dead, or necrotic, core of a tumour) appearing to contain radioactivity when they do not. 
This effect is often described as “spill-in” (where cold regions appear more active than they are) 
or “spill-out” (where hot regions appear less active than they are) of counts. This loss or gain of 
counts means that the images are no longer quantitative, since some of the counts are attributed 
to the wrong pixels, and the effect is illustrated in Figure 22. 
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Figure 22. Partial volume effect – illustrating the spill-out effect. The top row shows the physical size of 8 
cylinders (diameters ranging from 6 – 48 mm), with equal activity concentration. The middle row is a simulation of 
the images that would be acquired on a typical SPECT system. The bottom row shows the count profile for a line 
drawn through the centre of the eight cylinder on the SPECT image. Although the activity concentration is equal in all 
the cylinders, the apparent activity concentration (the maximum counts per pixel) reduces as the cylinder size 
approaches the resolution of the system. Counts are also obtained outside the physical size of the cylinders. In the 
situation of spill-in, the apparent activity contration would be higher than the true value. Copied from reference (25). 
The apparent loss (or gain) of activity concentration in an object can be compensated for by 
applying an appropriate recovery coefficient (111). The recovery coefficient of an object is the 
ratio of the apparent activity concentration to the true activity concentration (112): 
                     (  )  
                               
                           
 Equation 13 
A recovery curve is plotted by measuring recovery coefficients for a range of different sized 
radiouclide-filled objects of known activity, such as spheres (106,113–116), cylinders (75,107) 
or geometries that represent typical patient anatomies (115,117), as shown in Figure 23: 
 
Figure 23. A recovery curve for performing partial volume corrections. The solid line is the curve fitted to the 
data points, and the dashed lines are the upper and limits of the 95% confidence interval of the fitted curve.  Copied 
from reference (118). 
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The recovery curve is only valid for the clinical situation in which it was acquired. Generally, 
this is performed with active volumes imaged in a cold, non-active background (75,113). Some 
authors acquire a number of recovery curves for varying volume-to-background activity 
concentration ratios (113–115). In situations where non-active regions in active areas (such as 
a necrotic core of a tumour) are expected, a recovery curve would need to be acquired for non-
active volumes in an active background, in order to correct for spill-in. 
From the recovery curve, a recovery coefficient (RC) can be obtained for a given object size. The 
true activity concentration in the object can then be calculated by rearranging Equation 13: 
                            
                               
                    (  )
  Equation 14 
3.3.3 Noise  
Low count SPECT images typically have a speckled appearance due to the random noise in the 
image. This noise is due to the random nature of the radioactive source – that is the randomly 
varying number of radioactive decays per second. The noise in the image can be assumed to 
follow a Poisson distribution, and therefore the uncertainty in a single measurement, containing 
a total of N counts, is √  (25). Hence, the greater the number of counts in the image, the smaller 
the percentage uncertainty. As discussed previously in section 3.2.6.1 on page 48, the random 
noise within the image can be enhanced or suppressed by applying filters either within the 
reconstruction algorithm (for FBP reconstruction) or to the final image after reconstruction (for 
iterative reconstruction). Increasing the number of iterations used in iterative reconstruction  
results in increased random noise in the image (119). 
Since random noise is dependent on the total number of counts, it is also affected by the choice 
of matrix size (120). If the same total number of counts is acquired for a 128 x 128 matrix and a 
256 x 256 matrix, the mean count density per pixel in the 256 x 256 matrix will be 25% of the 
mean count density per pixel in the 128 x 128 matrix as the image contains 4 times more pixels. 
This reduction in count density will result in an increase in random noise.   
Performing scatter correction using scatter windows is a further method by which the noise 
levels in an image can be changed – this is discussed in the next section (section 3.3.4 on page 
58). 
Noise can also be structured – which refers to non-random variations in the count density in the 
image (25). In SPECT imaging, this is generally caused by non-uniformities in the gamma 
camera images, or artefacts introduced during the reconstruction algorithm. Non-uniformities 
in the gamma camera images occur due to the slight variations in response to radioactivity 
across the face of the gamma camera and is a normal feature of a gamma camera.  In particular, 
uniformity defects can cause ring artefacts in the reconstructed image, where the image 
contains a ring of apparent activity, or lack of activity, in the object being imaged (121). 
Artefacts introduced during the reconstruction algorithm are often due to an inadequate 
number of projection angles (25), which can cause streaking artefacts across the reconstructed 
image if using FBP reconstruction or loss of spatial resolution if using OSEM reconstruction. A 
second form of ring artefact, known as the Gibbs ring artefact, can be introduced during image 
reconstruction if there are sharp changes in activity distribution, such as high activity 
concentration urine in the bladder adjacent to low activity concentration abdominal soft tissue. 
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This is because the back-projection part of image reconstruction is performed in Fourier space, 
and if the Fourier series does not have a sufficient number of high frequency terms it is unable 
to approximate the sharp edges (122). Resolution recovery methods (see section 3.3.6 on page 
60 for details) can introduce textured noise in the reconstructed images as they tend to 
correlate the midfrequency noise (123). 
3.3.4 Scatter  
If emitted γ-rays are scattered within the patient body or collimator, but still retain an energy 
that is within the photopeak peak window, then they will be detected and incorrectly assumed 
to have been emitted from the direction in which they are travelling. This will result in a 
detected cps for the patient that is higher than the true cps. For 99mTc, when the standard 
photopeak window width of 140 keV ± 10% is used, up to 30% of the photons detected in the 
window are due to scatter (124). The most commonly used method to correct for scatter is the 
triple energy window (TEW) technique (125) where slim scatter windows are set up above and 
below the photopeak window, referred to as the upper and lower scatter windows respectively. 
A trapezoidal approximation is used to calculate the number of primary photons in the 
photopeak, Cprimary, using the following equation: 
                             (
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    Equation 15 
where Cphotopeak, Cupper and Clower are the number of photons detected in the photopeak window, 
the upper scatter window and the lower scatter window respectively and Wphotopeak, Wupper and 
Wlower are the total widths (in %) of the photopeak window, the upper scatter window and the 
lower scatter window respectively. See Figure 24 for illustration of the scatter windows used to 
perform triple energy window scatter correction: 
 
Figure 24. Scatter windows used for triple energy window correction for 131I. Copied from reference (126). 
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The subtraction of slim scatter windows (containing relatively few counts, and so a high amount 
of random noise) is liable to introduce noise into the scatter corrected data. Therefore, for 
radionuclides that do not have many, or any, photon emissions at energies higher than the 
energy being imaged, the upper scatter window is sometimes not used, and instead a wider 
Clower will be used: this technique is called dual energy window scatter correction (109). 
Another commonly used scatter estimation technique is referred to as effective scatter source 
estimation (ESSE) which uses iterative techniques to estimate the scatter. In this method, an 
estimate of the activity distribution is made from an attenuation map produced from the CT 
data (see next section) and a previously derived scatter response function for the system. The 
planar image projections that would have resulted from this initial estimate are forward 
projected, compared to the true projections, and the estimated scatter updated accordingly 
(127). See section 3.2.6.1 (Image Reconstruction) and Figure 18 for details on the iterative 
process. 
A third commonly used scatter correction technique is to use Monte Carlo simulations to model 
all the possible photon interactions within the patient and estimate the scatter component. This 
is a computationally intensive method (127), but is becoming more popular as computing 
capacity increases. 
There is no general consensus as to which scatter correction is the preferred option, and most 
users will be constrained to using whichever of these choices has been implemented by the 
manufacturers of the equipment or software used in their department. In recent years, Siemens 
and GE have introduced scatter-window based scatter corrections into their gamma camera 
reconstruction software (128), whilst Philips opted for ESSE scatter correction (128). Hermes 
(Hermes Medical Solutions, Stockholm, Sweden), a provider of a widely-used vendor neutral 
reconstruction software, use Monte-Carlo based scatter correction (129). 
Currently available guidance for quantitative imaging steers clear of explicitly recommending, 
or otherwise, the use of scatter correction and the choice as to whether to incorporate it or not 
is left to the discretion of the user (88,126,130). Nevertheless, the recent published research all 
performed scatter correction as part of the SPECT image reconstruction 
(21,75,76,101,113,117,131–134). 
3.3.5 Attenuation  
The soft tissue and bone in the body of a patient will attenuate the emitted γ-rays, and this effect 
is more significant for larger patients or in anatomical regions with large amounts of bone (25) 
since the greater the volume or density of the tissue through which the γ-rays must pass in 
order to reach the detector, the greater the chance of them being attenuated in the process. This 
means that the total detected cps for a patient will be reduced from the true cps since some of 
the emitted γ-rays will be attenuated within the body and not be detected. Attenuation 
correction is usually performed using the CT data acquired as part of SPECT/CT imaging (25). 
The pixel values in CT images are expressed in terms of Hounsfield units (HU) which are defined 
in terms of the linear attenuation coefficient of the tissue in the pixel, such that water has a 
value of 0 HU and air has a value of -1000 HU (25). Figure 25 demonstrates a plot of the typical 
bilinear relationship between linear attenuation coefficient and CT number for a 
99mTc-radiopharmaceutical (photon energy = 140 keV) imaged using a peak x-ray energy of 
60 
 
140 kV. The plot is bilinear since in materials with high atomic numbers, such as bone, there is a 
high probability of photoelectric effect interactions whilst for materials of lower atomic 
numbers, such as soft tissue, water and air, interactions are predominantly via Compton 
scattering. The exact slope and intercept of the bilinear plot varies according to radionuclide 
γ-ray emission energy and x-ray energy, but is tabulated within the gamma camera system. The 
bilinear plot is used to convert the HU value in each pixel in the CT data into a linear attenuation 
coefficient for the radionuclide being imaged – this new image is referred to as an attenuation 
map. This attenuation map is incorporated into the reconstruction process to compute the 
attenuation correction factors to apply to the image data based on the probability of attenuation 
of the γ-ray in the patient body between the point of emission and the gamma camera detector.   
 
Figure 25. Linear attenuation coefficient. Plot of linear attenuation coefficient at 140 keV (the energy of 99mTc) 
versus CT number in Hounsfield units for a peak x-ray energy of 140 kV for soft tissues, air, water, and bone. Copied 
from reference (135). 
3.3.6 Depth-dependent spatial resolution 
The spatial resolution of a gamma camera is proportional to the distance from point of 
emission of a γ-ray to the surface of the collimator (25). Therefore, as the distance between 
the face of the collimator and the location of the radiopharmaceutical in the patient body 
increases, there is a loss in spatial resolution. Since partial volume effects are encountered 
for hot or cold regions that are of the order of the resolution limit of the camera, any 
reduction in spatial resolution will worsen the partial volume effect encountered in the 
images. Conversely, improving the depth-dependent spatial resolution will reduce the 
partial volume effect, meaning that the activity in smaller volumes can be resolved without 
any partial volume effects reducing, or increasing, the apparent activity. Prior to 
commercially available methods to correct for this effect, Kim et al. (136) used computer 
simulations to demonstrate that the effect of depth-dependent spatial resolution was the 
predominant contributing factor to reduction in quantitative and qualitative accuracy in 
SPECT imaging as other effects were either smaller in magnitude, such as noise and scatter, 
or able to be corrected with reasonable accuracy, such as attenuation. 
 
The modern SPECT/CT systems available to purchase now usually have the optional ability 
to perform resolution recovery, RR, within the reconstruction algorithm (96). RR models 
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the influence of the geometry of the collimator on the spatial resolution with varying 
distance from the radiopharmaceutical within the OSEM reconstruction algorithm (137).  
 
There is very little published work comparing the effect of RR algorithms on SPECT imaging 
against the results obtained in the absence of performing RR – most published work is 
instead either performed with or without RR. Knoll et al. (138) demonstrated that the use of 
RR yielded an improvement in image resolution and contrast when incorporated into OSEM 
image reconstruction for 99mTc SPECT imaging. Onishi et al. (139) showed that OSEM+RR 
reconstruction improved the quantitative accuracy of 99mTc SPECT imaging in comparison 
to both OSEM and FBP reconstruction performed without RR but for spheres of diameters 
smaller than 30mm, an overestimation of the counts was encountered when OSEM+RR was 
used due to the creation of Gibbs ring artefacts (discussed in section 3.3.3) as a result of the 
enhanced edge definition 
 
A number of authors (140–146) have compared the use of OSEM+RR reconstruction to the 
use of FBP reconstruction without RR and concluded that the use of OSEM+RR 
reconstruction gave improved image resolution compared to FBP reconstruction without 
RR. Ismail and Mansor (144) showed that, for 99mTc, the use of OSEM+RR reconstruction 
gave enhanced image resolution and quantitative accuracy compared to FBP reconstruction 
without RR. The results obtained by Gilland et al. (145) were slightly different: they 
demonstrated an improvement in the quantitative accuracy for regions not adjacent to 
sharp changes in activity concentration when using OSEM+RR but for regions with these 
sharp changes, they observed visible Gibb ring artefacts that reduced the quantitative 
accuracy to below that obtained with FBP reconstruction. Other authors have observed the 
same ring artefacts: Liu and Farncombe (147) observed it when imaging 131I whilst Seret et 
al. (148) demonstrated the same effect when imaging 99mTc. 
 
3.3.7 Orbit type 
There are two detector orbit types that can be used for SPECT imaging: circular and 
contoured. For a circular orbit, the radius of the detector heads remains constant 
throughout the imaging process whilst for the contoured orbit the detector heads move as 
close as possible to the patient for each projection acquisition. Some camera systems 
perform elliptical orbits as “pseudo” contoured orbits, where the imaging staff set the 
minimum radius in the transverse and sagittal planes and the camera images in a smooth 
elliptical motion in order to pass more closely to the front and back of the patient, whilst 
moving wide enough to pass around the sides of the patient (or the imaging bed, if that is 
wider than the patient). If depth-dependent spatial resolution corrections are performed 
correctly, then the use of contoured orbits will yield an improved spatial resolution 
compared to circular orbits (123). However, due to the constantly changing radius of the 
detector heads, if these spatial resolution corrections are not applied correctly then the use 
of a contoured orbit may instead result in decreased spatial resolution (149). As discussed 
in the previous section, an improvement in spatial resolution will decrease the partial 
volume effect and vice versa. 
 
3.3.8 Reconstruction 
As mentioned in section 3.2.6.1 (Image Reconstruction), iterative reconstruction methods 
(specifically OSEM) are typically used to reconstruct the image data. In theory, if sufficient 
iterations are performed and all the effects discussed above are modelled correctly, this 
technique has the potential to produce quantitative images. However, when choosing the 
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reconstruction parameters (including post-reconstruction filtering), there is a trade-off between 
spatial resolution and noise, both of which increase with increasing iterations. There is a point 
at which convergence in the images is obtained, and performing further reconstruction 
iterations does not improve the spatial resolution or increase the number of recovered counts in 
the data but does continue to increase the noise.  Therefore, when performing quantitative 
imaging, it is common to establish the number of iterations (or iterations and subsets for OSEM 
reconstruction, often referred to as “updates”) at which approximate convergence occurs and 
use that number of updates for patient image reconstruction (150–152). Generally, authors 
have reported that a minimum of 50 updates should be used, as this yields convergence in small 
volumes whilst minimising image noise (76,116,150). 
Since the use of higher numbers of iterations/subsets increases the noise level in the 
reconstructed images, post-reconstruction filters are often applied to data. These filters smooth 
the images, removing some of the noise but also altering the counts in the image. Therefore, 
whilst post-reconstruction filtering can produce images that are more useful for clinical, 
qualitative, assessment authors generally recommended that, for quantitative imaging 
purposes, post-reconstruction filters are not applied (138,153).  
3.3.9 Image Segmentation 
In order to obtain count data from patient images, the volume for which the count data is 
desired must be segmented. This entails adding an outline around the volume of interest – all 
pixels included within this outline are considered to be part of the volume of interest and all 
pixels outside this volume are disregarded. 
Image segmentation can be performed on either the SPECT image or the CT image and is usually 
performed manually or using a thresholding or edge detection algorithm. The choice of which 
image to use is partially guided by what structure is to be segmented. For structures that are 
visible on CT, the better resolution of the CT images will allow for more accurate volume 
segmentation (150). However, soft tissues all have very similar CT properties and it is often 
hard to distinguish the outline of a radiopharmaceutical-avid structure on the CT image. In these 
situations it is often preferable to segment the volumes on the SPECT image (154).  
Manual segmentation involves the user segmenting the volume either free-hand or using some 
pre-defined shapes available within the gamma camera processing workstation, such as spheres 
and ellipses.  
When using thresholding algorithms, the user (fixed thresholding) or software (automated 
thresholding) specifies a threshold – this can be specified globally (for the entire image) or 
locally (for a particular region in the image), and as an absolute or relative (%) threshold value 
(154). All pixels in the image (for global thresholds) or in the region of the image selected (for 
local thresholds) with values higher than the specified threshold are included in the segmented 
volume(s).  
Edge detection algorithms are used to identify sharp differences in pixel values of neighbouring 
pixels (155).  
These techniques can also be used in conjunction with model-based algorithms, in which 
anatomical information for a patient population is used to guide the initial image segmentation. 
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In the clinical setting, a combination of the above techniques are often used, where the 
preliminary segmentation may be done using a rapid automated algorithm, before being 
reviewed and adjusted manually. 
In a bid to reduce partial volume effects, users sometimes choose to expand the true segmented 
volume (based on CT or SPECT data) in order to encompass the majority of the “spill-out” 
counts from the volume (156). 
There is no clear consensus as to which is the preferable option to use, with guidance 
documents (88,126,130,150,154) leaving the choice to the user. Gustafsson et al. (157) 
concluded that the use of an automated thresholding on the SPECT or CT data resulted in more 
accurate volumes than the use of fixed thresholding for volumes larger than 10cm3 at early time 
points, while at later time points the fixed threshold was more accurate – for smaller volumes, 
all thresholding methods performed poorly. Uribe et al. (134) concluded that both fixed 
thresholding and CT-based manual segmentation performed poorly, with automated 
thresholding producing more accurate results, although this method failed in situations of 
non-uniform activity concentration. Hughes et al. (158) segmented on the SPECT data and 
reported that automated thresholding gave more accurate results than fixed thresholding. 
3.3.10 Calibration technique 
The final step in quantitative imaging is to convert the number of counts in an image, or region 
of image, into activity or activity concentration. This is performed by calculating a calibration 
factor specific to the camera, radionuclide and image segmentation and reconstruction 
parameters used for the image in question. Calibration factors are calculated by imaging an 
object or phantom of accurately-known activity or activity concentration, using the same 
parameters as for the image to be quantified, and obtaining cps values for the resultant image, 
or region within the image. Since the activity/activity concentration is accurately known – a 
relationship can be calculated between activity/activity concentration and the cps. Calibration 
factors are generally stated in terms of cps/MBq (for activity) or cps/MBq/ml (for activity 
concentration). This relationship can then be used to calculate the activity in any image 
acquired with the same camera, radionuclide and image segmentation and reconstruction 
parameters: 
         
            
                  
    Equation 16 
There is no clear consensus as to the optimal calibration method to use for quantitative 
SPECT/CT imaging. The IAEA Human Health Report No 9 on quantitative Nuclear Medicine 
imaging (150) advises a SPECT acquisition(s) be performed, that is at least partially 
representative of the images to which the calibration factor will be applied. The MIRD pamphlet 
23 on quantitative SPECT (88) suggests that calibration can be performed in one of two ways. 
The first option is a SPECT acquisition representative of the scatter and attenuation likely to be 
seen in a patient, and the authors suggest the use of active spheres in a water-filled phantom or 
an active large volume phantom. The second option, in situations where the user is confident 
that the SPECT data is “reconstructed with high accuracy, including corrections for scatter and 
attenuation”, is to perform a planar acquisition, and the authors suggest a point source or Petri 
dish be used. A follow-on MIRD pamphlet, number 26, on quantitative SPECT for 177Lu (130) 
which was written in conjunction with the European Association of Nuclear Medicine, also 
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suggested planar imaging could be used in the same scenario, and suggested that a point source 
be used for the planar imaging, or a large volume phantom could be used for a SPECT 
acquisition. 
Two research group have previously compared the accuracy of calibration methods for 
quantitative 177Lu SPECT/CT imaging: d’Arienzo et al. in 2016 and 2017 (76,78) and Uribe et al. 
(134) in 2017.  
D’Arienzo et al. compared four calibration methods (76): a point source (planar image), a 16 ml 
sphere in air (SPECT), a 16 ml sphere in water (SPECT) and a large volume phantom (SPECT). 
The authors concluded that the 16 ml sphere in water was the optimal calibration method, with 
the point source performing the worst due to lack of correction for scatter and attenuation. 
However, work published by the same research group the following year (78) that compared 
two calibration methods (SPECT acquisitions of a 16 ml sphere in water and a large volume 
phantom) concluded that the large volume phantom was the better calibration method. 
Unfortunately, the authors did not discuss possible causes of this discrepancy. There were a 
number of differences between the two works, most notably the imaging systems used: the 
work in the first publication was performed on two gamma cameras manufactured by Philips 
that did not have CT available whilst the work in the second publication was performed on a GE 
gamma camera with diagnostic quality CT. 
Uribe et al. also compared four calibration methods (134): point source in air (planar image), 
bottles in air, ranging in size from 17ml to 199.5ml (SPECT), bottles in water, ranging in size 
from 17ml to 199.5ml (SPECT) and large volume (SPECT). The work concluded that all the 
SPECT acquisitions performed well as calibration measurements and that the planar method 
could be used so long as scatter correction is performed. 
A number of authors have published work on quantitative 177Lu SPECT imaging, and the most 
common choice of calibration method is the large volume source (59,114,116,159). Another 
commonly used approach is an active volume within a water-filled phantom, such as spheres 
(160) or bottles (117,157). The use of a point source is less widely reported in the literature for 
177Lu, with only two authors having reported using this method: one of them, Shcherbinin et al. 
(161) used planar images of a point source, whilst Beauregard et al. (101) used SPECT/CT 
images of the point sources. Two authors have reported using planar Petri dish acquisitions 
(162,163) and one author has reported using a line phantom (106). 
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4 Early Work: Development of Calibration Protocol 
This chapter details the early work of this PhD, on the development of a calibration protocol 
which was a key output from the MetroMRT project. The work involved acquiring and analysing 
calibration data to assess the usability of the proposed protocol, and assessing the suitability of 
the chosen activity and number of updates used for iterative reconstruction in the proposed 
protocol. 
There are multiple investigations included in this chapter and so, to aid the reader, the 
discussion of each set of results is performed immediately after the results are presented. 
Chapters 4 and 5 have both been presented in this manner. 
4.1 Introduction 
One of the desired outputs from the MetroMRT project (164) was the development and 
publication of a calibration protocol that could be readily performed at clinical sites in a timely 
manner. At the start of the MetroMRT project (164), a review of available phantoms was 
performed and a collective decision was made by all project participants to design a calibration 
protocol using an elliptical Jaszczak phantom in combination with a fillable 16 ml sphere to 
approximate an active lesion within the torso of a patient.  
The original Jaszczak phantom was developed by Ronald Jaszczak for the “testing nuclear 
imaging instruments, such as are used in nuclear medicine” and a patent was granted in 1985 
(165). The phantoms consist of a cylindrical or elliptical Perspex tank, with removable inserts 
consisting of 6 solid Perspex spheres and 6 sets of solid Perspex rods, each of varying sizes 
(166) – the elliptical phantom and standard inserts can be seen in the top row of Figure 26 and 
the set fillable spheres, including the 16 ml sphere used for the calibration, can be seen in the 
bottom row of Figure 26.  
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Figure 26. Elliptical Jaszczak phantom and hollow spheres. Top row: elliptical phantom (166), The phantom is 
supplied with a removable set of rods (shown in the bottom half of the phantom in the picture on the top right) and a 
removable set of solid plastic spheres. Bottom row: set of hollow spheres (167) – the largest of these spheres 
(nominal volume = 16 ml) was used for the calibration protocol. Copied from (166,167). 
 
There was debate within the project as to which phantom-sphere geometry to use and three 
were suggested: sphere in air, sphere in water at the centre of the phantom and the mean factor 
obtained by imaging the sphere in air, in water at the centre of the phantom and in water offset 
from the centre of the phantom. It was proposed that, whilst a single measurement of the sphere 
in air or the sphere in water would be more straightforward to perform, taking a mean of the 
three measurements may be more representative of the likely extreme attenuation and scatter 
scenarios seen within the torso of the patient: 
 Water-central: generally representative of the majority of patients who will have 
lesion(s) in the centre-most part of their abdomen 
 Water-offset: this captures the sub-set of patients who have lesion(s) towards the 
outer-most part of their abdomen 
 Air: this captures sub-set of patients who have lesion(s) in, or close to, the lungs – a 
section of the body that is predominantly air-filled. 
The method of uncertainty calculation was proposed to be the standard deviation in the three 
calibration measurements (water-central, water-offset and air). These three different 
phantom-sphere geometries had been suggested by the project participants and imaged on four 
different gamma camera systems using 131I prior to the start of this PhD work and the analysis 
of the data was performed as part of this PhD. As part of this PhD, the three same 
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phantom-sphere geometries were imaged on four different gamma camera systems using 177Lu. 
The purpose of this calibration protocol was to provide a robust, repeatable and easy to perform 
protocol – the project did not seek to produce an optimised protocol but rather one that could 
be readily performed by any hospital or clinical site. 
In the early stages of this PhD, further work was performed to assess whether the choice of two 
of the parameters proposed for the calibration protocol were appropriate: deadtime 
measurements to ensure that the proposed activity (50MBq) would not induce significant 
deadtime effects in the gamma camera and an investigation as to whether the proposed number 
of updates (50 updates: 5 iterations and 10 subsets) was appropriate.  
4.2 Materials and Methods 
4.2.1 Preparation of Sources 
All sources used in the work for this PhD were prepared either at NPL or at the Royal Surrey 
County Hospital (RSCH) and the procedures used at each site are detailed in this section. The 
major issue with preparing radioactive sources several days to weeks in advance of use (if 
shipping them to other sites) or for making repeated measurements over days to weeks (such 
as for deadtime measurements) is the potential for the radioactivity to disassociate from the 
solution over time and either settle at the bottom of the source, or become adhered to the 
surfaces of the source.  
The addition of 0.1M hydrochloric acid, HCl, to 131I or 177Lu solutions (sodium hydroxide, NaOH 
can also be used for 131I) prevents dissociation within the solution (168–172). Stability can be 
further enhanced by adding stable lutetium (in the form of lutetium chloride) or iodine (in the 
form of potassium iodide) to the solution (75,168,171). Deionised water was used for all 
solutions, to ensure that no additional impurities were added to the solution that may cause 
dissociation. Sources prepared at NPL were prepared using HCl or NaOH and stable 
lutetium/iodine with deionised water. Sources prepared at RSCH were prepared using HCl and 
deionised water. 
The activities of the sources prepared at NPL were determined by measuring 3 aliquots of the 
final radioactive solution on two independent Fidelis radionuclide calibrators (see section 
2.3.2.1 (Radionuclide Calibrators) on page 32 for details), calibrated directly against the 
national standards held at NPL, to determine activity concentration with the volume of solution 
used for each source determined using a 6 figure balance. The activities of sources prepared at 
the RSCH were determined by measuring the activity of the initial radioactive solution (4ml in a 
glass Schott vial), prior to dilution, on a Fidelis radionuclide calibrator, traceable to the national 
standards at NPL and then subdispensing or diluting the solution by weight using a 4 figure 
balance. Radiochemical purity checks were also performed using a secondary standard High-
Purity Germanium spectrometer at NPL for all solutions made at both NPL and RSCH. 
177Lu can be produced either directly or indirectly. The direct method involves neutron 
irradiation of 176Lu targets and the indirect method involves neutron irradiation of 
ytterbium-176 (176Yb) followed by chemical separation of 177Lu from the 176Yb target (173). Due 
to the additional steps required in the production process, the cost of 177Lu produced from 176Yb 
targets (usually referred to as no-carrier-added, n.c.a., 177Lu) is far more expensive than the 
direct method (carrier-added, c.a., 177Lu).  Due to the cost, all 177Lu-labelled molecular 
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radiotherapy products available on the market use c.a. 177Lu. One of the drawbacks of c.a. 177Lu 
is that irradiating 176Lu targets produces small quantities of metastable 177mLu in addition to 
177Lu (around 0.01 – 0.02% 177mLu). 177mLu has a 160.4 day half-life and decays to 177Lu – 
meaning that additional 177Lu is produced within the patient or source. For further details on 
the production of 177Lu, see reference (173) Therefore, all the 177Lu work in this PhD was 
performed using n.c.a. 177Lu to avoid any 177mLu contamination. 
131I is generally produced by neutron irradiation of tellurium-130 (130Te) targets to produce 
metastable 131mTe, which then decays via beta decay to 131I (174). There are a number of 
methods by which the 131I is then separated from the target, but the most straightforward is to 
heat the irradiated target is heated, and capture the 131I in a NaOH solution (174). 131I is also 
produced in the nuclear fission process, when neutron irradiation causes uranium-235 (235U) 
atoms split into smaller atoms including 131I (174). The 131I is removed from the uranium target 
by dissolving the target in NaOH and then separating the 131I using an anion exchange resin.  
4.2.2 Calibration Protocol 
An elliptical Jaszczak phantom (nominal volume 9.5l), model number ECT/ELP/P (166), was 
used in combination with 16 ml (nominal volume) fillable sphere, model number ECT/HS/SET6 
(167), both manufactured by Data Spectrum Corporation (DSC, Durham, North Carolina). The 
phantom and sphere are shown in Figure 26 on page 66. 
The three phantom-sphere geometries analysed were: 
1. Sphere in centre of empty phantom: “air” 
2. Sphere in centre of water-filled phantom: “water-central” 
3. Sphere off-set 150mm from the centre of the water-filled phantom: “water-offset” 
See Figure 27 for SPECT/CT images of the three phantom-sphere geometries. 
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Figure 27. Sphere-phantom geometries(SPECT/CT images). Top left: “air”, top right: “water-central”, bottom: 
“water-offset” The grey-scale images are the CT images and the colour-scale images are the co-registered SPECT 
images. 
Prior to the start of this PhD, these three phantom-sphere geometries had been imaged at four 
hospitals around the UK using a single 16 ml sphere containing 131I, prepared at NPL. Three 
further 16 ml spheres containing 177Lu, all prepared at NPL, were imaged at four European 
hospitals (three in the UK and one in Germany) as part of this PhD work. The cameras and the 
sphere activities (at the mid-point of the SPECT imaging for the sphere in water at the centre of 
the elliptical Jaszczak phantom, are detailed in Table 7. 
 131I 177Lu 
Hawkeye 1, UK 15.10 MBq ± 0.38 % * - 
Hawkeye 4, UK 13.42 MBq ± 0.38 % * - 
Hawkeye 4 (5/8” crystal), UK 17.46 MBq ± 0.38 % * - 
Discovery 670, UK 15.97 MBq ± 0.38 % * 54.35 MBq ± 0.52 % ^ 
Symbia T2 (5/8” crystal), Germany - 6.05 MBq ± 0.52 % 
Symbia T6, UK - 50.73 MBq ± 0.47 % 
Optima 640, UK - 49.46 MBq ± 0.52 % ^ 
Table 7. Gamma cameras and sphere activities. * / ^ = same sphere. The activities quoted are the activities of the 
spheres at the mid-point of the SPECT imaging for the sphere in water. Note – a significantly lower activity was used 
for the Symbia T2 in Germany in order to reduce shipping costs. 
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The acquisition parameters used are detailed in Table 8. 
 131I 177Lu 
Collimator High energy Medium energy 
Photopeak(s), keV 365 ± 10% 113 ± 10% 
  208 ± 10% 
Scatter windows, keV 318 ± 3% and 413 ± 3% 98.7 ± 3% and 131 ± 5% 
  178 ± 5% and 241 ± 5% 
Matrix size 128 x 128 128 x 128 
Number of projections 120 120 
Time per projection, sec 60 60 
Table 8. Acquisition parameters. 
The 177Lu data was all reconstructed on the native workstations on site (Xeleris 3.0 for the 
Discovery 670 and Optima 640 and Syngo for the Symbia systems), and resolution recovery was 
performed for all the data. The 131I data acquired on the Discovery 670 was reconstructed on the 
native workstation on site, and resolution recovery performed. The three Hawkeye gamma 
cameras used for 131I imaging did not have resolution recovery available on the system, and that 
data was reconstructed on a single Xeleris 3.0 workstation without resolution recovery. The 
parameters detailed in Table 9 were used for all image reconstructions. Spherical VOIs were 
drawn on the surface of the sphere on the CT image and the corresponding counts in the SPECT 
image obtained. Counts per second (cps) / MBq values were calculated for each of the three 
geometries in addition to the standard deviation of the three cps/MBq values.  
Reconstruction type OSEM 
Iterations / subsets 5 / 10 
Attenuation correction CT-based 
Scatter correction Triple Energy Window 
Table 9. Reconstruction parameters. Additionally, resolution recovery was performed where available. 
4.2.3 Deadtime 
The National Electrical Manufacturers Association (NEMA) Standards Publication NU1-2012 
Performance of Measurements of Gamma Cameras (108) recommends two methods of 
assessing deadtime for gamma cameras: one method is an intrinsic deadtime measurement in 
air in which a decaying point source is imaged on the gamma camera without collimators. The 
second method is an extrinsic deadtime measurement in which a decaying disc source 
positioned within a scatter medium is imaged on the gamma camera with collimators. The 
second method (extrinsic deadtime with scatter) was the one performed for this work, since the 
calibration protocol will be performed with the collimators attached to the gamma camera 
detectors. The NEMA method allows for the use of a water filled phantom or a solid Perspex 
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phantom – in this work a custom-made solid Perspex phantom was used. Two 10mm deep, 
150mm diameter disc sources were filled with deionised water and 0.1M hydrochloric acid to 
which 3.265 GBq ± 0.5% of 131I or 6.927GBq ± 0.5% of 177Lu was added. The activities were 
measured using a Fidelis ionisation chamber, traceable to the national standards at the National 
Physical Laboratory. The disc source was then positioned inside a solid Perspex phantom 
(dimensions given in Figure 28) and planar images were acquired on the GE Optima 640 
SPECT/CT gamma camera at RSCH using the 131I photopeak of 364 keV ± 10% or the 177Lu 
208 keV ± 10% photopeak as appropriate. The image acquisition length was set to be the longer 
of 10 seconds or 100 000 counts, as recommended by NEMA.  
Regular measurements were made as the source decayed, over a period of 2 months. The total 
counts in each image was recorded. Initially measurements were performed on a daily basis for 
the first two weeks, and then at least twice weekly thereafter.  NEMA recommend that when 
performing these measurements using 99mTc the final measurement be performed at a count 
rate of less than 4 000 cps, with no recommendations provided for alternative radionuclides.  
The equations for paralysable (Equation 10) and non-paralysable (Equation 11) deadtime were 
fitted to the experimental data using the Microsoft Excel solver add-in.  
The final measurement, performed when the activity remaining in the source was slightly less 
than 10MBq (giving a count rate of under 300 cps for both radionuclides), was assumed to have 
negligible deadtime and a deadtime-free linear relationship between cps and MBq was 
calculated based on this datapoint. The difference between the appropriate deadtime curve and 
the deadtime-free linear fit allows quantification of the deadtime losses for a given activity. The 
deadtime losses for a 50MBq source (the activity proposed for use in the calibration protocol) 
were calculated. 
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Figure 28. NEMA method for measuring extrinsic deadtime with scatter. Copied from reference (108). 
4.2.4 Iterative Reconstruction 
The number of updates used in the iterative reconstruction algorithm proposed for the 
calibration protocol was selected based on the recommendations of an IAEA Human Health 
Reports No 9: Quantitative Nuclear Medicine Imaging: Concepts, Requirements and Methods 
(150) which recommended a minimum of 50 updates be used to ensure that convergence was 
achieved. Some of the 131I and 177Lu data acquired for the previous section of work, section 4.2.2 
(Calibration Protocol), was analysed – the 16 ml sphere in the centre of the water-filled 
phantom was used in each case. The reconstructions were performed on the workstation used 
for the hospital inter-comparison work performed in Chapter 6 (Hospital Inter-Comparison 
Using a Common Calibration Protocol) – a Hermes GOLDTM version 4.16. The number of 
iterations and subsets was limited by the workstation, but every combination of 
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iteration/subset number that was possible on the system was tested, up to 100 updates. The 
reconstructions were performed both with and without resolution recovery enabled since the 
application of resolution recovery algorithms is expected to increase the number of iterations 
required in order to obtain convergence. Spherical VOIs were drawn around the spheres on the 
CT data and the corresponding counts in the SPECT data were recorded. 
4.3 Results and Discussion 
4.3.1 Calibration Protocol 
Results 
The cps/MBq values for each of the sphere positions for the proposed calibration protocol 
performed on the gamma cameras are shown in Figure 29 (131I results) and Figure 30 (177Lu 
results), along with the mean cps/MBq value for each camera. The standard deviation of the 
three measurements on each camera was proposed as an estimate of uncertainty on the 
calibration procedure and is noted in the figures. The maximum standard deviation for 131I was 
11.2% measured on a Hawkeye 4 with a 5/8” crystal (without resolution recovery). For the 
177Lu measurements, the maximum standard deviation was 9.0% for the measurement 
performed on a Symbia T6 (with resolution recovery). 
 
Figure 29. 131I calibration measurements performed on four gamma cameras. The mean calibration factor, 
cps/MBq, for each camera is plotted as a dashed line. The uncertainty values displayed on the graph are the combined 
uncertainties on the activity and the Poisson noise in the VOI, and do not account for the uncertainty in the 
calibration method. The Hawkeye data was all rescontructed without resolution reovery, whilst the data acquired on 
the Discovery 670 was reconstructed with resoluton recovery incorporated. Error bars (in black) are displayed on 
the graph, but are smaller than the size of the data points. 
For the 131I measurements, there was no single measurement position that consistently matched 
the mean value most closely: the water-offset measurement most closely matched the mean of 
the three measurements for two of the four cameras (the 3/8” crystal Hawkeye 4 and the 
74 
 
Discovery 670) whilst the air measurement was closest for the 5/8” crystal Hawkeye 4 and the 
water-central measurement most closely matched the mean value for the Hawkeye 1: 
 
Figure 30. 177Lu calibration measurements performed on four gamma cameras. The mean calibration factor, 
cps/MBq, for each camera is plotted as a dashed line. The uncertainty values displayed on the graph are the combined 
uncertainties on the activity and the Poisson noise in the VOI, and do not account for the uncertainty in the 
calibration method. All data was rescontructed with resolution recovery enabled. Error bars (in black) are displayed 
on the graph, but are smaller than the size of the data points. 
For three of the four 177Lu measurements, the water-central measurement most closely matched 
the mean of the three measurements (for the Discovery 670, Optima 640 and Symbia T6) whilst 
for the 5/8” crystal Symbia T2, the water-offset measurement most closely matched the mean. 
Discussion 
No single measurement position for the sphere consistently yielded a cps/MBq value that 
matched the mean of the three measurements more closely than the other measurement 
positions on each gamma camera. For the 177Lu measurements, the water-central position most 
closely matched the mean value for three of the four gamma cameras investigated, but for 131I, 
the water-central position most closely matched the mean value for only one of the four gamma 
cameras whilst the water-offset position most closely matched the mean value for two of the 
four gamma cameras. Whilst the 177Lu results suggest that it may be appropriate to use the 
water-central sphere position as a single calibration measurement, the results indicate that this 
would not be appropriate for 131I imaging as it could add large additional uncertainties when 
applying the water-central calibration factor to a patient lesion located in peripheral soft tissue 
or in the lungs. Since the purpose of the calibration protocol is for it to be generic enough to be 
applied to any gamma-emitting radionuclide and for lesions located anywhere within a patient 
these results indicate that the use of the mean of the three measurements would result in a 
cps/MBq factor that has smaller uncertainties for use in these more extreme lesion locations. 
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For example, in the case of the 3/8” crystal Hawkeye 4 where the water-central sphere position 
gives the smallest cps/MBq factor and the water-offset position gives the largest cps/MBq 
factor, using the water-central factor to calculate the activity in the water-offset position would 
yield an activity 17.3% higher than the true value, whilst using the mean factor from the three 
measurements would yield an activity only 5.9% higher than the true value. Furthermore, use of 
a single measurement position would require additional work on the part of the hospital in 
order to obtain an uncertainty estimation for the cps/MBq factor. 
The maximum standard deviation between the three measurements on any one camera was 
11.2% for the 131I spheres and 9.0% for the 177Lu spheres. The reduced maximum standard 
deviation for the 177Lu data in comparison to the 131I data is likely to reflect the use of resolution 
recovery within the reconstruction algorithm for all 177Lu data, since resolution recovery 
reduces the partial volume effects. Whilst it would have been preferable to perform all 
reconstructions with and without resolution recovery to identify whether this was the case, the 
reconstruction options on the Siemens Syngo workstations (used for the Symbia gamma camera 
data) only allow scatter correction to be performed in conjunction with resolution recovery. 
Reconstructing the Symbia datasets without resolution recovery would have required 
reconstructing them without scatter correction either, and the proposed calibration protocol 
required image reconstruction to be performed with both scatter and attenuation correction. 
The impact of the use of resolution recovery was investigated in main body of the PhD work, see 
section 7.1.4 (Reconstruction parameters). 
The use of 50MBq calibration sphere would give a minimum of 1.5 million counts for 30 minute 
131I measurements and 4.5 million counts for 30 minute 177Lu measurements (calculated using 
the mean cps/MBq obtained for 131I on the Discovery 670 and for 177Lu on the Symbia T2 – the 
lowest cps/MBq value measured for each radionuclide). This allows each of the three 
calibration measurements to be acquired with Poisson noise of less than 0.1% in 30 minutes. 
The measurement procedure was straightforward to perform, requiring three 30 minute 
SPECT/CT acquisitions and a single radioactive source, and was performed with ease by staff at 
all the hospitals. 
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4.3.2 Deadtime 
Results 
The deadtime results are shown in Figure 31 (131I) and Figure 32 (177Lu) and the fold-over effect 
seen in paralysable systems is demonstrated in the deadtime data for 131I. The maximum cps 
was calculated to be 24403 cps at an activity of 2327MBq. The fold-over effect was not observed 
with 177Lu, in which the maximum activity measured was 6297 MBq for which a detected count 
rate of 17567 cps was observed.  
 
Figure 31. Deadtime observed for 131I source imaged in a scatter medium with high energy collimators. The 
data points plotted are the detected cps on each detector, whilst the solid black line is a linear extrapolation from the 
cps:MBq ratio of the final (lowest activity) datapoint. Assuming that the final datapoint is not affected by deadtime, 
this line represents the cps-MBq relationship for the gamma camera in the absence of deadtime effects. The blue solid 
line is the paralysable model as fitted to the data, with a τ value of 15.1 µs and a χ2 value of 72. The black dashed line 
is the non-paralysable deadtime model as fitted to the data, with a τ value of 26.1 µs and a χ2 value of 3080. Whilst 
uncertainties on the cps and the true activity have been calculated, they are smaller than the datapoints on the graph. 
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Figure 32. Deadtime observed for 177Lu source imaged in a scatter medium with medium energy collimators. 
The data points plotted are the detected cps on each detector, whilst the solid black line is a linear extrapolation from 
the cps:MBq ratio of the final (lowest activity) datapoint. Assuming that the final datapoint is not affected by 
deadtime, this line represents the cps-MBq relationship for the gamma camera in the absence of deadtime effects. The 
blue solid line is the paralysable model as fitted to the data, with a τ value of 15.3µ s and a χ2 value of 103. The black 
dashed line is the non-paralysable deadtime model as fitted to the data, with a τ value of 18.3 µs and a χ2 value of 76. 
Whilst uncertainties on the cps and the true activity have been calculated, they are smaller than the datapoints on the 
graph. 
If it is assumed that negligible deadtime at 10MBq and below results in zero deadtime losses, 
then the deadtime loss for 50MBq of 131I are 0.57%, whilst for 50MBq of 177Lu the deadtime 
losses are 0.09%.  
The paralysable deadtime model gave the best fit to the data for the 131I data, with a χ2 value of 
72. In comparison, the non-paralysable deadtime model had a χ2 value of 3080. 
Both deadtime models fitted the 177Lu data well, up to the maximum activity measured, with 
similar χ2 values: 103 for the paralysable deadtime model and 76 for the non-paralysable 
deadtime model.  
For the paralysable deadtime model, which fitted both datasets well, similar τ values were 
obtained for both radionuclides: 15.3 µs for 177Lu and 15.1 µs for 131I. 
Discussion 
The paralysable deadtime model fitted the experimental data well for both radionuclides. The 
non-paralysable model is inappropriate to use for 131I as it is a poor fit to the data. For 177Lu, a 
marginally improved fit for 177Lu was obtained using the non-paralysable model in comparison 
to the paralysable model, although either model could be used.  
Since deadtime, τ, is a measure of the speed with which a detector processes an input pulse, it 
would be expected that radionuclides with higher γ-ray energies (such as 131I: 364 keV) would 
have larger τ values than for radionuclides with lower γ-ray energies (such as 177Lu: 113 and 
208 keV). This is because the pulse height detected by the gamma camera is proportional to the 
energy of the incoming γ-ray, and a larger pulse height (for a higher energy γ-ray) would 
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require a longer recovery time. However, this work did not demonstrate that and, when both 
datasets were fitted with the paralyable deadtime model, almost identical τ values were 
obtained for 131I and 177Lu.  
However, deadtime effects were nevertheless far more significant for 131I than for 177Lu, with the 
deadtime fold-over effect seen for 131I but not for 177Lu. This can be readily explained by the 
γ-ray yield of the two radionuclides. Table 1 outlines the imaging properties of 131I and 177Lu and 
shows that 100% of the radioactive decay events for 131I produce a γ-ray whilst only 17% of the 
radioactive decay events for 177Lu produce a γ-ray. This means that a given activity of 131I will 
produce almost 6 times as many γ-rays (and hence a true count rate, Rt, that is almost 6 times 
greater) than the same activity of 177Lu. For 99mTc, 89% of the radioactive decay events produce 
a γ-ray (24). Therefore, it is likely that at similar activities to those used in this work (several 
GBq), the fold-over effect would be seen for 99mTc (and, indeed, this has been demonstrated by 
previous authors (99,102)).  
Using the NEMA recommended method of calculating deadtime, deadtime losses of around 0.6% 
can be expected for 50MBq 131I sources and around 0.1% for 50MBq 177Lu sources. The 
uncertainty introduced into the calibration protocol due to not correcting for deadtime effects 
for these sources would be significantly less than the likely uncertainty in the source activity – 
2% uncertainty if a reference radionuclide calibrator were used or 5% if a field radionuclide 
calibrator were used, see section 2.3.2.1 (Radionuclide Calibrators) for details. Combining a 
0.6% uncertainty due to deadtime losses in quadrature with a 2% uncertainty in the activity of 
the source would give a total uncertainty of 2.1%, whilst combining it with a 5% uncertainty 
would give a total uncertainty of 5.04%. 
50MBq therefore is an appropriate sphere activity to recommend for use in the calibration 
protocol, since it allows rapid acquisition of images with low Poisson noise (see section 3.3.3 
(Noise) on page 57) with deadtime losses of less than 0.6%. 
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4.3.3 Iterative Reconstruction 
Results 
The results for the investigation into the number of updates to be used in the iterative 
reconstruction algorithm are shown in Figure 33. The non-resolution recovery (“noRR”) data 
demonstrated convergence in the total number of recovered counts at 10 updates, whilst for the 
reconstruction algorithms incorporating resolution recovery (the “RR” data), the total number 
of recovered counts continued to gradually increase but approached approximate convergence 
at around 25 updates.  
 
Figure 33. Effect of number of updates on total recovered counts for a 16 ml sphere containing 
15.10 MBq of 131I imaged on a Hawkeye 1 SPECT/CT gamma camera and a 16 ml sphere containing 
50.73 MBq of 177Lu imaged on a Symbia T6 SPECT/CT gamma camera. Both spheres were imaged at the 
centre of a water-filled elliptical Jaszczak phantom. Reconstructions were performed on a Hermes GOLDTM 
version 4.16 workstation and were performed both with and without resolution recovery (RR). 
Discussion 
The proposed calibration protocol recommended a minimum of 50 updates (5 iterations and 10 
subsets) be performed in the reconstruction process. The results obtained in this work 
demonstrated that convergence was obtained at around 10 updates for data reconstructed 
without resolution recovery, whilst data reconstructed with resolution recovery approached 
convergence at around 25 updates. 50 updates therefore appears to be an adequate number of 
updates to recommend in order to reach, or approach, convergence in the number of recovered 
counts for a variety of reconstruction software, including those not tested in this work. 
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4.4 Conclusions 
The aim of the work in this chapter was to analyse data previously acquired using the proposed 
calibration protocol for 131I, acquire and analyse data for 177Lu using the calibration protocol and 
to assess whether the proposed activity and number of updates in the calibration protocol were 
appropriate. 
The proposed calibration protocol requires SPECT/CT measurements to be performed of a 
16 ml sphere of approximately 50MBq of activity. SPECT/CT images are acquired of the sphere 
in the centre of an empty Jaszczak phantom, in the centre of the phantom filled with water and 
off-set from the centre of the water-filled phantom. The calibration factor is then calculated to 
be the mean of the cps/MBq values obtained for each of the three SPECT/CT images. 
The proposed protocol was demonstrated to be an easy to perform procedure that can be 
conducted by hospital staff without specialised knowledge or experience, using equipment that 
is readily available. The total imaging time required is 1.5 hours (3 x 30 minute SPECT/CT 
acquisitions), which can be performed in a single imaging session after the clinical workload is 
completed for the day. Using sources of around 50MBq enables acquisition of low Poisson noise 
image data (<0.1%) with low deadtime losses (<0.6%) in comparison to the likely uncertainty in 
the source activity (<2% or <5%, depending on the radionuclide calibrator used). The proposed 
use of 50 updates in the reconstruction algorithm was demonstrated to be more than adequate 
for the data acquired, and is therefore likely to be adequate for a variety of reconstruction 
algorithm software not tested in this work. 
This findings from this work were reported back to the project, and the project participants 
agreed to the use of this protocol for the inter-comparison exercise performed in section 5 
(Hospital Inter-Comparison). 
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5 Hospital Inter-Comparison 
This chapter presents the results from a pan-European hospital inter-comparison quantitative 
imaging exercise that was conducted as part of the MetroMRT project. Participants were 
provided with a pre-prepared radioactive 177Lu source, the activity of which was not revealed to 
them. They were asked to image it in whichever manner they wished and to report activity and 
volume values.  
As with the previous chapters, there are multiple investigations included in this chapter and so, 
to aid the reader, the discussion of each set of results is performed immediately after the results 
are presented.  
5.1 Introduction 
There are many different methods that can be used for performing quantitative imaging, but 
there is a lack of specific recommendations as to which method should be used and those used 
in the literature for the purposes of 177Lu quantitative imaging have been summarised in 3.3.10 
(Calibration technique) on page 63. The result is that different centres use different techniques, 
making verification or comparison of any reported results difficult. With the exception of 
yttrium-90 (90Y) radioembolisation treatment for liver cancer (175), a treatment in which 
90Y-labelled microspheres are injected into the hepatic artery where they travel through the 
blood vessels in the liver and become lodged in the tumour site, there have been no large-scale 
multi-centre randomised controlled trials (RCTs) looking specifically at dosimetry for molecular 
radiotherapy.  
In the UK, decisions as to whether to offer a clinical service to patients are based on the strength 
of the evidence regarding the efficacy of the service as assessed by the National Institute for 
Health and Care Excellence. The highest quality evidence is that of meta-analysis of randomised 
controlled trials, followed by large-scale multi-centre randomised controlled trials and then 
meta-analysis of small RCTs or cohort studies (176). Thus, in the absence of large-scale 
multi-centre RCTs, it is still possible to demonstrate efficacy of a clinical service through 
meta-analysis of small RCTs or cohort studies. Unfortunately, in the field of molecular 
radiotherapy dosimetry this is generally not possible due to the variation in (or lack of 
information about) the methods used for performing quantitative imaging and dosimetry in 
molecular radiotherapy studies. 
The need to establish equivalence between sites is therefore critical, particularly if large-scale 
multi-centre randomised clinical trials are to take place. As a result, one of the tasks of the 
MetroMRT project was to perform an inter-comparison exercise of quantitative SPECT/CT 
imaging of 177Lu across a number of the different clinical sites that were partners in the project 
to assess equivalence between centres. The sites were provided with an independently 
calibrated radioactive source and a phantom in which to position the source. The staff at each 
site used their own choice of calibration, acquisition, reconstruction and image processing 
protocols to calculate the activity within the source.  
A similar multi-centre inter-comparison study has previously been performed using solid epoxy 
resin 133Ba sources as a surrogate for 131I, in order to compare the quantitative imaging results 
using various planar and SPECT imaging protocols (73).  See section 2.3.2.2 (Quantitative SPECT 
Imaging: IAEA Inter-Comparison Exercise) for further details. 
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5.2 Materials and Methods 
5.2.1 Inter-comparison phantom 
The inter-comparison exercise used six accurately calibrated radioactive sources (prepared at 
NPL) and a single phantom. Two researchers, including the PhD researcher, travelled to each of 
the seven clinical sites, taking the phantom with them and shipping the radioactive sources via 
courier.  
A quasi-anthropomorphic phantom (see Figure 34 for photograph and Figure 35 for SPECT/CT 
images) was used, consisting of the 9.5 litre elliptical Jaszczak phantom (model ECT/ELP/P 
(166)) supplied by Data Spectrum Corporation (DSC, Durham, US) which had been used 
previously to develop the MetroMRT calibration protocol, see section 4 (Early Work: 
Development of Calibration Protocol). To this phantom, Perspex body contour rings (model 
ECT/BCR/SET3 (177)) were added to more closely simulate the shape of a patient and lung and 
spine inserts (model ECR/LUNG/I (178)) were added, both supplied by Data Spectrum 
Corporation (DSC, Durham, US). The DSC Large Spherical Shell spheres (model ECT/SPS-LG/A 
(179)), were used for the comparison sources (Figure 34). This set-up was designed to mimic a 
complex, but clinically realistic, scenario in which a large lesion (the inner sphere of the shell 
sphere) was positioned close to the lungs (low attenuation/scatter properties) and the spine 
(high attenuation/scatter properties) and surrounded by a small amount background activity 
(the outer shell of the shell sphere). The volume of background activity was constrained for 
practical reasons: the phantom could not be filled with radioactivity (making the entire 
phantom “background activity”) as the phantom needed to be used at all sites and so could not 
be made radioactive.  
 
 
Figure 34.  Inter-comparison phantom – photograph. Phantom consists of: elliptical Jaszczak phantom 
surrounded by Perspex body contour rings with the lung and spine inserts. One of the radioactive shell spheres (the 
inner core is red and the outer shell is green) was screwed into one of the positioning holes at the base of the 
phantom, and the phantom filled with water. 
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Figure 35.  Inter-comparison phantom – SPECT/CT images. Top row: transaxial view of the inter-comparison 
phantom. Bottom left: coronal view, bottom right: sagittal view. The CT data in displayed on a grey-scale and the co-
registered SPECT data is displayed on a colour-scale. 
The lungs (0.9 litres and 1.1 litres in volume) were filled with Styrofoam© beads mixed with 
water with a resulting composition of 60 % Styrofoam and 40 % water by volume, resulting in a 
density of approximately 0.3 g/cm2 to mimic lung tissue (178). The spine insert (170 ml) was 
filled with bone equivalent solution of dipotassium hydrogen orthophosphate (100 g 
dipotassium hydrogen phosphate dissolved in 67 g water (180)). No modifications were made 
to the components of the phantom between each clinical site, but the phantom was filled with 
water prior to starting the measurements at each site, and emptied out afterwards for 
transportation to the next site. 
The shell spheres consisted of two isolated concentric spheres allowing the creation of a red 
‘lesion’ of nominal diameter 36mm filled with a high radioactivity concentration, surrounded by 
a less-active ‘background’ shell with nominal thickness 11mm (179), see Figure 36. The white 
screw at the top of the sphere provides access to the outer shell for filling, whilst the 
transparent threaded rod at the bottom of the sphere unscrews to allow filling of the inner 
sphere. The elliptical phantom has a number of pre-drilled threaded holes, and the rod attached 
to the sphere can be screwed into position – allowing the positioning to be reproduced at each 
site. 
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Figure 36. DSC Large Spherical Shell sphere. Image copied from reference (179) 
 
Six different shell spheres were used in this work (seven sites were visited in total but one 
source was used at two different hospitals). The true volumes of the spheres were measured 
using a calibrated 5 figure balance when the sources were prepared, and the measured volumes 
are given in Table 10. Each source was prepared at NPL immediately prior to the site visit such 
that an approximately equal amount of radioactivity was measured at each site. 
 
 H1 H2 H3 H4 & H5 H6 H7 
Inner sphere volume, ml 26.06  26.03 26.33 26.67 26.00 27.16 
Uncertainty on inner 
sphere volume, % 
1.9x10-5 1.9x10-5 1.9x10-5 1.9x10-5 1.9x10-5 1.8x10-5 
Outer shell volume, ml 80.83 81.28 80.82 79.29 81.59 80.69 
Uncertainty on outer 
shell volume, % 
6.2x10-6 6.2x10-6 6.2x10-6 6.3x10-6 6.1x10-6 6.2x10-6 
Ratio inner sphere:outer 
shell volume 
1:3.1 1:3.1 1:3.1 1:3.0 1:3.1 1:3.0 
Table 10. True volumes of shell spheres, as measured at NPL. H1 to H7 are the anonymised clinical sites that 
participated in the work. The same source was used at H4 and H5. The uncertainty attributed to the volumes was 
±5 µg, since a 5 figure balance was used that could measure volumes to 10 µg. 
5.2.2 Preparation of shell spheres and phantom 
Each shell sphere was prepared at NPL using the method detailed in section 4.2.1 (Preparation 
of Sources). A carrier solution was prepared, comprising of 0.1M hydrochloric acid plus 10 µg g-1 
inactive lutetium. The shell sphere was filled with this carrier solution and left for at least 24 
hours to ensure that the radioactivity didn’t adhere to the walls of the shell sphere (181). After 
85 
 
at least 24 hours, the remaining carrier solution was divided into two and n.c.a. 177Lu was added 
to each in a mean ratio of 14:1 [range: 11.6:1 – 15.3:1, see Table 11 for further details]. Three 
aliquots were taken of each solution and later used to analyse the activity concentration (on two 
independent secondary standard ionisation chamber systems that had previously been 
calibrated directly against primary standards at NPL) and to ensure there were no radionuclidic 
impurities present (on a secondary standard High-Purity Germanium spectrometer).  
 H1 H2 H3 H4 & H5 H6 H7 
Ratio inner sphere:outer 
shell activity concentration 
14.1:1 14.4:1 11.6:1 13.3:1 14.4:1 15.3:1 
Table 11. Ratio of activity concentration of the solutions used to fill the shell spheres. H1 to H7 are the 
anonymised clinical sites that participated in the work. The same source was used at H4 and H5. 
 
The shell sphere was then emptied and the two radioactive solutions were used to fill it. The 
higher activity concentration was used to fill the inner sphere and the lower activity 
concentration was used for the outer shell. The activity concentrations were chosen such that 
the total activity of each shell sphere at the time of measurement was approximately 70 MBq – 
the exact activities of the shell spheres at the time of inter-comparison measurements are 
shown in Table 12. This resulted in a quantity of radioactivity that was relatively straight 
forward to transport (as it could be shipped as an excepted package under the European 
Agreement concerning the International Carriage of Dangerous Goods by Road (182) rather 
than as a higher classification which would have added many thousands of pounds in transport 
fees and made performing the inter-comparison exercise financially unfeasible), whilst being 
active enough to measure on a gamma camera within a reasonable time frame.  
 Inner sphere activity, 
MBq 
Outer shell activity, 
MBq 
Ratio inner 
sphere:outer 
shell activity 
H1 53.88 MBq ± 0.52% 11.60 ± 0.52% 4.6:1 
H2 48.80 MBq ± 0.52% 10.57 MBq ± 0.52% 4.6:1 
H3 51.81 MBq ± 0.52% 15.23 MBq ± 0.52% 3.4:1 
H4 56.22 MBq ± 0.55% 12. 58 MBq ± 0.56% 4.5:1 
H5 62.88 MBq ± 0.55% 14. 07 MBq ± 0.56% 4.5:1 
H6 60.35 MBq ± 0.52% 13.14 MBq ± 0.52% 4.6:1 
H7 40.37 MBq ± 0.52% 7.04 MBq ± 0.57% 5.7:1 
Table 12. Activity at mid-point of imaging. H1 to H7 are the anonymised clinical sites that participated in the work. 
The same source was used at H4 and H5. 
 
Although the shell spheres were filled with activity concentrations in a sphere:shell ratio of 
approximately 14:1, the two volumes within the shell sphere were not the same (see Table 10), 
86 
 
with the volume of the outer shell being on average 3.1 [range: 3.0 – 3.1] times larger than that 
of the inner sphere. This resulted in a mean sphere:shell activity ratios of 4.6:1 [range: 3.4 – 5.7], 
see Table 12 for details.  
The inactive parts of the phantom were transported to each site by the researchers and were 
assembled with the active shell sphere before being filled with inactive water, excluding as 
many air bubbles as possible, and sealed.  
5.2.3 Phantom measurement 
Each site used their own choice of quantitative imaging protocol and all SPECT/CT quality 
assurance procedures including uniformity, energy peaking and CT/NM registration had been 
performed prior to the phantom imaging, as according to their local protocols and routine QC 
schedule.  
The collimators of choice were loaded onto the camera, the phantom positioned centrally on the 
imaging couch in a ‘head first’ position and (for those sites that used circular orbits rather than 
contoured orbits) positioned centrally between the two heads. 
A SPECT/CT image of the phantom was acquired using the site’s choice of protocol and a copy of 
the imaging data obtained. The sites were asked to complete a reporting form providing details 
of the gamma camera and reconstruction software plus details (free-text) of the calibration and 
segmentation method used for the analysis in addition to reporting the volume, total activity 
and the associated uncertainty for both the inner sphere and the outer shell. Unfortunately, due 
to an oversight in the design of the reporting template, it was not evident that an estimation of 
uncertainty for the volumes was also desired and so only uncertainty values for the activities 
were obtained from the participants. 
5.2.4 Gamma cameras 
Whilst an attempt was made to include gamma cameras from all the major gamma camera 
manufacturers (GE, Siemens and Philips), unfortunately the data from the imaging performed 
on the only Philips gamma camera involved in the study (a Philips BrightView XCT) was not 
useable since the sources had been prepared incorrectly. The sources for this camera were 
prepared at another NMI in Europe, rather than at NPL, and were prepared using 177Lu and tap 
water, without the addition of any products to stabilise the solution and prevent dissociation – 
see section 4.2.1 (Preparation of Sources) for details on how the sources should have been 
prepared. This resulted in 177Lu dissociating from the solution and adhering to the internal 
surfaces of the shell sphere, resulting in an inhomogeneous activity distribution. 
The final dataset included four Siemens cameras and three GE cameras: 
1. Three Siemens Symbia T series cameras 
o Symbia T2 (a two slice CT scanner) with a 5/8” crystal 
o Symbia T2 with a 3/8” crystal 
o Symbia T6 with a 3/8” crystal 
2. Siemens Intevo camera with a 3/8” crystal 
3. Two GE 600 series cameras: 
o Discovery 670 with a 3/8” crystal 
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o Optima 640 with a 3/8” crystal 
4. GE Hawkeye camera with a 3/8” crystal 
5.2.5 Collimators 
All sites had medium energy collimators available, and so chose to image using these as 
recommended by the MIRD Committee (130), since the primary photon emission of 177Lu is 
208 keV. The specification of the medium energy collimators for each manufacturer are 
summarised in Table 13. 
 
Manufacturer GE Siemens 
Hole type Hexagonal Hexagonal 
Hole diameter, mm 3.0 2.94 
Septal thickness, mm 1.05 1.14 
Hole length, mm 58 40.64 
Number of holes 15210 14 x 103 
Calculated penetration (for 67Ga), % 2.0 1.2 
System sensitivity @ 100mm for 3/8” crystal (for 67Ga), 
cpm/MBq 
65 124 
System resolution @ 100mm for 3/8” crystal (for 99mTc), mm 9.4 9.9 
Table 13. Technical specifications of medium energy collimators used in the inter-comparison exercise. 
5.2.6 Acquisition parameters 
There were some similarities between the sites in the choice of acquisition parameters, 
including: 
 Matrix size of 128 x 128 
 120 projections 
 30 seconds per projection 
o One site had an acquisition time of 60 seconds per projection. There was a delay 
in transporting the inter-comparison source resulting in an activity at the time of 
measurement of approximately 50% of that at the other sites, so the acquisition 
time was double to compensate. 
5. Main photopeak set to 208 keV ± 10% 
The differences in the imaging protocols between sites were all related to the photopeaks, 
scatter corrections and orbit type and are summarised in Table 14. 
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 Site 
H1 H2 H3 H4 H5 H6 H7 
Photopeak(s), 
keV 
- 
208±10% 
113±7.5% 
208±10% 
113±10% 
208±10% 
113±10% 
208±10% 
- 
208±10% 
- 
208±10% 
- 
208±10% 
Scatter 
windows, keV 
- 
- 
176.8±5% 
239.2±5% 
- 
- 
- 
- 
- 
- 
- 
- 
98.7±5% 
131±5% 
178±5% 
214±5% 
- 
- 
178±5% 
214±5% 
- 
- 
- 
- 
- 
- 
- 
- 
Orbit type contoured circular contoured contoured contoured circular contoured 
CT-quality diagnostic non-
diagnostic 
non-
diagnostic 
non-
diagnostic 
non-
diagnostic 
non-
diagnostic 
non-
diagnostic 
Table 14. Acquisition parameters used by the seven sites in the inter-comparison exercise. 
As Table 14 illustrates, three sites chose to use the 113 keV photopeak in addition to the 
208 keV, with two sites using the same ± 10% window width as for the 208 keV. Site H2 chose 
to reduce the width of the 113 keV photopeak window to ± 7.5% whilst setting the 208 keV 
photopeak window at ± 10%. Three of the sites also chose to set scatter windows in order to 
perform TEW scatter correction on the data.  
Five of the hospitals used a contoured orbit, whilst two used a circular orbit with the heads 
positioned as close as possible to the phantom to obtain as small a diameter of rotation as 
possible.  
5.2.7 Reconstruction parameters 
All sites used OSEM reconstruction algorithms, with four sites performing it in the native 
software provided with the camera, and three using an independent software (two used a 
vendor-neutral commercial software and one used an in-house reconstruction software). A 
wide range of iteration and subsets were used by the sites within the OSEM algorithms, ranging 
from 32 updates (8 iterations and 4 subsets) to 576 updates (24 iterations and 24 subsets). See 
Table 15 for details. 
All sites chose to use the acquired CT data to perform CT-based attenuation correction. Six of 
the sites corrected the data for scatter: three used TEW, two used Monte Carlo techniques and 
one used ESSE. Five of the sites performed resolution recovery to correct for depth-dependent 
spatial resolution. See Table 15 for details. 
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 Site 
H1 H2 H3 H4 H5 H6 H7 
Reconstruction 
type 
OSEM OSEM OSEM OSEM OSEM OSEM OSEM 
Software type Native Native Vendor- 
neutral 
Native Native + in-
house 
Vendor-
neutral 
In-
house 
Iterations / 
subsets 
6 / 6 8 / 4 16 / 5 24 / 24 5 / 10 5 / 15 8 / 10 
Attenuation 
correction? 
CT CT CT CT CT CT CT 
Scatter 
correction? 
TEW No Monte Carlo TEW TEW  
(in-house) 
Monte 
Carlo 
ESSE 
Resolution 
recovery? 
Yes No Yes Yes No Yes Yes 
Post-
reconstruction 
filtering? 
No No No No No Yes No 
Table 15. Reconstruction parameters used by the seven sites in the inter-comparison exercise. 
One site corrected for partial volume effects by acquiring and applying a recovery curve 
correction. 
5.2.8 Calibration techniques 
The calibration techniques used by the sites could broadly be divided into four categories: 
1. SPECT/CT of a small 16 ml radioactive sphere imaged in a water or air filled phantom 
with the counts in the entire physical volume used for obtaining a calibration factor (3 
sites: H3, H4, H5) 
2. SPECT/CT of a larger radioactive volume in, or close to, a scatter medium (2 sites: H1, 
H6) 
3. Planar imaging of radioactive Petri dishes with the region drawn such that it 
encompassed all counts from the Petri dishes (1 site: H7) 
4. “Patient-specific” calibration – SPECT/CT of a shell sphere of the same design as those 
used in the comparison exercise was filled with a known activity (1 site: H2) 
It is instructive to mention at this point that the methods used by the hospital staff were not 
necessarily the method they would choose to use if they had a wider choice of options and more 
time, but they were limited by phantoms and equipment available to them at the sites. Most 
clinical sites in Europe will have fillable spheres (or phantoms containing fillable spheres) 
available for use since they are used for both SPECT and PET image quality testing. 
Most sites opted to calibrate their camera using SPECT/CT imaging, since they felt that this 
incorporates any changes in quantification due to the reconstruction process and eliminates any 
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uncertainty introduced by applying a planar calibration factor to a three dimensional image. 
One site opted to use planar imaging, with the opinion that if the reconstruction process is 
performed correctly then there should be no changes in quantification, and that using planar 
imaging eliminates any uncertainty introduced by the reconstruction process.  
The sites that chose to calibrate their cameras using 16 ml spheres did so because they felt that 
this volume was an appropriate representation of a likely lesion size, whilst being large enough 
to be mostly unaffected by partial volume effects. Those sites that chose to use larger volumes 
did so to ensure that their calibration sources were definitely free of partial volume effects. 
Most sites used an imaging set-up that incorporated a large volume of water as a scatter 
material to represent the likely scatter conditions within a patient. The only site that chose to 
perform calibration in air only (the site that performed planar imaging of Petri dishes) reasoned 
that if the reconstruction process is performed correctly than it will correct for scatter in the 
patient. 
Most sites used a generic calibration procedure that they would apply to all patients, but one 
site used a “patient-specific” calibration with the view that they could use 3D printing 
techniques to perform patient–specific calibration measurements if they started performing 
routine quantitative imaging and dosimetry on patients. 
The details of the calibration technique used on each camera are given in sections 5.2.11 to 
5.2.17 and Table 16 summarises the majority of the parameters and methods used at each site.  
5.2.9 Segmentation techniques 
The segmentation techniques used by the sites could divided into three categories: 
1. VOIs drawn on CT volumes (H3, H4, H5, H7) 
2. VOIs drawn on CT volumes with an additional margin added to the volume, in an 
attempt to encompass all counts spilt-out of the volume (H1) 
3. VOIs drawn on SPECT volumes using a thresholding technique (H2, H6, H7) 
4. VOIs drawn on SPECT volumes manually with an additional margin added to the 
volume, in an attempt to encompass all counts spilt-out of the volume (H6) 
One site (H6) used a combination of technique 3 and 4 for the two different sections of the 
comparison phantom whilst H7 used a combination of technique 1 and 3. 
The details of the segmentation techniques used at each site are given in sections 5.2.11 to 
5.2.17 and Table 16 summarises the majority of the parameters and methods used at each site.  
5.2.10 Uncertainty analysis techniques 
Sites were asked to report an uncertainty on the reported activities, but (in an oversight) not for 
the reported volumes. As such, all uncertainties presented in this work are for the uncertainty 
on the reported activity only. Most sites calculated a percentage uncertainty based entirely on 
the calibration measurements, with one site also including information from the comparison 
exercise imaging. The three techniques used were: 
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1. The standard deviation in the counts (Poisson noise) in the VOI(s) drawn to obtain 
calibration factor(s) (H1, H3) 
2. The standard deviation in calibration factors (where more than one calibration image 
was acquired) (H2, H4, H5, H7) 
3. Uncertainty in the activity concentration of the calibration source (H3, H5) 
One site combined technique 1 in quadrature with technique 3 (H3). 
One site combined technique 2 in quadrature with technique 3 (H5). 
One site combined technique 2 in quadrature with the standard deviation in the counts in the 
VOIs in the comparison phantom (H4). 
One site was unable to report an uncertainty estimate since the calibration was performed using 
previously acquired data that had no associated uncertainty values (H6). 
5.2.11 Site H1 – Siemens Symbia T2 (5/8” crystal) 
Camera calibration 
A plastic bottle of approximately 130 ml in volume and a 9.7 litre phantom containing six hollow 
glass spheres (ranging in size from 10mm to 37mm internal diameter) was used. The bottle and 
the three largest spheres (37mm, 28mm and 22mm diameter) were filled with a known 
quantity of homogenous 177Lu solution (2.0 MBq/ml). The three remaining spheres and the 
phantom were filled with water. The bottle was positioned immediately adjacent to the 
phantom and a SPECT/CT image acquired. 
VOIs of the physical volume plus 10mm were drawn on the CT image for the bottle and the three 
spheres. The cps/MBq measured in the bottle was deemed to be the calibration factor. The 
apparent activity in each of the three spheres was then calculated by multiplying the counts in 
the sphere VOIs by the calibration factor. The relative deviations between the nominal activity 
and the apparent activity in the spheres were compared to establish that the attenuation and 
scatter corrections had been correctly performed.  
Identical imaging parameters were used for the calibration and the inter-comparison imaging. 
Image segmentation 
The inner sphere was segmented using a spherical VOI on the CT images, with the sphere 
diameter set to be the physical diameter of the sphere, as measured on the CT, plus 10mm.  
The external surface of the outer shell was segmented using a spherical volume on the CT data, 
with the sphere diameter set to be the physical diameter of the external surface of the shell plus 
10mm. The VOI of the inner sphere was then subtracted from the VOI of the external surface of 
the outer shell to obtain the data for the shell.  
Uncertainty estimation 
The standard deviation in counts (Poission noise) in the calibration measurement.  
92 
 
5.2.12 Site H2 – Siemens Symbia T2 (3/8” crystal) 
Camera calibration 
A shell sphere of the same design as that used for the inter-comparison was filled with a known 
quantity of 177Lu and the following images of the shell sphere positioned within a cylindrical 
water-filled phantom were obtained: 
1. The outer shell was filled with activity, and the inner sphere left empty with no activity 
in it. 
2. Activity added to the inner sphere (resulting in a shell sphere with activity in both the 
inner sphere and outer shell) 
3. Several images acquired for the shell sphere with activity in the inner sphere and outer 
shell, with the shell sphere positioned at different depths within the water-filled 
phantom.  
The two sets of projection data (113 keV and 208 keV) for each image were reconstructed 
individually and then summed after reconstruction.  
The images obtained in steps 1 and 2 were used to select appropriate thresholds on the SPECT 
images for the image segmentation (see below for details). 
The images obtained in step 3 were segmented using the determined thresholds from steps 1 
and 2, and a cps/MBq factor calculated for each image. The average cps/MBq was used as the 
calibration factor. 
Identical imaging parameters were used for the calibration and the inter-comparison imaging. 
Image segmentation 
An SPECT threshold of 35% was used to segment the surface of the inner sphere and 10% to 
segment the external surface of the outer shell on the SPECT data. The VOI of the inner sphere 
was subtracted from the external surface of the outer shell to obtain the data for the outer shell. 
The SPECT thresholds used were determined by varying the thresholding value to obtain a 
volume that most closely matched the known physical volumes of the shells.  
Uncertainty estimation 
The standard deviation in calibration factors calculated for each of the calibration images. 
5.2.13 Site H3 – GE Infinia Hawkeye (3/8” crystal) 
Camera calibration 
A 16 ml plastic sphere filled with approximately 20 MBq n.c.a. 177Lu was imaged in the centre of 
a water-filled elliptical Jaszczak phantom.  
The two sets of projection data (113 keV and 208 keV) were reconstructed individually and 
then summed after reconstruction. A spherical VOI was drawn on the sphere on the CT image to 
obtain a cps/MBq factor. 
Identical imaging parameters were used for the calibration and the inter-comparison imaging. 
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Image segmentation 
The inner sphere and external surface of the outer shell were segmented using spherical VOIs 
drawn on the CT image. The VOI of the inner sphere was then subtracted from the VOI of the 
external surface of the outer shell to obtain the data for the outer shell.  
Uncertainty estimation 
The standard deviation in counts (Poisson noise) in the calibration measurement combined in 
quadrature with the uncertainty in the activity concentration of the calibration sphere. 
5.2.14 Site H4 – Siemens Symbia Intevo 16 (3/8” crystal) 
Camera calibration 
A 16 ml plastic sphere filled with approximately 35 MBq n.c.a. 177Lu was imaged in an elliptical 
Jaszczak phantom in three positions (in air at the centre of the phantom, in water at the centre 
of the phantom and in water at a 15cm displacement from the centre of the phantom).  
The two sets of projection data were reconstructed individually and then summed after 
reconstruction. 
VOIs were drawn freehand by the operator on the CT images. A cps/MBq value was calculated 
for each geometry and an unweighted mean of the three calibration measurements was taken to 
determine the mean cps/MBq factor. 
Identical imaging parameters were used for the calibration and the inter-comparison imaging. 
Image segmentation 
VOIs were drawn freehand by the operator on the sphere and outer shell walls on the CT data.  
Uncertainty estimation 
The mean standard deviation in counts (Poisson noise) in the calibration volumes was 
combined in quadrature with the standard deviation in counts in the individual volumes of 
interest in the inter-comparison images.  
5.2.15 Site H5 – GE Optima 640 (3/8” crystal) 
Camera calibration 
A 16 ml plastic sphere filled with approximately n.c.a. 25 MBq 177Lu was imaged in an elliptical 
Jaszczak phantom in three positions (in air at the centre of the phantom, in water at the centre 
of the phantom and in water at a 15cm displacement from the centre of the phantom).  
The projection data was corrected for scatter prior to reconstruction, using an in-house TEW 
algorithm. 
Spherical VOIs were drawn on the CT images and since volumes on the reconstruction 
workstation only include whole pixels, two VOIs were drawn for each geometry: one slightly 
smaller than the physical size of the sphere, and one slightly larger.  
A cps/MBq value was calculated for each VOI and the mean of the six calibration measurements 
was taken to determine the final cps/MBq factor. 
Identical imaging parameters were used for the calibration and the inter-comparison imaging. 
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Image segmentation 
The inner sphere and external surface of the outer shell were segmented using spherical VOIs 
drawn on the CT images. The VOI of the inner sphere was then subtracted from the external 
surface of the outer shell VOI to obtain the data for the outer shell.  
Uncertainty estimation 
The standard deviation in the six calibration factors combined in quadrature with the 
uncertainty in the activity concentration of the calibration sphere. 
5.2.16 Site H6 – Siemens Symbia T6 (3/8” crystal) 
Camera calibration 
A 6.9 litre cylindrical Jaszczak phantom containing a homogenous solution of approximately 
120 MBq of 177Lu-DOTA-(Tyr3)-octreotate was imaged.  
A Gaussian filter with a full-width half-maximum (FWHM) of 8mm was applied to the data 
post-reconstruction. A cps/MBq factor was determined using a large VOI positioned centrally 
within the phantom. 
Identical imaging parameters were used for the calibration and the inter-comparison imaging. 
Image segmentation 
The inner sphere was segmented on the SPECT data using a threshold of 50%. The external 
surface of the outer shell was segmented using an 8cm diameter spherical VOI centered on the 
SPECT data, deemed by the participant to be sufficiently large to include all activity. This 
resulted in a VOI diameter approximately 10mm larger than the physical volume of the outer 
shell. The VOI of the inner sphere was then subtracted from the external surface of the outer 
shell VOI to obtain the data for the outer shell. 
Uncertainty estimation 
No estimation of uncertainty was performed as the calibration performed by this hospital was 
done using previously acquired data that did not have any associated uncertainty values. 
5.2.17 Site H7 – GE Discovery 670 (3/8” crystal) 
Camera calibration 
Five stock vials, each containing approximately 40 MBq of 177Lu-DOTA-(Tyr3)-octreotate in a 
4ml solution were made.  These were then dispensed into five Petri dishes, each 6cm in 
diameter and planar images were acquired for each camera head, at 10cm distance from the 
collimator. The counts in a circular region of interest (ROI) with a diameter of 10cm drawn 
around the Petri dish on each image was obtained. The diameter was set at 10 cm, as previously 
determined by gradually increasing the diameter until it encompassed the counts contribution 
from the source. ROIs were also drawn outside the Petri dish to assess the number of counts in 
the background. The mean cps/MBq factor was determined based on the five sources.  
A recovery curve was also acquired, by obtaining SPECT images of various sized spheres (with 
known activity). An auto-contouring algorithm, based on the Otsu method (183), was used to 
delineate the spheres, and a recovery coefficient calculated for each sphere as a ratio of 
measured activity concentration to true activity concentration. The recovery coefficient data 
was plotted as a function of segmented volume, and an equation fitted to the data.  
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Identical imaging parameters were used for the recovery curve imaging and the inter-
comparison imaging. 
Image segmentation 
The inner sphere was segmented on the SPECT data using an auto-contouring algorithm based 
on the Otsu method (183) and the previously determined recovery coefficient equation applied 
to the result to obtain the activity in the inner sphere.  The external surface of the outer shell 
was segmented manually by the operator on the CT data. The VOI of the inner sphere was then 
subtracted from the VOI of the external surface of the outer shell to give the data for the outer 
shell. 
Uncertainty estimation 
The standard deviation in the five calibration factors. 
5.2.18 Summary of parameters and methods used at each site 
Table 16, summarises the majority of the acquisition/reconstruction parameters and the 
calibration/segmentation techniques used at each site. 
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Table 16. Summary of methods used at each site. CT quality: D = diagnostic CT, ND = non-diagnostic CT. Recon 
Corrections = corrections applied in OSEM reconstruction algorithm: AC = attenuation correction (CTAC = CT-based 
attenuation correction), SC = scatter correction (TEW = triple energy window SC, ESSE = effective scatter source 
estimation SC, MC = Monte Carlo simulation SC), RR = resolution recovery (RR = resolution recovery applied, nor = 
resolution recovery not applied), filtering = application of a post-reconstruction filter (Filt = a post-reconstruction 
filter was applied to the data, noFilt = no post-reconstruction filter was applied). Segmentation techniques: M = 
manual, % = thresholding technique, +margin = fixed margin added to manual or % volume. 
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5.3 Results and Discussion 
Participants reported results independently following the completion of the exercise and their 
results are presented in this section. All results presented here are reported as the difference 
between the locally measured volume and/or activity values and the true volume and/or 
activity, as calibrated at NPL. The absolute differences in activity values presented in this 
section are in terms of the activity at the time of calibration at NPL. 
5.3.1 Measured volumes 
Results 
The deviation of the volumes of the comparison source as measured by the participants from 
the true volumes, as measured at NPL when the sources were prepared, are given in Table 17.  
  Deviation from true volume, % 
H1 H2 H3 H4 H5 H6 H7 
Inner sphere -2.1 -17.0 -9.4 22.2 21.0 -24.0 28.7 
Outer shell 4.3 -60.3 25.0 0.7 36.2 212.4 49.9 
Total source 2.8 -49.7 16.3 6.1 32.4 149.1 44.6 
Table 17. Percentage deviation of measured volumes from true volumes. The true volumes can be found in 
Table 10. 
The volumes reported by the participant who used diagnostic-quality CT images to outline 
assess the volumes (H1) reported the results closest to the truth. The range of volumes 
measured by participants who used non-diagnostic quality CT images to assess the volumes 
(H3, H4, H5) reported answers deviating from the truth by -9.4% (-2.5 ml) to +36.2% (+ 9.6 ml). 
Participant H2 assessed the volumes using thresholding on the SPECT data and underestimated 
the volumes for both sections of the comparison source. Participant H6 underestimated the 
volume of the inner sphere using thresholding on the SPECT data and overestimating the outer 
shell volume using an expanded spherical VOI drawn on the SPECT data. Participant H7 
overestimated both volumes, and used a combination of outlining methods: the inner sphere 
was outlined using auto-contouring on the SPECT data whilst the external surface of the outer 
shell was outlined using the CT data.  
To assess the impact of VOI size on reported activity, the deviation from the true volume of the 
chosen VOI against the deviation from the true activity for the inner shell, outer shell and total 
comparison source was also analysed and presented in the following sections. Note, that for all 
participants except H1, the reported volumes detailed in Table 17 were the VOIs used for the 
activity determination. H1 expanded the external surfaces of both the inner sphere and outer 
shell by 10mm to create their VOIs of choice, resulting in an enlarged VOI for the inner sphere 
and a VOI for the outer shell that was enlarged on the external surface and reduced on the 
internal surface. 
Discussion – volume assessment using manual outlining on CT data 
The data indicates that manual outlining of volumes on diagnostic quality CT images results in 
more accurate volume assessment compared to when using non-diagnostic CT images. The only 
hospital that acquired diagnostic quality CT images was H1, and their reported volume for the 
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inner sphere was 2.1% lower (-0.6 ml) than the true value, for the outer shell they reported a 
value 4.3% higher (+ 3.5 ml) than the true value and for the total source, they reported a volume 
2.8% higher (3 ml) than the true value. Only H4 reported a volume from the CT images that 
more closely matched the true volume: the volume they reported for the outer shell was 0.7% 
higher (+0.2 ml) than the true value, but the value they reported for the inner sphere was 22.2% 
higher (+17.6 ml) than the true value. All other hospitals that performed volume assessment 
using manual outlining on non-diagnostic CT images reported values that were -9.4% (-2.5 ml) 
to +36.2% (+ 9.6 ml) different to the true volumes. Whilst it is impossible to draw definite 
conclusions from the dataset, since only one hospital had the ability to acquire diagnostic 
quality CT, this is an area of work that would be straightforward to replicate on other systems in 
order to verify this finding. 
It is pertinent at this point to discuss the radiation protection issues surrounding this comment: 
all radiation exposure to patients must be clinically justified and so the clinician performing the 
justification must be of the opinion that the CT dose is necessary and appropriate prior to 
performing the imaging. As a result, there is a range of protocols chosen by centres when 
performing CT imaging in the MRT pathway: 
1. None at all: use a CT scan acquired previously for the patient  
o Likely to be diagnostic if acquired in as a stand-alone CT but may be non-
diagnostic if previously acquired as part of a SPECT/CT study 
o Very unlikely to be in same position for CT scan and SPECT scans 
o Disease progression and/or physiological changes may have occurred in the 
elapsed time 
2. One: acquire a single SPECT/CT scan and apply CT to all other SPECT scans 
o Despite best efforts of clinical staff to keep patient positioning identical between 
scans, it will never be possible to be completely identical each time 
o There may also be internal anatomical differences due physiological changes 
between scans, such as the volume of the bladder etc 
3. Multiple: acquire all 3D scans as SPECT/CT scans 
o No differences in patient positioning between SPECT and CT 
Patients undergoing 177Lu-somatostatin analogue molecular radiotherapy receive four cycles of 
therapy, with a post-therapy abdominal SPECT/CT scan performed after each therapy. For an 
abdominal CT scan, the national diagnostic reference levels in the UK are set to: 
 Non-diagnostic: 240 mGy.cm (184) 
 Diagnostic: 910 mGy.cm (185) 
Therefore, for a typical patient undergoing 177Lu-somatostatin analogue molecular radiotherapy, 
four non-diagnostic CT scans will give approximately the same absorbed dose as one diagnostic 
CT.  
Clinicians must use this information, advice from other healthcare professionals and their own 
expertise to assess the optimal choice of CT imaging protocol for a given patient. 
Discussion – volume assessment using auto-contouring on SPECT data 
Segmenting the images using thresholding on the SPECT data resulted in values that deviated 
from the true value by between 17.0% (4ml) and 60.3% (49 ml) and yielded a wider range of 
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volumes than segmenting on the CT data. For the inner sphere, a mean absolute deviation from 
the true volume of 23% was obtained when segmenting using auto-contouring on the SPECT 
data in comparison to the mean absolute deviation from the true volume of 14% for the 
volumes obtained by segmenting on the CT data. It is likely that this is partially due to the 
structure of the comparison source as the outer shell is reasonably slim (10mm). This is close to 
the spatial resolution of the systems (see Table 5 for typical spatial resolution values for gamma 
cameras) and is therefore likely to be subject to partial volume effects, meaning that the shell 
would appear to have an inhomogeneous activity concentration on the images. This 
inhomogeneity in the apparent activity concentration may have made it difficult to assess the 
position of the division between the active inner sphere and the less active outer shell. In 
addition, H2 chose their thresholding values based on their calibration images and so it is 
possible that the thresholding values chosen were not the most appropriate for the comparison 
source. If this is the case then it is likely that the activity concentration ratio chosen by H2 for 
their calibration was different to that used in the comparison source and highlights the need for 
additional care to be taken when attempting to use patient specific calibrations.  
Discussion – volume assessment using manual outlining on SPECT data 
Although there is only one datapoint for manual outlining on the SPECT data (H6, outer shell), 
this reported volume deviated from the true volume by +212.4% (+173 ml), the largest 
deviation of all the reported volumes. As with the diagnostic CT data information, with one 
datapoint it is impossible to draw definite conclusions but this result indicates that manual 
outlining on the SPECT data is not a reliable segmentation method. The participant noted the 
difficulty of assessing the volume of the source in this manner. 
Discussion – volume assessment 
This data suggests that manual outlining on the CT data is likely to be the most robust method, 
although significantly more labour-intensive than using an auto-thresholding on the SPECT 
data. However, many systems allow the user to perform thresholding on the SPECT data, 
applying the outline to the CT data and then adjusting the outline on the CT data which can 
enable significant time savings.  
Some issues were encountered with the study due to different participants interpreting this 
part of the task in different ways. These issues could have been addressed has the instructions 
been clearer and the various possible interpretations considered when designing the 
comparison study. Different participants used different outlining methods depending partially 
on whether they used the knowledge that the comparison source was spherical, and drew 
spherical VOIs on the CT (H1, H3, H5), or whether they assumed no prior knowledge and 
segmented the source by hand (H4, H6, H7) and/or using thresholding techniques (H2, H6, H7). 
Guidance could have been provided to the participants regarding this. However, the choice of 
outlining method(s) will also affect the quantitation of the images and guidance was 
deliberately kept to a minimum to allow participants to use their own choice and judgement. 
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5.3.2 Inner sphere activity 
Results 
The results in Figure 37 demonstrate a spread of 90% (126.5 MBq) [range: -71% (-99.4 MBq) to 
+19% (+27.1 MBq)] in reported activity values between the seven sites. 
 
Figure 37. Participants’ reported results for the activity of the inner sphere, plotted as deviation from true 
activity. The dashed lines represent the uncertainty on the true activity (as calibrated at NPL). The uncertainties 
presented are those reported by the participants. H6 did not report any uncertainty values.  
 
H3 reported the result that was most consistent with the NPL value for the inner sphere (it was 
the closest absolute value, and the NPL value was included within the reported uncertainty 
range) and also had the lowest uncertainty of the participants.  Three of the participants’ (H2, 
H3 and H7) reported ranges included the NPL value. Four participants reported values within 
10% of the true value and six of the participants reported values that were within 20% of the 
true value. 
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The results of the relationship between deviation in VOI and deviation in activity are shown in 
Figure 38. For all participants that used a generic calibration protocol (that is, all participants 
other than H2, circled in red), an increased deviation in VOI resulted in an increased deviation in 
reported activity, and vice versa: expanding the VOI resulted in an overestimate in the activity 
by up to 19% (27.1 MBq) whilst an underestimate of the VOI resulted in an activity that was 
underestimated by up to 71% (99.4 MBq).  
 
Figure 38. Deviation of participants’ chosen VOI from true volume against deviation in reported activity from 
true activity for the inner sphere.  The only result the does not demonstrate an increase in deviation of reported 
activity with an increase in deviation of VOI is H2 (circled in red), who used a patient-specific calibration protocol 
rather than a generic protocol as used by all other participants. Due to an oversight when designing the reporting 
template, participants were not asked to return an uncertainty estimate for the reported volumes, but reported 
uncertainties for the activity values are displayed, except for H6 who did not report any uncertainty values. 
All participants who used a VOI that was at least 83% of the true volume of the inner sphere 
returned activity values of between -2% (-1.2 MBq) and +19% (+27.1 MBq) of the true activity. 
H6 used a VOI that was 24% smaller (-6.3 ml) than the true volume of the inner and reported an 
activity value that was 71% lower (-99.4 MBq) than the true value. 
Discussion 
The overestimation of activity for the inner sphere is likely to be partly due to the inclusion of 
spill-in of counts from the warm background shell surrounding the core. Indeed, H1, H4, H5 and 
H7 all used VOIs larger than the true size volume of the inner sphere, and all overestimated the 
activity by between 6% (+7.8 MBq) and 19% (+27.1 MBq). In contrast, H3 and H6 used VOIs 
smaller than the true volume and underestimated the activity by 2% (-1.2 MBq) and 71% 
(-99.4 MBq) respectively.  
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The only site that did not report results that matched this trend was H2, who used a 
phantom-specific calibration protocol. Since the calibration was performed using an identical 
shell sphere to the comparison source, spill-in and spill-out effects were accounted for in the 
calibration method and any deviation here is likely to be due to an inaccurate calibration factor. 
5.3.3 Outer shell activity 
Results 
The results in Figure 39 have a spread of 350% (107.4 MBq) [range: -34% (-10.5 MBq) to 
+316% (+96.9 MBq)] in reported activity values between the seven participants. 
 
Figure 39. Participants’ reported results for the activity of the outer shell, plotted as deviation from true 
activity. The dashed lines represent the uncertainty on the true activity (as calibrated at NPL). The uncertainties 
displayed are those reported by the participants, with the exception of H6 who did not report any uncertainty values.  
 
H4 reported the closest result to the NPL value, but the NPL value was not included in the 
reported range. Only H2 reported a range that included the NPL value. Three of the participants’ 
(H1, H2, H4) results were within 50% of the NPL value, with six of the seven results being 
within 100%. 
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Figure 40 shows the deviation in VOI against the deviation in activity for the outer shell. The 
results for all participants who used a VOI that was centred on the shell (that is, all except H1, 
circled in red who reduced the inner surface of the outer shell by 5mm) demonstrate that an 
increased VOI results in an increased activity and vice versa.  
 
Figure 40. Deviation of chosen VOI from true volume against deviation in reported activity from true activity 
for the outer shell. The only result the does not demonstrate an increase in deviation of reported activity with an 
increase in deviation of VOI is H1 (circled in red), who removed a margin of 5mm (10mm diameter) from the inner 
surface of the outer shell. The uncertainties displayed on the graph are those reported by the participants – 
uncertainties were not provided for volumes. 
Discussion 
Due to its small thickness (11mm), the outer core was subject to significant partial volume 
effects due to both image sampling (pixelation) and image blurring (low spatial resolution).  
Only one participating site corrected for partial volume effects (H7) whilst five of the sites used 
resolution recovery (H1, H3, H4, H6 and H7). It should also be noted that the radioactivity 
concentrations in the surrounding shell were relatively low compared to the main core, and 
Poisson noise due to low counting statistics may have been a significant factor in the observed 
deviations. Only one site (H4) accounted for Poisson noise in the inter-comparison image in 
their uncertainty estimation, whilst two sites (H3 and H5) incorporated Poisson noise in the 
calibration images into their uncertainty estimation. 
H1, who had used spherical VOIs larger than the inner sphere and outer shell and estimated the 
activity in the outer shell by subtracting the counts in the inner sphere VOI from those in the 
outer shell VOI, underestimated the activity in the outer shell by the largest amount. This is 
likely to be because their choice of segmentation method meant that whilst they excluded much 
of the spill-out from the inner core, they also excluded the counts from radioactivity within the 
inner part of the shell. This is borne out in the results – the difference between the reported 
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value and the true activity value drops from -34 % for the outer shell to +10 % when the total 
comparison source is considered. 
H2 was the only other site that underestimated the outer shell activity and they selected their 
SPECT thresholding levels to be those that most closely matched the physical sizes of the 
comparison source at calibration. They underestimated both volumes: the inner sphere volume 
by 17% (-4.4 ml) and the outer shell by 61% (-49.6 ml). Whilst underestimating the inner 
sphere volume would have meant that counts from the inner sphere would have been 
incorrectly included in the outer shell volume, this was not sufficient to compensate for the 
exclusion of many of the outer shell counts, and the activity in the outer shell was still 
underestimated by 25.3% (-7.7 MBq). As for H1, this is borne out in the results – there is no 
difference between the reported and true activity value for the total comparison source. 
All other sites (H3, H4, H5, H6 and H7) overestimated the outer shell volume, and also 
overestimated the outer shell activity, with two of the three largest activity overestimations 
(H3, H5 and H6) occurring where the volume of the inner sphere was also underestimated (H3 
and H6). However, even the sites for whom the inner sphere volume was overestimated (H4, H5 
and H7) the reported activities for the outer shell was still overestimated, suggesting that the 
overestimation is due to the calibration technique rather than the volume segmentation. 
It is difficult to assess whether the application of corrections for the partial volume effect, as 
performed by H7, was helpful or not in this situation since the VOIs used by H7 did not align 
particularly well with the physical volumes (both the inner sphere and outer shell VOIs were 
larger than the true volumes). 
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5.3.4 Total activity in comparison source 
Results 
Due to questions as to whether the large deviations from the true value seen for the outer shell 
was due to spill-in from the inner sphere, the results reported by the sites for the total activity 
of the comparison source (the sum of the activity for the inner sphere and the outer shell) were 
also investigated. The results, shown in Figure 41, demonstrate a spread of 24% (22.2 MBq) 
[range: -1% (-2.5 MBq) to +23% (+19.7 MBq)]. In total, the participants overestimated the total 
activity by +10%.  
 
Figure 41. Participants’ reported results for the total activity of the inter-comparison source, plotted as 
deviation from the true value. The dashed lines represent the uncertainty on the true activity (as calibrated at 
NPL). The uncertainties presented are the uncertainties reported by the sites for the inner sphere and outer shell, 
combined in quadrature. 
Three of the participants’ (H2, H5 and H7) reported ranges included the NPL value and all 
results were within 30% of the NPL value. 
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Figure 42 shows the deviation in VOI against the deviation in total activity in the comparison 
source.  
 
Figure 42. Deviation of chosen VOI from true volume against deviation in reported activity from true activity 
for the total comparison source. The uncertainties presented are the uncertainties reported by the sites for the 
inner sphere and outer shell, combined in quadrature – uncertainties were not provided for volumes. 
Discussion 
When the activity of the inner sphere and the outer shell were summed to give a total source 
activity, the participants still overestimated the activity in the source but by substantially less, 
on average, than for the outer shell. In the case of H1, H2, H4 and H6 the reported total activity 
was closer to the true total activity than the reported inner sphere value was to the true inner 
sphere value. On the other hand, there was a greater difference between the total activity 
reported by H3, H5 and H7 and the true total activity than there was between the reported and 
true inner sphere value. 
The total reported activity for H2 was almost exactly the true activity (with a deviation of 0% to 
2 significant figures). However, this was the only site (apart from H1) who had underestimated 
the shell activity: they underestimated the outer shell activity by 25% (-7.7 MBq) and 
overestimated the inner sphere activity by 6% (+7.8 MBq). Since the activity in the inner sphere 
was approximately 5 times greater than that of the outer shell, the relatively small over 
estimation of the high inner sphere activity was almost exactly compensated for by the larger 
under estimation of the lower outer shell activity.  
This result highlights the significant impact of spill-in and spill-out, but due to the varied 
methods used by the participants, does not clearly point either of the two methods used in this 
work (expanded VOIs or applying partial volume corrections) being superior to the other. 
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5.3.5 Comparison of all activity results 
Figure 43 summarises all the activity results. 
 
Figure 43. Deviation in reported activity from true activity – summary of all data. The uncertainties presented 
are the uncertainties reported by the sites for the inner sphere and outer shell, and the uncertainties 
presented for the total sources are the two reported uncertainties combined in quadrature. H6 did not 
report any uncertainty values. The uncertainties for H3 and H4 are plotted, but not easily visible in 
comparison to the size of the data points. 
 
5.3.6 Choice of photopeak 
177Lu has two main gamma emissions (90), at 113 keV (6%) and 208 keV (10%). Three 
participants (H2, H3, H4) chose to acquire both photopeaks to maximise the total number of 
counts acquired, whilst four participants (H1, H5, H6, H7) acquired only the 208 keV energy 
window in order to reduce scatter within the image (186). The data showed no advantage to 
using 208 keV in comparison to using both 113 keV and 208 keV, but other variations in the 
protocols used by each participant makes it impossible to draw any conclusions. 
5.3.7 Orbit type 
Two participants (H2 and H6) chose to use a circular orbit for the comparison exercise whilst 
the remaining five used a contoured orbit. With the variations in protocols used by each 
participant, it was impossible to draw any conclusions as to the relative merits of each orbit 
type for the purposes of this exercise. 
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5.4 Conclusions 
The aim of this work was to perform a pan-European inter-comparison quantitative imaging 
exercise and analyse the results reported by the participants.  
The participants described a variety of methods used to determine the calibration factor, mostly 
centred on the measurement of a simple sphere in a Jaszczak phantom, however no single 
method was identified as yielding significantly improved accuracy compared to the others due 
mostly to the small number of participants. Reasonable uncertainties were reported by some of 
the participants and various methods were used to determine these uncertainties, however 
further research into the sources of uncertainty should be performed in order to fully determine 
a realistic total overall uncertainty as only three of the six participants reported uncertainties 
that encompassed the true activity for the inner sphere and only one participant reported 
uncertainties that included the true activity for the outer shell. This inter-comparison exercise 
only investigated a simple geometry, and corrections for partial volume effects, deadtime or 
background concentration were not fully incorporated; however, the results reinforce the need 
for more guidance and presents a method for assessing consistency in this area. 
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6 Hospital Inter-Comparison Using a Common Calibration Protocol 
Whilst visiting the sites for the inter-comparison exercise, additional SPECT/CT images were 
acquired on each system using the protocol discussed in chapter 4 (Early Work: Development of 
Calibration Protocol). The purpose of this exercise was to assess the use of the common 
calibration protocol to see if this minimised the differences in reported activity results by sites, 
and the results are presented in this chapter.  
6.1 Materials and Methods 
The calibration method used for this exercise was the one investigated at the early stages of this 
PhD research – see chapter 4 (Early Work: Development of Calibration Protocol) for further 
details. In short, the calibration protocol consisted of imaging a 16 ml (nominal volume) fillable 
sphere, model number ECT/HS/SET6 (167) in three different geometries in a 9.5 litre elliptical 
Jaszczak phantom (model ECT/ELP/P (166)). The elliptical Jaszczak phantom and the fillable 
sphere were both supplied by Data Spectrum Corporation (DSC, Durham, US) and the 
geometries geometries were (see Figure 27 for SPECT/CT images):  
a. Sphere in centre of empty phantom: “air” 
b. Sphere in centre of water-filled phantom: “water-central” 
c. Sphere off-set 150mm from the centre of the water-filled phantom: “water-offset” 
Spherical VOIs were then drawn on the surface of the sphere on the CT image and the 
corresponding counts in the SPECT image obtained. Counts per second per MBq values were 
calculated for each of the three geometries and the mean of the three values was defined to be 
the calibration factor. The standard deviation in the three calibration measurements (water-
central, water-offset and air) was used as an estimate of uncertainty. 
The template spreadsheet used to analyse the data can be found in Appendix 2. 
The details of the imaging protocol and reconstruction parameters are also detailed in section 4 
(Early Work: Development of Calibration Protocol). 
6.1.1 Preparation of sphere sources 
Each sphere source was prepared at NPL using the method detailed in section 4.2.1 
(Preparation of Sources). A carrier solution was prepared, comprising of 0.1M hydrochloric acid 
plus 10 µg g-1 inactive lutetium. The shell sphere was filled with this carrier solution and left for 
at least 24 hours to ensure that the radioactivity didn’t adhere to the walls of the sphere (181). 
After at least 24 hours, n.c.a. 177Lu was added to the remaining carrier solution and used to fill 
the spheres. Three aliquots were taken of each solution and later used to analyse the activity 
concentration (on two independent secondary standard ionisation chamber systems that had 
previously been calibrated directly against primary standards at NPL) and to ensure there were 
no radionuclidic impurities present (on a secondary standard High-Purity Germanium 
spectrometer). The sphere volumes and activities are detailed in Table 11. 
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 Sphere 
volume, ml 
Uncertainty on 
volume, % 
Activity at mid-point of 
water-central imaging, MBq 
Uncertainty on 
activity, % 
H1 16.17 3.1x10-5 23.14 0.52 
H3 * 15.91 3.2x10-5 27.41 0.52 
H4 * 15.91 3.2x10-5 33.37 0.52 
H5 * 15.91 3.2x10-5 32.27 0.52 
H7 15.98 3.1x10-5 24.11 0.45 
Table 18. Activity of spheres at mid-point of water-central calibration SPECT image. The same source was used 
at H3, H4 and H5. The uncertainty attributed to the volumes was ±5 µg, since a 5 figure balance was used that could 
measure volumes to 10 µg. 
6.1.2 Calibration measurements 
The calibration measurements were made either on the same visit as for the inter-comparison 
exercise or had been made previously at a separate visit. For four of the sites, the calibration 
measurements were performed on a separate visit to the inter-comparison measurements 
whilst for three sites the calibration measurements were performed on the same day as the 
inter-comparison. 
6.1.3 Image analysis 
All of the image analysis was performed by the PhD researcher as an independent operator, 
using a Hermes GOLDTM 4.16 (Hermes Medical Solutions, Stockholm, Sweden) workstation 
located in East Surrey Hospital for both the image reconstruction and data analysis. 
Unfortunately, on return to the UK, the CT data from H2 and H6 was found to be corrupted and 
despite best efforts it proved impossible to retrospectively retrieve the data. Therefore, the data 
in this chapter is limited to five of the seven sites (H1, H3, H4, H5 and H7). 
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6.2 Results 
The results using the calibration protocol are shown in Figure 44, Figure 45 and Figure 46 for 
the inner sphere, outer shell and entire comparison source respectively. The absolute 
differences in activity values presented in this section are in terms of the activity at the time of 
calibration at NPL. 
6.2.1 Inner sphere 
The use of the calibration protocol reduced the variance in the deviation from the true activity 
for the inner sphere from a spread of 90% (126.5 MBq) [range: -71% (-99.4 MBq) to +19% 
(+27.1 MBq)] reported by the participants to a spread of 17% (23.4 MBq) [range: -5% 
(-3.8 MBq) to +12% (+19.6 MBq)]. When only the five hospitals for whom the calibration 
protocol was performed (H1, H3, H4, H5 and H7) were considered, the range for the reported 
results had a spread of 21% (28.3MBq) [range: -2% (-1.2 MBq) to +19% (+27.1 MBq)]. H3 was 
the only site for whom the use of the calibration protocol enlarged the deviation from the true 
activity in the inner sphere (from -2% to +8%). When using the calibration protocol, the activity 
was overestimated for two sites (H1 and H3) and underestimated for the other three (H4, H5, 
H7), with a mean overestimate of activity of +1%. The reported results for these five sites 
overestimated the activity in the inner sphere by a mean of +9%.  
 
Figure 44. Use of the calibration protocol for assessing the activity of the inner sphere, presented as deviation 
from the true activity. Uncertainties on participant reported data are those reported by the participants. The 
uncertainty on the calibration protocol data is the standard deviation of the three calibration measurements. 
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6.2.2 Outer shell 
The use of the calibration protocol resulted in an increase in the deviation of the activity from 
the value for all five sites, from a mean overestimate of +38% in the participant reported 
activity compared to +138% when using the calibration protocol. 
When all seven sites were considered, the use of the calibration protocol reduced the variance 
in the deviation from the true activity for the outer sphere from a spread of 350% (107.4 MBq) 
[range: -34% (-10.5 MBq) to +316% (+96.9 MBq)] when the participants reported the results to 
a spread of 177% (80.0 MBq) [range: +58% (+11.6 MBq) to +235% (+68.4 MBq)]. However, 
when only the five sites for whom the calibration protocol was used are considered, the spread 
was increased in comparison to the participant reported results with a spread of 117% (23.7 
MBq) [range: -34% (-10.5 MBq) to +83% (+13.2 MBq)].  
 
Figure 45. Use of the calibration protocol for assessing the activity of the outer shell. Uncertainties on 
participant reported data are those reported by the participants. The uncertainty on the calibration protocol data is 
the standard deviation of the three calibration measurements. 
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6.2.3 Entire comparison source 
When the activity of the inner sphere and the outer shell were summed to give a total source 
activity, the calibration protocol overestimated the total source activity for all sites and 
increased the deviation from the true activity for all sites except H4 in comparison to the 
participants’ own protocols.  
 
Figure 46. Use of the calibration protocol for assessing the activity of the entire comparison source. The 
uncertainty values are the uncertainty values for the inner sphere and outer shell combined in quadrature. 
6.3 Discussion 
The use of the calibration protocol reduced the variation in activities for the inner sphere for all 
sites from 19% maximum deviation in the participant reported results to 12% when using the 
calibration protocol. However, the opposite was true for the outer shell in which case the 
calibration protocol increased the variation in activities for all sites (from a maximum deviation 
of 83% for the five participants reported results to a maximum deviation of 235% for the 
calibration protocol method). These results suggest that whilst the calibration protocol does 
reduce variability in results for hot lesions (the inner sphere), it can lead to a worsening in the 
quantification of activity in regions subject to partial volume effects. It is likely that this is 
caused by the method of reconstruction used for this work: all data for the calibration protocol 
was reconstructed using a manufacturer-independent work station (a Hermes GOLDTM version 
4.16). Whilst the theory of resolution recovery is relatively straightforward (see Section “Depth-
dependent spatial resolution”), it is not possible to extract the details of how this is performed 
in the manufacturer reconstruction software. In order to perform resolution recovery as part of 
the image reconstruction process in Hermes GOLDTM, the user is required to input information 
pertaining to the collimator holes dimensions, detector details and energy resolution details. 
Most of this information is available in the camera manufacturer manuals or datasheets (92–
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94), whilst some was provided by Hermes Medical support staff (telephone call to Hermes 
Medical helpdesk on 24th July 2014). It is quite possible that the resolution recovery algorithm 
performed in the camera manufacturer software may have more detailed information 
incorporated into it than is possible with the Hermes GOLDTM system using only the published 
system data. This is something that could be investigated as part of future work if ready access 
to the various manufacturer workstations were available. During the course of the PhD there 
was ready access to a Hermes GOLDTM workstation and a GE workstation, but not a Siemens 
workstation. Since Siemens data cannot be readily reconstructed on a GE workstation (and vice 
versa – it is possible to force the systems to do basic reconstructions, but not to incorporate, for 
example, resolution recovery corrections), it was decided to reconstruct all data on a Hermes 
system. 
The uncertainty estimates generated from the common calibration protocol method (where the 
uncertainty was the standard deviation in the three calibration measurements) were generally 
smaller or approximately equal to those estimated by the participants. From the data, the 
uncertainty values appear to be generally underestimated, since only a few of the uncertainty 
ranges included the true activity value. For reported activities to be of clinical value, it is vital 
that the uncertainty range reported for an activity encompasses the true activity. Whilst 
uncertainties shouldn’t be wildly overestimated, this dataset suggests sites are likely to report 
uncertainty values that are too small and that the uncertainty calculation method proposed by 
the common calibration protocol is also insufficient. The two likely reasons for the inaccurate 
uncertainty values is that the uncertainty values incorporated into the uncertainty assessment 
have been underestimated and that not all sources of uncertainty have been incorporated into 
the uncertainty assessment. Further research into the sources, and size, of uncertainty in this 
field is therefore necessary in order to allow more complete uncertainty calculations to be 
performed.  
6.4 Conclusions 
This purpose of this work was to investigate whether the use of a common calibration protocol 
provided more accurate quantitative results than allowing hospitals to use their local 
procedures. 
The use of the calibration protocol was shown to reduce the variation in activities reported for 
volumes of around 26ml (the inner sphere), but not necessarily for smaller areas of interest 
(such as the outer shell) that are likely to be subject to partial volumes effects. Since a range of 
sizes were not investigated, it is not possible to state a minimum volume for which this 
calibration protocol may be suitable, or indeed confirm that the protocol can be used for larger 
volumes. The method of uncertainty estimation used in the calibration protocol is 
acknowledged to be incomplete, and the results demonstrate this. Further exploratory work 
could be done to establish whether the poorer performance of the calibration protocol for 
regions affected by partial volume could be due to using a vendor neutral workstation (such as 
Hermes GOLDTM), and whether using the resolution recovery on the native gamma camera 
workstation would produce superior results. 
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7 Methods Comparison 
This chapter contains the results of the follow-on work performed after the pan-European 
inter-comparison exercise in which all the imaging methods used by the participants were 
replicated on a single gamma camera in order to individually assess the impact of each variable. 
7.1 Materials and Methods 
In order to individually assess the impact of the different calibration, acquisition, reconstruction 
and segmentation methods on the quantification of the activity in the inter-comparison 
phantom, almost all of the methods used by the various participating sites for the inter-
comparison study were replicated on a single gamma camera (an Optima 640 SPECT/CT – a 
non-diagnostic CT) with the data reconstruction and image segmentation all performed on the 
same Hermes GOLDTM 4.16 workstation as used for the calibration protocol work in section 6 
(Hospital Inter-Comparison Using a Common Calibration Protocol). The one method that wasn’t 
replicated on the gamma camera was the use of a circular orbit rather than a contoured orbit. 
H2 and H6 were the only two sites who used circular orbits for the inter-comparison imaging 
and they were also the two sites who proved the most difficult to liaise with. Despite 
communicating with them about the inter-comparison over a number of months in the 
preparation phase, neither site mentioned their intention to use a circular orbit when acquiring 
the data until the day of imaging. By that point, a substantial number of the calibration 
measurements for methods comparison imaging work and already been carried out and it was 
impossible to repeat the work due to the financial cost of n.c.a. 177Lu. Acquiring all the 
calibration and imaging data on a single gamma camera removed any inter-camera variability.  
The template spreadsheet used to analyse the data can be found in Appendix 2. 
7.1.1 Calibration methods 
The calibration methods investigated are listed below, with the corresponding participants 
noted in brackets: 
1. 130 ml bottle imaged in air, SPECT/CT (none of the participants) 
2. 130 ml bottle imaged in water, SPECT/CT (H1)  
3. 16 ml sphere imaged in water, SPECT/CT (H3) 
4. The mean cps/MBq factor obtained when imaging a 16 ml sphere in air, in the centre of 
a water-filled phantom and at a 15cm off-set from the centre of a water-filled phantom, 
SPECT/CT (H4, H5) 
5. Large volume source, SPECT/CT (H6) 
6. 3 x Petri dishes, planar (H7) 
7. Point source imaged in air, SPECT/CT (none of the participants) 
8. Point source imaged in water, SPECT/CT (none of the participants) 
9. The mean cps/MBq factor for a point source imaged in air and in water, SPECT/CT 
(none of the participants) 
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The diagrams in Figure 47 visually illustrate the calibration methods used in this work. 
    
   
 
Figure 47. Calibration geometries used.  Radioactive solutions are depicted in yellow. Top row: left = side view of 
130 ml bottle in circular Jaszczak phantom (bottle secured to the rod usually used to secure the spheres in place), 
middle = side view of 16 ml sphere at centre of elliptical Jaszczak phantom, right = side view of 16 ml sphere off-set 
from centre of elliptical Jaszczak phantom. Middle row: left = side view of point source in circular Jaszczak phantom, 
right = side view of large volume source: circular Jaszczak phantom filled with radioactive solution. Bottom row: top 
view of Petri dish positioned centrally on face of detector (shown in grey). 
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130 ml bottle 
A 130 ml plastic bottle was filled with a homogenous solution of n.c.a. 177Lu and imaged in a 
circular Jaszczak phantom (model ECT/STD/P (187)) with a nominal volume of 6.8 litres 
supplied by Data Spectrum Corporation (DSC, Durham, US). The phantom was subsequently 
filled with water and imaged again. 
The measurement in water represented the technique used by participant H1 (a 130 ml bottle 
filled with 177Lu, positioned adjacent to a large water filled phantom and imaged). H1 also filled 
three spheres with activity within the phantom to perform validation measurements on the 
calibration factor obtained, meaning that the bottle could not be positioned inside the water-
filled phantom. Since the purpose of the water-filled phantom was to provide a scatter-material, 
and validation measurements were not required for this work, the bottle was instead positioned 
inside the phantom and no sphere measurements were obtained. 
The measurement in air was not a technique used by any participant but was included as the 
measurement of a calibration source in air is a commonly used calibration method in the field of 
Nuclear Medicine, and this was a non-conventional calibration shape. 
Calibration factors (cps/MBq) were obtained for the bottle in air and the bottle in water. 
16 ml sphere 
A 16 ml sphere was filled with a homogeneous solution of n.c.a. 177Lu, and imaged three times 
within a Jaszczak phantom:  
1. At the centre of the phantom, with the phantom unfilled (i.e. in air) 
2. At the centre of the phantom, with the phantom filled with water 
3. At a 15cm off-centre position in the phantom, with the phantom filled with water  
Calibration factors (cps/MBq) were obtained for the sphere at each of the above imaging 
positions. The calibration factors used for this work were the sphere in water at the centre of 
the phantom, and the mean calibration factor for the three positions. 
Large volume source 
A Jaszczak phantom was filled with a homogenous solution of n.c.a. 177Lu. An 8cm spherical VOI 
was drawn in the centre of the phantom, and a calibration factor derived. An additional 
calibration factor was also obtained for the total counts in the image (i.e. without any 
segmentation or selection of counts). Although this was not a technique used by any of the 
participants, it is a method that is often used in the field of Nuclear Medicine. 
Petri dishes 
Three Petri dishes of diameter 8.6cm were filled with a homogenous solution of n.c.a. 177Lu. 
Each Petri dish was in turn placed in the centre of each head of the dual-headed gamma camera 
and a planar acquisition obtained. Circular ROIs of 14cm diameter (size determined by scaling 
up the diameter used by H7 for their 6cm diameter Petri dishes) were drawn around each of the 
planar dishes on the images, with four further ROIs of the same dimensions drawn in the 
background region to correct for background counts. A mean cps/MBq factor was calculated for 
the three sources over both heads. 
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Point source 
A 31μL fillable micro-sphere (the smallest sphere in the set ECT/MI-HS/SET4 (167) supplied by 
DSC, Durham, US) was used to approximate a point source. It was filled with a homogenous 
solution of n.c.a. 177Lu and imaged in air and in water. Two in-air cps/MBq values were 
calculated: one for which a VOI was drawn around the point source and one in which the total 
counts in the image was used. 
The use of both a point source calibration and the “total counts” method was included in this 
investigation because, although not used by any of the participants, they are frequently used 
calibration methods in the field of Nuclear Medicine and literature.  
7.1.2 Activity Determination 
The preparation of all sources were performed using the technique detailed in section 4.2.1 
(Preparation of Sources). 
In summary, standard solutions of n.c.a. 177Lu with 0.1M HCl in deionised water were created 
(4ml in a glass Schott vial), and measured in Fidelis ionisation chamber, directly traceable to the 
NPL primary standard. All further dilution and sub-dispensing of 177Lu was performed by mass 
using a four figure electronic balance. The template worksheet used for this work can be found 
in Appendix 2. 
7.1.3 Acquisition parameters 
As discussed in the section entitled 5 (Hospital Inter-Comparison), many of the acquisition 
parameters were identical at all sites, and were therefore used for this work: 
 Matrix size of 128 x 128 
 120 projections 
 30 seconds per projection 
 Main photopeak set to 208 keV ± 10% 
The acquisition parameters that varied between sites are shown below, with the acquisition 
parameters used for this part of the work outlined in italics: 
 Choice of photopeak(s): 4 sites used only the 208 keV photopeak, whilst three used both 
the 208 keV and the 113% keV photopeaks. Both photopeaks were acquired 
simultaneously with ± 10% photopeak width. 
 Scatter windows: three sites acquired scatter windows, four didn’t. Of the four that 
didn’t, two performed scatter correction using Monte Carlo simulation. Image 
reconstruction was performed on Hermes GOLDTM which uses Monte Carlo simulation for 
scatter correction and so no scatter windows were acquired. 
 Orbit type: 2 sites used a circular orbit and 5 used a contoured orbit. As discussed at the 
start of this chapter, calibration measurements were already well underway when the use 
of a circular orbit was proposed – therefore all this work was performed using contoured 
orbits. 
 CT-quality: 1 site used a diagnostic quality CT and 6 used non-diagnostic CT images. 
Non-diagnostic CT data was used since diagnostic CT data was not available on the 
gamma camera used for this work. 
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7.1.4 Reconstruction parameters 
All reconstructions were performed on a single Hermes GOLDTM version 4.16 workstation (the 
same workstation used for the work performed in Chapter 6) to remove any inter-software 
variability. 
Image reconstructions were performed using an OSEM algorithm (5 iterations and 10 subsets), 
as this is the number of updates in the common protocol. Every site used a different 
combination of number of iterations and subsets, from a minimum of 32 updates (H2: 8 
iterations and 4 subsets) through to 576 (H4: 24 iterations and 24 subsets). The median number 
of updates used by the seven sites was 75 updates with all sites except H4 using between 32 and 
80 updates. The time required to perform the reconstructions for all seven combinations of 
iterations and subsets rendered this infeasible to perform due to the limited access to the 
Hermes GOLDTM workstation. 
 CT-based attenuation correction and Monte Carlo-based scatter correction were incorporated 
into the reconstructions. 
The dataset was reconstructed using the 208 keV photopeak only and also the 113 keV and 
208 keV photopeaks in combination, plus the addition and absence of resolution recovery. 
The effect of applying a Gaussian filter with a FWHM of 8mm (as used by H6, the only 
participant to perform post-reconstruction filtering) was also investigated. 
7.1.5 Image segmentation methods 
All image segmentation was performed by a single operator (the PhD researcher) on the same 
Hermes GOLDTM 4.16 workstation as used for the reconstructions in order to remove any 
inter-operator variability. 
The image segmentation methods used were: 
 VOIs drawn tight to the CT volumes: 
a. The spherical VOI drawing tool for the inter-comparison phantom plus the 
calibration methods performed using the 16 ml sphere, point source and large 
volume source. 
b. Manual outlining was performed on a slice-by-slice basis for the bottle 
 The VOIs from method 1, with the diameter expanded by 10mm (the technique used by 
H1) 
 VOIs drawn on SPECT volumes using a thresholding technique: thresholds of 35% for 
the inner sphere and 10% for the outer shell were used. These were the thresholds used 
by H2. Assessment of the suitability of these thresholds were performed by applying 
these thresholds to the calibration data acquired and the volumes of the VOIs yielded 
using these thresholds were a close visual match to the VOIs drawn on the CT volumes. 
For all calibration techniques except the Petri dishes (where planar image segmentation was 
used) and the total counts for the point source in air (where no image segmentation was 
performed at all), the same image segmentation methods were used for the calibration and 
inter-comparison phantom.  
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Figure 48. An illustration of image segmentation performed on the Hermes GOLDTM for the 177Lu 
inter-comparison phantom. Left: VOIs on CT data, right: VOIs on SPECT data. The spherical VOIs are those drawn 
manually on the CT data whilst the pixelated VOIs are those generated on the SPECT data using thresholding. The 
Hermes GOLDTM workstation automatically displays all VOIs on both datasets. 
 
7.1.6 Uncertainty analysis 
An uncertainty was estimated for each calibration method as the standard deviation in counts 
(Poisson noise) in the calibration measurement combined in quadrature with the uncertainty in 
the activity of the calibration source. The uncertainty analysis method given in the common 
protocol cannot be used in this scenario, since it  
7.2 Results 
Since the variables used in this work were categorical, it was not possible to present all the data 
in a single graph (such as a surface plot). Instead the data is presented three times, with one of 
the three categorical variables fixed each time. In each scenario, the categorical variables was 
selected to match the common protocol discussed in the previous chapter, that is: 
 Calibration method: 
o 16 ml sphere imaged in elliptical Jazsczak phantom in air, water and water off-
set 
o Calibration factor = mean cps/MBq from the three images 
 Image reconstruction parameters: 
o 113 and 208 keV photopeaks 
o Resolution recovery performed 
o No post-reconstruction filter applied 
 Image segmentation method: 
o Spherical VOIs drawn to match the CT volumes. 
As in the previous chapters, the data is presented as the % difference between the calculated 
activity using the derived calibration factors and the true activity. In addition to using the 
calibration factors to calculate the activities within the inner sphere and outer shell, the factors 
were also used to calculate the activity within a 16 ml sphere imaged in water at the centre of 
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the phantom. This was included in order to provide three different complexities of imaging 
situations: 
1. 16 ml sphere imaged in water. Active “lesion” surrounded by inactive “background” 
2. Inner sphere. Active “lesion” surrounded by less active “background” 
3. Outer shell. Low activity area close to a higher activity “lesion” 
The first imaging situation (16 ml sphere in water) was included due to concerns about the 
impact of spill-in/spill-out of counts in the comparison phantom due to partial volume effects 
(discussed in the previous chapters). Whilst the 16 ml sphere imaged in water is one of the 
calibration methods used and therefore is of limited use when looking at that particular 
calibration method, it is nevertheless a useful comparison to make due to the absence of a 
neighbouring activity and is of the same shape and similar size to the inner sphere of the 
comparison phantom (the inner spheres were approximately 26ml in volume). 
To aid the reader, the same scale is used on both y axes on all graphs. 
Notation used in graphs: 
 113+208: 113 keV photopeak was used in image reconstruction in addition to 208 keV 
 208: only the 208 keV photopeak was used in image reconstruction 
 RR: resolution recovery was performed 
 noRR: resolution recovery was not performed 
 noFilt: no post-reconstruction filtering was performed 
 GaussFilt: a Gaussian filter (with FWHM = 8mm) was applied post-reconstruction 
 CT tight: spherical VOIs drawn to the volume on the CT 
 CT+10mm: spherical VOIs drawn to the volume on the CT and then expanded by 5mm 
in each direction 
 35% contour: image segmentation performed using thresholding on the SPECT data, 
and a threshold value of 35% was used 
 10% contour: image segmentation performed using thresholding on the SPECT data, 
and a threshold value of 10% was used 
 Air – bottle: calibration performed using 130 ml bottle imaged in air 
 Air – point source: calibration performed using point source imaged in air 
 Air – point source, whole image: calibration performed using point source imaged in 
air and counts in entire image used 
 Water – bottle: calibration performed using 130 ml bottle imaged in water 
 Water – point source: calibration performed using point source imaged in water 
 Water – sphere: calibration performed using 16 ml sphere imaged in water 
 Large volume source, 8cm sphere: calibration performed using 6.8 litre source, with 
counts obtained from 8cm diameter sphere at centre of phantom 
 Large volume source, 8cm sphere: calibration performed using 6.8 litre source and 
counts in entire image used 
 Planar – Petri dishes: 3 x 8.6 cm diameter Petri dishes imaged at centre of gamma 
camera detector 
 Mean – point source: mean cps/MBq from point source measured in air and in water 
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 Mean – sphere: mean cps/MBq from 16 ml sphere measured in air, water-central and 
water-offset (i.e. the common protocol calibration method)  
7.2.1 Fixed calibration method 
The results for the fixed calibration method are shown in Figure 49, Figure 50 and Figure 51. 
The data is presented in three graphs, since the scale on Figure 50 is too large to show the detail 
of the measurements that yielded activity values for the inter-comparison source that were 
close to the true activity. The same data is therefore presented again in Figure 51 on a smaller 
scale. 
The calibration for all data in this section was performed as stipulated by the common 
calibration protocol – the 16 ml sphere imaged in an elliptical Jazsczak phantom in air, water 
and water off-set, with the calibration factor calculated as the mean cps/MBq from the three 
images. 
 
Figure 49. Difference between calculated and true cps/MBq values for inner sphere and 16 ml sphere 
(labelled “NPL sphere”) for fixed calibration method (16 ml sphere imaged in air, water-central and 
water-offset). Uncertainties plotted are the standard deviation (Poisson noise) in the calibration measurement 
combined in quadrature with the uncertainty in the activity of the calibration source. 
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Figure 50. Difference between calculated and true cps/MBq values for inner sphere and outer shell for fixed 
calibration method (16 ml sphere imaged in air, water-central and water-offset). Uncertainties plotted are the 
standard deviation (Poisson noise) in the calibration measurement combined in quadrature with the uncertainty in 
the activity of the calibration source. 
 
Figure 51. Difference between calculated and true cps/MBq values for inner sphere and outer shell for fixed 
calibration method (16 ml sphere imaged in air, water-central and water-offset). Same data as in Figure 50, but 
plotted on a smaller scale – thereby not displaying some of the calculated activities that differed most from the true 
activity. Uncertainties plotted are the standard deviation (Poisson noise) in the calibration measurement combined in 
quadrature with the uncertainty in the activity of the calibration source. 
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Image segmentation method 
The choice of image segmentation method resulted in deviations of less than 4% from the true 
cps/MBq for the NPL sphere in a cold background, with the use of a VOI of the CT volume + 
10mm resulting in the correct answer for all reconstructions. Using VOIs equal to the CT volume 
resulted in deviations of up to 4% from the true cps/MBq, whilst using thresholding on the 
SPECT data consistently overestimated the cps/MBq by up to 3%. 
Deviations of up to 10% were observed in the reported cps/MBq for the inner sphere compared 
to the true value. Using a VOI equal to the size of the CT volume resulted in deviations of up to 
10%, whilst thresholding on the SPECT data gave deviations of up to 8%. The use of a CT 
volume +10mm VOI gave the most correct answers but consistently underestimated the 
cps/MBq by up to 6%.  
Deviations of greater than 1000% were observed for the outer shell. Thresholding on the SPECT 
data resulted in the smallest range of results across all reconstructions, consistently 
underestimating the cps/MBq by up to 40%. Using a VOI of the same volume as the CT resulted 
in cps/MBq underestimates of up to 70% whilst using the expanded CT volume (CT + 10mm) 
overestimated the cps/MBq by between 90% and 1000%. 
Resolution recovery 
Performing resolution recovery during the image reconstruction process generally decreased 
the deviation in the calculated cps/MBq in comparison to the non-resolution recovery corrected 
data. The situations in which this was not true, and use of resolution recovery resulted in an 
increased deviation in the calculated cps/MBq were: CT+10% contour segementation on outer 
shell (for all reconstructions) and the inner sphere, when the data was reconstructed with no 
post-reconstruction applied. For all calculated cps/MBq values for the outer shell using a CT 
tight or 35% contour segmentation, the use of resolution recovery decreased the deviation. 
Using resolution recovery on all inner sphere data for all reconstructed performed with a 
post-reconstruction filter applied also reduced the deviation from the true value. 
Overall, the use of resolution recovery corrections resulted in a smaller range of cps/MBq 
values, improving the accuracy of the calculated activities. 
Post-reconstruction filtering 
Performing post-reconstruction filtering on the image data had little effects on the NPL sphere 
results, but for the inner sphere and outer shell generally decreased the deviation (or had no 
effect) resulting in a more accurate calculated cps/MBq. 
113 keV photopeak 
Inclusion of the 113 keV photopeak did not make a consistent difference in the quantification of 
the activity in the NPL sphere, but for the inner sphere and outer shell using the 113 keV 
photopeak decreased the accuracy of the reported cps/MBq in comparison to using only the 
208 keV. 
 
 
 
125 
 
7.2.2 Fixed image reconstruction parameters 
The results for the fixed image reconstruction parameters are shown in Figure 52, Figure 53 
and Figure 54. The data is presented in three graphs, since the scale on Figure 53 is too large to 
show the detail of the measurements that yielded activity values for the inter-comparison 
source that were close to the true activity. The same data is therefore presented again in Figure 
54 on a smaller scale. 
All data presented in this section is reconstructed with the parameters detailed in the common 
calibration protocol: 113 keV and 208 keV photopeaks used, resolution recovery performed and 
no post-reconstruction filter applied. 
 
 
Figure 52. Difference between calculated and true cps/MBq values for inner sphere and 16 ml sphere (“NPL 
sphere”) for fixed image reconstruction parameters. Uncertainties plotted are the standard deviation (Poisson 
noise) in the calibration measurement combined in quadrature with the uncertainty in the activity of the calibration 
source. 
126 
 
 
Figure 53. Difference between calculated and true cps/MBq values for inner sphere and outer shell for fixed 
image reconstruction parameters. Uncertainties plotted are the standard deviation (Poisson noise) in the 
calibration measurement combined in quadrature with the uncertainty in the activity of the calibration source. 
 
Figure 54. Difference between calculated and true cps/MBq values for inner sphere and outer shell for fixed 
image reconstruction parameters. Same data as in Figure 53, but plotted on a smaller scale – thereby not 
displaying some of the calculated activities that differed most from the true activity. Uncertainties plotted are the 
standard deviation (Poisson noise) in the calibration measurement combined in quadrature with the uncertainty in 
the activity of the calibration source. 
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The use of point sources as a calibration method resulted in an underestimate in the cps/MBq 
values for all image segmentation methods. Conversely, dispersed sources (including the point 
source, when using the total counts in the entire image) resulted in an overestimate in the 
cps/MBq. 
The smallest spread in deviation from the true cps/MBq was seen for the 16 ml sphere and the 
130 ml bottle – where the calibration source was a reasonably close approximation to the 
comparison source. 
The two methods that had the largest range of answers were the “whole image” methods (point 
source in air where the total counts in the image were used and the large volume source) 
followed by a VOI drawn within a large volume source. 
The Petri dish method was the only independent method (i.e. the only method that did not use 
the NPL sphere for calibration) for which the range of answers included the true cps/MBq for 
the inner sphere. 
All calibration methods either systematically over or underestimated the cps/MBq for the outer 
shell, regardless of the image segmentation method used. 
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7.2.3 Fixed image segmentation method 
The results for the fixed image segmentation method are shown in Figure 55 and Figure 56. 
All data presented in this section has been segmented in the manner stated in the common 
calibration protocol: spherical VOIs drawn to the volume on the CT data. 
 
 
Figure 55. Difference between calculated and true activity values for inner sphere and 16 ml sphere (“NPL 
sphere”) for fixed image segmentation method. Uncertainties plotted are the standard deviation (Poisson noise) 
in the calibration measurement combined in quadrature with the uncertainty in the activity of the calibration source. 
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Figure 56. Difference between calculated and true activity values for inner sphere and outer shell for fixed 
image segmentation method. Uncertainties plotted are the standard deviation (Poisson noise) in the calibration 
measurement combined in quadrature with the uncertainty in the activity of the calibration source. 
When the image segmentation method is fixed, it becomes clear that the whilst the dispersed 
sources are not optimal for calculating cps/MBq values for the NPL sphere or inner sphere of 
the comparison phantom, they do provide more accurate values for the outer shell of the inter-
comparison phantom than the 16 ml sphere, 130 ml bottle and the Petri dishes are able to. The 
dispersed sources are the only sources for which the range of values reported for the outer shell 
contains the true value. 
7.3 Discussion 
7.3.1 Calibration method 
Inner sphere 
The most accurate calibration method for the inner sphere, that is an active lesion surrounded 
by a lower activity concentration background, was obtained using the 16 ml sphere calibrations, 
followed by the Petri dishes. The Petri dish and 16 ml sphere calibrations were the only method 
for which the range of calculated cps/MBq values (over all reconstructions and image 
segmentation methods) included the true value. 
The third most accurate calibration method was the 130 ml bottle, although this method 
consistently overestimated the cps/MBq values across all reconstructions and image 
segmentation methods. 
The use of dispersed calibration sources yielded the least accurate results. 
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The point source calibration methods were the only methods that underestimated the cps/MBq 
values. 
Where calibrations can be performed using objects of a similar size to those seen clinically, the 
best results are obtained, and even where the calibration object is only very approximately 
representative of the clinical objects (as for the 130 ml bottle), good results are still obtained. 
However, for a generic whole-system calibration method that is independent of object size, the 
use of planar Petri dishes performed very well. Concerns often raised over the use of planar 
calibrations is that this method is reliant on the image reconstruction software to be robust 
enough to correct for all attenuation, scatter and depth-dependent spatial resolution effects but 
this work has demonstrated that, for active lesions, this is a viable and recommended option. 
Outer shell 
Due to the spill-in and spill-out of counts to and from the outer shell, the dispersed calibration 
sources gave the most accurate cps/MBq values for the outer shell (where the CT+10mm image 
segmentation results were excluded). This held true across all reconstructions and image 
segmentation methods with the exception of the CT+10mm segmentation method. 
The Petri dish and point source calibration methods were the least accurate when assessing the 
cps/MBq for a region affected by spill-in and spill-out. 
7.3.2 Imaging parameters 
113 keV photopeak 
More accurate results were obtained when the 113 keV photopeak was not used – the improved 
quantification due to reduction in scatter by not using the 113 keV photopeak appears to 
compensate well for the reduction in counts. 
Resolution recovery 
The use of resolution recovery is recommended since it reduces the range of cps/MBq values 
obtained over all calibration and image segmentation methods. 
Post-reconstruction filtering 
The use of post-reconstruction filtering appears to be generally beneficial, resulting in either 
increased accuracy of cps/MBq values, or having no effect. It should be noted here, however, 
that this result is likely to vary considerably depending on the filter parameter used, and that 
was not something that was investigated in this work. 
7.3.3 Image segmentation method 
The CT+10mm image segmentation method was the most accurate when assessing cps/MBq for 
the inner sphere and 16 ml sphere. It was, however, by far the worst method for calculating the 
cps/MBq for the outer shell. 
The SPECT thresholding method was the most robust for the outer shell, and also performed 
well for the inner sphere and 16 ml sphere. It would therefore be recommended to outline 
lower activity regions using an SPECT thresholding method and selecting a threshold value that 
produces a volume approximately equal to that obtained by outlining on the CT data. 
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Outlining using the CT volumes (i.e. without any consideration for spill-in / spill-out of counts) 
results in less accurate cps/MBq values. 
7.4 Conclusions, Recommendations and Further Work 
7.4.1 Conclusions and Recommendations 
The work in this chapter replicated all of the calibration, acquisition, reconstruction and 
segmentation methods used by the participants in the pan-European inter-comparison study 
that was performed in Chapter 5. The methods were replicated on a single gamma camera in 
order to individually assess the impact of each variable on the quantification of the activity in 
the inter-comparison phantom. 
From this body of work, the following conclusions and recommendations are made: 
Calibration Method 
For assessing activities within active lesions or objects, the use of calibration sources of a 
similar size and geometry are likely to yield the most accurate results. However, where a more 
generic calibration is desired that can be used for lesions and objects of a range of shapes and 
sizes, the use of planar calibrations provides the most accurate results. 
When determining activities in low activity areas adjacent to higher activity areas, the use of a 
dispersed calibration source provides the most accurate results. 
Imaging parameters 
It is recommended that only the counts from the 208 keV photopeak are used, where feasible. In 
some, low count circumstances it may still be necessary to use the 113 keV photopeak too but 
users should be aware that this will decrease the accuracy of the results. 
It is recommended that resolution recovery be performed for quantitative imaging since, in the 
situations investigated in this work, it yields increased quantitative accuracy. 
The work performed in this thesis demonstrated an advantage to performing 
post-reconstruction filtering, however care should be taken by the users to ensure that suitable 
filtering parameters are used. 
Image segmentation method 
For active lesions in low activity regions, the use of an expanded VOI (compared to the VOI as 
seen on the CT) gives the best results, but this method doesn’t work well for low activity regions 
close to higher activity regions. The method of using an expanded VOI is likely to have an ever 
greater impact as the size of the object decreases and partial volume effects play a more 
significant role. 
The SPECT thresholding method was the most robust for the outer shell, and also performed 
well for the inner sphere and 16 ml sphere. It would therefore be recommended to outline 
lower activity regions using a SPECT thresholding method and selecting a threshold value that 
produces a volume approximately equal to that obtained by outlining on the CT data. 
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7.4.2 Further work 
From this body of work, the following areas are suggested for further work in the field of 
quantitative SPECT/CT imaging: 
Calibration Method 
In this work, only planar images of the Petri dishes were obtained. However, if SPECT/CT 
images were obtained of the Petri dishes, and the total counts in the images used to obtain a 
“dispersed calibration source” cps/MBq factor then it is feasible that cps/MBq factors could be 
obtained for both high and low activity regions using a single set of calibration sources. This 
would require further investigation. 
Imaging parameters 
There is concern that the use of resolution recovery corrections can result in image artefacts in 
SPECT/CT imaging. Although not demonstrated in this work, further work needs to be done into 
the effect of resolution recovery on quantitative accuracy for smaller lesions than those used in 
this work, as they will be more greatly affected.  
A significant amount of work needs to be performed before the use of post-reconstruction 
filtering can be recommended, looking into the effects of the various parameters that can be 
used on the range of likely clinical scenarios. 
Image segmentation method 
The work performed in this thesis needs to be expanded to include segmentation of 
cold/in-active regions within active regions (such as necrosis in tumours). 
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8 Conclusions, Clinical Impact, Recommendations and Further Work 
The aims of the PhD were to: 
1. Assist in developing a practical, consensus-based calibration protocol for quantitative 
SPECT/CT imaging for γ-emitting radiopharmaceuticals as part of the MetroMRT 
project. 
2. Perform a hospital inter-comparison exercise for quantitative SPECT/CT imaging of 
177Lu, using both the local clinical protocols decided by the hospital and the calibration 
protocol developed in aim 1. 
3. Replicate all calibration, imaging, reconstruction and segmentation methods and 
parameters used in the local clinical protocols in aim 2 on a single gamma camera to 
assess the impact of each method and parameter on activity quantification and make 
recommendations as to which methods and parameters to use for quantitative 
SPECT/CT imaging of 177Lu. 
The hypotheses were that the use of a common calibration and imaging protocol would reduce 
inter-hospital variability in reported activity values and that activity uncertainty can be reduced 
if careful selection of quantitative imaging parameters is performed. 
This chapter reviews the results and conclusions from this thesis with details regarding the 
potential clinical impact of the recommendations, summarises the recommendations and makes 
suggestion of further work that could be conducted in this area of research. 
8.1 Conclusions and Recommendations 
The hypothesis that the activity uncertainty can be reduced if careful selection of quantitative 
imaging parameters is performed was demonstrated to be correct, and the relevant parameters 
that influence quantitation are detailed in this section. 
8.1.1 Volume assessment 
Assessment of volume was demonstrated to be best performed using manual outlining on CT 
data, with results from the inter-comparison exercise indicating that use of diagnostic-quality 
CT further improves accuracy, but this could not be verified due to the lack of access to systems 
with diagnostic-quality CT. Assessing volumes by using a thresholding algorithm on the SPECT 
data yielded a far wider range of reported volumes than when using CT data and use of SPECT 
thresholding segmentation appeared to be particularly detrimental in situations likely to be 
subject to partial volume effects. Manual outlining on the SPECT data gave the worst result, but 
was only performed by one participant so this cannot be verified as a valid conclusion.  
Volumes can be used as an indication as to whether disease has progressed, gone into remission 
or remained stable. Inaccurate volume assessment may result in patients being erroneously 
diagnosed with progressive disease when their disease is actually stable, they may 
unnecessarily experience emotional distress due to the diagnosis, undergo further treatment to 
treat the progressive disease or have therapy stopped as they appear to not be responding to it. 
8.1.2 Common Calibration Protocol 
The use of the common calibration protocol improved the accuracy of the measured activity in 
the central sphere (from a maximum of 19% to 12 % difference between the true and measured 
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activity) of the inter-comparison phantom, but decreased the accuracy of the measured activity 
in the outer shell (from a maximum of 117% to 235% difference between the true and 
measured activity). This could be due to the fact that the calibration protocol does not account 
for the partial volume effects likely to be seen in the slim (11mm thickness) outer shell. 
However, as only one of the sites accounted for partial volume effects in their system 
calibration, it is more likely that this difference was caused by the use of a manufacturer-
independent workstation. Whilst resolution recovery was performed on the calibration protocol 
data, it is possible that more detailed gamma camera information is incorporated into a native 
workstation than is possible for a manufacturer-independent workstation.  
The uncertainty estimates generated from this calibration protocol method (where the 
uncertainty was the standard deviation in the three calibration measurements) were generally 
smaller or approximately equal to those estimated by the participants. The participants 
generally chose to include an uncertainty of the activity of the calibration source and/or the 
Poisson noise of the calibration or inter-comparison images. This work demonstrates that 
uncertainty values are generally underestimated, since only a few of the uncertainty ranges 
included the true activity value. For reported activities to be of clinical value, it is vital that the 
uncertainty range reported for an activity encompasses the true activity. Whilst uncertainties 
shouldn’t be wildly overestimated, this dataset suggests sites are likely to be reporting 
quantitative data that appears to be more precise than it is.  
The work indicates that hospitals may be reporting quantitative data and quoting a higher 
degree of accuracy than is true. This may lead to clinicians being concerned about changes in 
uptake that are supposedly clinically significant, but are actually not significant once realistic 
uncertainties are included.  
The hypothesis the use of a common calibration and imaging protocol would reduce 
inter-hospital variability in reported activity values was true for the central sphere, but further 
developments to the protocol need to be conducted before it can be reliably used to quantify 
activity in small low activity regions located immediately adjacent to high activity regions. 
8.1.3 Calibration method 
For assessing activities within active lesions or objects, the use of calibration sources of a 
similar size and geometry are likely to yield the most accurate results. However, where a more 
generic calibration is desired that can be used for lesions and objects of a range of shapes and 
sizes, the use of planar Petri dish calibrations provides the most accurate results. 
When assessing activities in low activity areas adjacent to higher activity areas, the large 
volume, dispersed sources were the most accurate though this calibration method gave the 
worst results for assessing the activity within small, active objects such as the inner sphere. 
These results pave the way for Nuclear Medicine staff to be able to make an informed decision 
as to which calibration method is likely to be most accurate and suitable for their local 
requirements, without having to perform and compare each calibration method themselves. 
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8.1.4 Imaging parameters 
Accuracy in measured activity was improved when counts from the 113 keV photopeak were 
disregarded and performing resolution recovery also improved the quantitative accuracy. 
Whilst it is recommended that only the counts from the 208 keV photopeak are used, in some, 
low count circumstances it may still be necessary to use the 113 keV photopeak too but users 
should be aware that this will decrease the accuracy of the results and care should be taken to 
ensure that the clinical staff using the results are aware of this. 
The work performed in this thesis indicated that appropriate use of post-reconstruction filters 
can improve quantitative accuracy.  
8.1.5 Segmentation methods 
The use of an expanded VOI based on the CT volume gave the best results for active lesion in 
low activity areas, but performed poorly for low activity regions in close proximity to higher 
activity areas. SPECT thresholding was the most accurate segmentation method for the outer 
shell and also performed well for the inner sphere. It is therefore recommended that lower 
activity regions be outlined using SPECT thresholding and selecting a threshold value that 
produces a volume that is approximately equal to that obtained by manual outlining on the CT 
data. It is possible on most workstations to perform initial outlining using SPECT thresholding 
and then adjust the outlines based on the CT data – this is likely to be an appropriate 
compromise between accuracy and time-efficiency.  
Incorrect or inaccurate segmentation of regions of interest will have a profound effect on the 
quantitative values obtained, and make it very difficult to compare patient images to assess (for 
example) progression or remission of disease. As with incorrect volume assessment, this could 
potentially result in patients being erroneously diagnosed with progressive disease when their 
disease is actually stable, they may unnecessarily experience emotional distress due to the 
diagnosis, undergo further treatment to treat the progressive disease or have therapy stopped 
as they appear to not be responding to it. 
8.1.6 Molecular Radiotherapy Inter-Comparison Exercises 
This work has demonstrated the feasibility of performing inter-comparison exercises on a 
pan-European geographical scale for molecular radiotherapy radionuclides with half-lives of 
approximately one week. Careful organisation and co-ordination was required at the planning 
stage to ensure that the clinical sites would be able to image the sources on, or shortly after, the 
planned delivery date. Individual sources had to be prepared for each site, with the exception of 
some clinical sites that were in the same country and geographically close enough to allow 
imaging at one site followed by onward shipping and imaging at a second site, which increases 
the time commitment required from the staff preparing the sources. However, for sites 
performing the imaging within a few days of each other, stock solutions can be made up and 
used to fill multiple inter-comparison sources which reduces the burden over preparing each 
source independently. All the inter-comparison sources imaged in clinical sites in continental 
Europe were imaged within a few days of each other and so those sources were all prepared 
from the same stock solutions.  
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Performing international inter-comparison exercises in molecular radiotherapy on a routine 
basis, as is performed for radionuclide calibrator and in the field of external beam radiotherapy, 
would allow comparisons to be made between quantitative images obtained at different clinical 
sites. It also paves the way for large multi-centre dosimetry trials to be established that would 
require the use of common protocols or inter-comparison exercises. 
8.2 Clinical Impact 
This work details methods that can be utilised to improve the accuracy of clinical quantitative 
imaging for 177Lu molecular radiotherapy from choosing a suitable calibration method, to image 
acquisition and reconstruction parameters through to how best to segment the volumes of 
interest in the reconstructed images. Not all clinical sites will be able to implement all 
recommendations and for some of the recommendations, alternative options are suggested 
(such as performing SPECT thresholding followed by adjusting the resultant volumes of interest 
based on the CT data). In situations where clinical sites are either unable or unwilling to use the 
recommended methods, the work presented in this thesis can provide guidance as to the 
potential reduction in accuracy that their method of choice may introduce into the activity 
quantification in patient or phantom images. 
Any improvements in the accuracy of activity quantification will increase the accuracy of 
molecular radiotherapy dosimetry, since absorbed dose is dependent on the activity 
distribution within the body of the patient and the more accurately known the activity 
distribution is, the more accurate the calculated or modelled absorbed will be. 
In the absence of plentiful large-scale multi-centre randomised clinical trials within molecular 
radiotherapy, this work provides some limited guidance on how to compare outcomes from 
small randomised clinical trials or cohort studies using a variety of different quantitative 
imaging methodologies. The work also demonstrates the feasibility of performing international 
inter-comparison exercises – if such inter-comparisons were to become routine practice then 
this would enable clinical sites to establish equivalence (or not) between sites and enable 
genuine comparison of clinical trial or cohort study outcomes. 
The benefits of improving accuracy and establishing equivalence in quantitative imaging 
between clinical sites would be two-fold: firstly there is the benefit to the individual patient 
undergoing molecular radiotherapy – an absorbed dose reported by one clinical site can be 
directly compared to the absorbed doses at another clinical site. This means that in instances 
where patients undergo molecular radiotherapy treatments at more than one site, or where 
patients also receive external beam radiotherapy, the individual treatment absorbed doses can 
be compared, and combined to give a total absorbed dose. Secondly, there is a longer-term 
benefit whereby meta-analysis of small randomised clinical trials or cohort studies can be 
performed since the reported absorbed doses can be meaningfully compared. The number of 
patients that receive molecular radiotherapy treatments are very small in comparison to the 
numbers that receive other Oncology therapies, such as chemotherapy and external beam 
radiotherapy, and so published studies usually contain very small patient numbers. The ability 
to combine patient data from multiple published studies, or combine unpublished data from a 
large number of hospitals, would enable the relationship between absorbed dose and 
therapeutic outcomes to be investigated in far greater detail, paving the way for more 
personalised, dosimetry-driven molecular radiotherapy in order to optimise patient outcomes. 
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8.2.1 Current/Recent Multicentre Clinical Trials 
The SEL-I-METRY multicentre clinical trial in the UK, see section 2.3.2.3 (Quantitative SPECT 
Imaging: SEL-I-METRY Clinical Trial) on page 34 for details, and the Iluminet multicentre 
clinical trial in Sweden (188) have both successfully calibrated multiple hospitals to perform 
equivalent quantitative SPECT/CT imaging that can be directly compared.  
The SEL-I-METRY study has 8 hospitals established, and is in the midst of patient recruitment 
for 131I therapy for thyroid cancer. If successful, then the researchers hope to demonstrate that 
pre-therapy dosimetry can be used to predict the outcome of the therapy. This would enable 
patients to avoid having a therapy, and a radiation dose, that was unlikely to benefit them. 
The Iluminet study was performed at two hospitals and has published interim results with the 
final results yet to be published. The study calculates renal (kidney) dose to patients given 
177Lu-DOTATATE therapy for neuroendocrine cancers and the interim results reported that the 
majority of patients were able to receive more treatment cycles than would have been possible 
without dosimetry calculations. The patients will undergo long-term follow-up, but the hope is 
that receiving additional treatment cycles will increase survival of patients. 
8.3 Further Work 
There is a large amount of research and investigation still to be conducted in this field. In 
particular, the work in this thesis has only investigated a relatively simplistic geometry, with the 
effects of partial volume, deadtime and the presence of background activity not considered.  
Whilst partial volume effects and deadtime significantly impact quantitation of SPECT/CT 
imaging, there is already a reasonable interest in this area. Therefore efforts should be 
concentrated into the area of uncertainty assessment, in particular identification of all sources 
of uncertainty since this work demonstrated that participants generally underestimated the 
uncertainty on the reported activity values, and the method of uncertainty assessment in the 
calibration protocol also generally underestimated the uncertainty. The provision of robust 
methods of uncertainty estimation would more easily allow comparison of data from different 
clinical sites. This is something that is not currently possible due to both the variation in 
quantification methods used but also the non-standardised manner in which uncertainty 
estimates are calculated.  
It would be interesting to investigate whether the use of diagnostic-quality CT consistently 
improves volume assessment, alongside discussions with Nuclear Medicine clinicians as to 
whether any improvement in volume assessment is justified by the use of diagnostic-quality CT 
(and the subsequent increased dose to the patient). Manual outlining on the SPECT data could 
also be investigated, and would likely require several operators to outline a number of volumes 
in order to assess inter-operator and intra-operator variation. 
If ready access to the various manufacturer workstations were available, it would be desirable 
to investigate whether resolution recovery is improved on native workstations with more 
detailed camera-specific corrections in comparison to vendor neutral workstations. 
Substantial further research into the sources of uncertainty in area of quantitative imaging for 
molecular radiotherapy is necessary in order to allow more complete uncertainty calculations 
to be performed. 
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Since the use of Petri dishes performed well as a generic calibration it would be interesting to 
consider the feasibility of acquiring SPECT/CT images of the Petri dishes. If the total counts in 
the Petri dish SPECT/CT images could be used to obtain a “dispersed calibration source” 
cps/MBq factor then valid cps/MBq factors could be obtained for both high and low activity 
regions using a single set of calibration sources. 
There is concern that the use of resolution recovery corrections can result in image artefacts in 
SPECT/CT imaging. Although not demonstrated in this work, further work needs to be done into 
the effect of resolution recovery on quantitative accuracy for smaller lesions than those used in 
this work, as they will be more greatly affected.  
A significant amount of work needs to be performed before the use of post-reconstruction 
filtering can be recommended, looking into the effects of the various parameters that can be 
used on the range of likely clinical scenarios. 
It would be very useful to investigate segmentation of cold/inactive regions within active 
regions (such as necrosis in tumours) and reproducibility of segmentation methods. 
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Worksheet for performing data analysis of image data: 
 
